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 Lipid peroxidation has long been correlated to and proposed to be a causative factor in a 
myriad of human diseases. However, identifying a causative mechanistic role of lipid 
peroxidation has proven challenging and the role of oxidized lipids in disease pathogenesis 
remains enigmatic. We posited that a potent small molecule inhibitor of lipid peroxidation could 
be a useful probe to understand the role of lipid peroxidation in human disease. Carotenoids are 
an extensively studied class of polyene containing small molecules with antilipoperoxidant 
activity. Yet no significant progress has been made towards utilizing carotenoids either as 
clinically proven treatments or to definitively probe the role of lipid peroxidation in disease 
pathogenesis. We therefore sought to identify an exceptionally potent small molecule inhibitor of 
bilayer lipid peroxidation to advance our understanding of the specific role(s) this process plays 
in disease pathogenesis. Additionally, such a molecule could serve as a starting point for the 
development of small molecule replacements for missing or dysfunctional antilipoperoxidant 
proteins. We questioned whether environmental pressures might have driven the evolution of 
exceptional natural product antilipoperoxidants in microorganisms that thrive in environments of 
extreme oxidative stress. We specifically sought to characterize the antilipoperoxidant activity of 
three highly atypical carotenoids, peridinin, synechoxanthin, and chlamydaxanthin. 
 We synthesized each of these natural products utilizing an efficient and modular building 
block based approach. This strategy allowed for initial activity assays as well synthesis of 
isotopically labeled carotenoids and scale-up for animal experiments. We found that the atypical 
carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic bilayer lipid 
peroxidation in both chemically defined liposomes and primary human endothelial cells. 
Mechanistic investigation showed, as compared to astaxanthin, peridinin does not act through 
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inhibition of lipid lateral diffusion nor does it have a higher inherent rate of radical quenching 
activity. SSNMR experiments with a synthesized isotopologue showed that the increased 
potency of peridinin is due to its increased propensity to embed within the lipid bilayer. That is, 
in contrast to the primarily extramembranous localization of the widely used but much less 
potent antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically 
spans the hydrophobic core of POPC membranes, maximizing its concentration at the site of the 
targeted lipid peroxidation reactions. 
 In a final set of experiments, we utilized peridinin to probe the role of lipid peroxidation 
in atherosclerosis and asthma. In primary human endothelial cells, we found that small molecule-
mediated inhibition of bilayer lipid peroxidation blocks stress-induced monocyte-endothelial cell 
adhesion, a key step in atherogenesis. In contrast, in two different mouse models of acute 
asthma, our preliminary results suggest that lipid peroxidation does not drive the pathogenesis of 
asthma. We did not observe a consistent increase in oxidized lipids in these models, nor did 
peridinin have any measurable effect on the asthmatic phenotype. Further studies are required to 
understand the biodistribution of peridinin and evaluate lipid peroxidation in clinically relevant 
chronic mouse models of asthma. In conclusion, we have identified peridinin as a potent and 
membrane embedded inhibitor of lipid peroxidation with the potential to further probe the role of 
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Adam G. Hill and Martin D. Burke 
1 – 1 BIOLOGICAL SIGNIFICANCE OF LIPID PEROXIDATION  
 Oxidized lipids have been correlated to many human diseases1, 2 including: 
atherosclerosis,3-8 asthma,9-16 hemorrhagic stroke,17-19 cancer,20-24 neurodegenerative diseases,25-
28 ischemia/reperfusion injuries,29-31 rheumatoid arthritis,32-34 and diabetes (type I35-37 and II38, 39). 
Lipid peroxidation may also contribute to aging.40-46 However, it is challenging to determine 
whether oxidized lipids play a causative role in disease pathogenesis or alternatively are 
correlative biomarkers. We chose to study two diseases connected to lipid peroxidation: 
atherosclerosis and asthma.  In both of these diseases, lipid peroxidation is proposed to be a key 
step in disease pathogenesis and we sought to test this hypothesis using a potent small molecule 
inhibitor of lipid peroxidation.  
 Epidemiological studies have connected both of these diseases to the presence of 
oxidized lipids and missing or inactive antilipoperoxidant proteins. Increased levels of oxidized 
lipids in the blood have been correlated with an increased risk for major cardiovascular events in 
atherosclerosis.47, 48 Additionally, atherosclerotic plaques isolated and removed during 
endarterectomies from patients have shown increased levels of oxidized lipids as compared to 
healthy arterial tissue.49-51 Finally, patients missing the glutathione peroxidase (GPXs)52, 53 and 
glutathione-S-transferase (GSTs)54, 55 antilipoperoxidant enzymes have increased incidence 
and/or severity of their atherosclerotic phenotype. A protective role of the antilipoperoxidant 
protein GPX-1 in atherosclerosis has also been observed in the ApoE-/- mouse model. In this 
model, the ApoE-/-/GPX-1-/- double knock-out mice showed a higher percentage of 
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atherosclerotic lesions, greater smooth muscle cell proliferation and macrophage infiltration 
within the arterial wall relative to the ApoE-/- single knock-out mice.56-60  
Increased levels of oxidized lipid byproducts in the exhaled breath condensate and 
bronchoaveolar lavage (BAL) fluid of asthmatic patients, including malondialdehyde (MDA),61, 
62 4-hydroxyl nonenal (4-HNE),63 and 8-iso-PGF2α64-74 has been correlated with asthma severity. 
Genetic studies have revealed correlations between asthma and deleterious mutations in 
endogenous antioxidant proteins, including superoxide dismutase75 and glutathione transferase.55, 
76 Similarly, knockout mice missing either glutathione peroxidase77 or transferase78 show an 
exaggerated asthmatic response, and high oral doses of N-acetylcysteine, a glutathione precursor, 
has been shown to ameliorate the asthmatic phenotype in murine asthma models.79, 80 It has also 
been shown that lipid breakdown products induce loss of bronchial epithelial tight junctions and 
increases in mucus production in vitro,81, 82 two key characteristics of an asthma phenotype.83 
While these studies suggest a potential role for lipid peroxidation in the pathogenesis of asthma, 
it remains unknown if there is a causative and thus therapeutically addressable relationship 
between asthma pathophysiology and lipid peroxidation. 
1 – 2 LIPID PEROXIDATION IN THE PATHOGENESIS OF ATHEROSCLEROSIS 
 There are two pathways connecting lipid oxidation to atherosclerosis (Fig. 1 – 1): (i) the 
oxidized LDL (oxLDL) model which is dependent on the oxidation of exogenous LDL84-87 and 
(ii) the lipid whisker model which is dependent on the oxidation of endogenous endothelial cell 
lipids.3, 88-90 The formation of atherosclerotic plaques was first connected to cholesterol and the 
low-density lipoprotein (LDL) particles which carry cholesterol within the bloodstream.85 It was 
noted at the time that native highly purified LDL was uptaken by macrophages too slowly to 
account for atherogenesis.91, 92 In 1979, Goldstein and co-workers86 predicted that LDL had to be 
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modified prior to being taken up by macrophages and four years later it was shown that oxidation 
of LDL was required prior to endocytosis by macrophages.93 These discoveries led to the 
subsequent elucidation of the oxidized LDL model of atherosclerotic plaque formation. 
 
Figure 1-1. Schematic of the oxidized LDL and lipid whisker models of monocyte binding. 
 In this model, LDL enters the sub-endothelial space and an equilibrium is established 
between circulating LDL and LDL bound to glycosaminoglycans on the endothelial and smooth 
muscle cells surfaces.94 The lipids in the sub-endothelial LDL become oxidized84, 86 and this 
oxLDL upregulates the production of chemokines, including monocyte chemoattractant protein-1 
(MCP-1), and interleukin-8. 7, 95-97 These chemokines bind to integrin receptors on circulating 
monocytes which induce monocyte binding to the arterial endothelium followed by migration 
and differentiation into macrophages.87, 98 Macrophages in the sub-endothelial space internalize 
the oxidized LDL and convert these macrophages into foam cells containing oxidized LDL and 
cholesterol.85, 99 This is the “fatty streak” stage of atherosclerosis characterized by the presence 
of macrophages and initial thickening of intimal layer of the arterial endothelium.94 The 
macrophage derived foam cells release pro-inflammatory cytokines which initiate an 















This represents the fibroatheroma stage and is characterized by a fibrotic collagen cap covering 
an acellular necrotic core generated by macrophage laden foam cells.94 The cap on the plaque 
can thicken leading to constriction of the artery causing angina, heart failure or even sudden 
death. This cap can also rupture causing blood clots that can cause strokes and/or heart attacks.94 
 This model has been leveraged for the development of therapies to prevent major 
cardiovascular events and atherosclerosis. The most successful of these efforts is the 
development of the statins, HMG-CoA reductase inhibitors.85 The first statin was discovered in 
1976102 and it was hypothesized that inhibition of HMG-CoA would inhibit cholesterol synthesis 
within liver cells and thereby increase uptake of plasma LDL by the liver through LDL 
receptors.103 This mechanism proved active in animals and humans causing significant reduction 
in plasma LDL upon treatment with stains and significantly reduced major cardiovascular events 
and death in patients with coronary artery disease.103, 104  
 Further confirming the importance of LDL in atherosclerosis, patients with familial 
hypercholesterolemia have exceptionally high levels of plasma LDL and significantly increased 
risk of atherosclerosis and cardiovascular related death.105 These patients experience a dramatic 
improvement in cardiovascular outcomes upon LDL apheresis in which the patients blood is 
passed through an immunoaffinity column coated with lipoprotein(a) antibodies to remove 
excess LDL particles. LDL apheresis resulted in a five-fold decrease in major cardiovascular 
events in the two years after lipid apheresis as compared to the two years prior.106, 107  
 In the second pathway, (ii) oxidized lipids in endothelial cell membranes signal to 
circulating monocytes and thereby induce the formation of atherosclerotic plaques.3 In this Lipid 
Whisker Model, lipids within the endothelial cell bilayer become oxidized and these polar lipid 
oxidation products flip out of the hydrophobic core to become expressed on the endothelial cell 
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surface.88 These oxidized lipids act as ligands for scavenger receptors, such as CD36,108-110 SRB-
1,109 TLR-2,110, 111 and TLR-4,112 on circulating monocytes thereby inducing monocyte binding 
and migration to the sub-endothelial space.113 Upon migration these monocytes differentiate into 
macrophages which undergo the same process of LDL uptake and foam cell formation as 
described previously. This model was first described by Hazen et al.89 who showed through a 
series of NMR experiments that polar lipid oxidation products in chemically defined liposomes 
were surface exposed. Additionally, doping in lipid oxidation products, prepared through total 
synthesis induced binding of monocytes to these liposomes.89 However, no monocyte binding 
occurred in the absence of lipid oxidation products or in the presence of minimally oxidized 
lipids that remained embedded within the hydrophobic core of the liposomes.89 The scavenger 
receptor, CD36, was shown to be responsible for monocyte binding as shRNA mediated 
knockdown of CD36 abrogated monocyte-liposome binding.89 While there is extensive evidence 
to support role of oxidized phospholipids in the pathogenesis of atherosclerosis, no significant 
progress has been made towards clinically relevant inhibition of this process.114 
Given the epidemiological and experimental evidence suggesting the importance of lipid 
peroxidation in heart disease, numerous clinical trials have studied the effects of purported small 
molecule antilipoperoxidants including β-carotene,115-118 vitamin E,115-118 and astaxanthin,119-121 
on cardiovascular health. Paradoxically, the majority of these trials demonstrated neutral or even 
adverse outcomes associated with treatment. In clinical trials enrolling patients at increased risk 
for cardiovascular disease, due to either previous major cardiovascular events or smoking, two of 
the three studies (ATBC122 and CARET123) showed a significant increase in cardiovascular 
deaths upon β-carotene supplementation as well as an unexpected increase in incidences of lung 
cancer compared to the placebo treated group. The third study (HPS) showed no effect of β-
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carotene on cardiovascular deaths.124 Additionally, the two studies (WHS125 and PHS126) 
comparing β-carotene supplementation in healthy patients both showed no statistically 
significant changes in major cardiovascular events or cardiovascular deaths. Finally, multiple 
meta-analyses of randomized controlled trials of β-carotene supplementation have shown an 
increased relative risk for major cardiovascular events, cardiovascular mortality and all cause 
mortality.115-118 
The second molecule tested in large scale clinical trials was vitamin E and its major iso-
form α-tocopherol. Despite promising results in two studies, the CHAOS127 and SPACE128 
studies in which vitamin E supplementation reduced the risk for major cardiovascular events and 
myocardial infarctions, respectively, several other large-scale trials have demonstrated no benefit 
of Vitamin E treatment. In the GISSI129, 130 HOPE/HOPE-TOO131, 132 MRC/BHF,124 Women’s 
Angiographic Vitamin and Estrogen (WAVE),133 Primary Prevention Project (PPP),134 Women’s 
Health Study (WHS) studies, 135 supplementation with between 50-600 mg/day vitamin E 
resulted in no significant reduction of major cardiovascular events, such as myocardial 
infarctions, coronary events, stroke, and cardiovascular death. The results of these trials has lead 
to β-carotene and vitamin E supplementation no longer being recommended for the prevention of 
cardiovascular disease and has lead to skepticism regarding antioxidant supplementation for 
disease prevention and treatment. 
Finally, astaxanthin, a polar carotenoid which has been shown in vitro136 to inhibit lipid 
peroxidation has been tested in small scale clinical trials. In the largest clinical trial to date 
(XANTHIN), supplementation with astaxanthin did not effect the progression of atherosclerosis 
in renal transplant recipients who are particularly prone to this disease.119 Other smaller trials in 
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healthy patients have shown mixed results on plasma lipid profile with short-term astaxanthin 
supplementation.120, 121 
 It remains unclear if these failures reflect a lack of relevance and importance of the lipid 
whisker model in atherosclerosis or rather major limitations of the currently available small 
molecule antilipoperoxidants. Supporting the latter hypothesis, β-carotene has been found to 
promote bilayer lipid peroxidation under high oxygen concentrations,137 and our own studies 
have found it to be a pro-lipoperoxidant promoting the oxidation of chemically defined 
liposomes (chapter 3-1). Vitamin E is a relatively weak and non-specific inhibitor of non-
enzymatic lipid oxidation. Our own studies have demonstrated that vitamin E requires very high 
concentrations (>6 mol% relative to lipid) to inhibit the oxidation of chemically defined 
liposomes (chapter 3-1). This suggests that its antilipoperoxidant effects in vivo may be 
primarily due to other mechanisms.138 Vitamin E has also been shown to inhibit lipoxygenase 
(LOX) enzymes, perturbing what is thought to be physiologic enzymatic oxidation of 
arachidonic acid.139-143 It also targets key anti-inflammatory signaling cascades and inhibit 
enzymatic lipid oxidation,144-147 including direct inhibition of AP-1 transcription factor and 
modulation of NF-kb signaling through inhibition of protein kinase C activity, leading to off-
target anti-inflammatory effects.148-151 Astaxanthin requires greater than 5 mol% relative to lipid 
to inhibit lipid oxidation in chemically defined liposomes (chapter 3-1) and similarly lacks 
potency in primary human endothelial cells requiring >40 µM to reach 50% inhibition of lipid 
peroxidation (Chp. 3-1). Animal models of ischemia-reperfusion injury or atherosclerosis 
required high doses of astaxanthin, either 50 mg/kg I.V. or 500 mg/kg P.O., to observe any effect 
on disease progression30, 31, 152-157 Based upon these important limitations, we hypothesized that 
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the clinical failure of typical antilipoperoxidants is due to the lack of potent, selective and 
intramembranous inhibitor of lipid peroxidation. 
 
1 – 3 LIPID PEROXIDATION IN THE PATHOGENESIS OF ACUTE ASTHMA 
 
Figure 1-2. Lipid peroxidation may contribute to the exaggerated inflammatory response observed in asthmatics. 
 Lipid peroxidation may represent an important and addressable pathway to pathogenesis 
in asthma; however, this hypothesis remains unverified. Asthma is a complex and heterogeneous 
disease158 which effects 8-10% of the US population159 and presents a broad range of severity 
from mild to fatal.160, 161 Current first-line treatment for this disease starts with fast acting β2-
adrenergic receptor agonists which cause bronchodilation (i.e. salbutamol inhalers)162 and 
progress to daily treatment with inhaled corticosteroids (i.e. dexamethasone, fluticasone, 
prednisone/prednisolone or hydrocortisone).163, 164 A significant population of asthmatic patients 
are refractory to steroid treatment and require treatment through different therapeutic 
mechanisms such as directly inhibiting the pro-inflammatory pathways.165 There have been 
important recent advances in directly inhibiting the pro-inflammatory signals that induce 
bronchoconstriction and airway remodeling.166 The anti-IgE antibody omalizumab is currently 
approved for treatment of asthma and multiple anti-IL-4 and anti-IL-13 antibodies (dupilumab,167 







































treatment of asthma.172 Despite this progress there remains a significant unmet medical need for 
a non-steroid based treatment for this disease.  
 The acute phase of the asthmatic reaction is characterized by an initial inhaled allergen, 
such as house dust mite, cockroach or viral antigens, which sets off an inflammatory immune 
response within the airway.173, 174 This immune response is most often dominated by IgE 
mediated eosinophilic inflammation, but there is a growing body of evidence suggesting the 
importance of neutrophils and basophils in airway inflammation.175 In this model, cross-linking 
of IgE to mast-cells induces degranulation and the release of pro-inflammatory signaling 
molecules including lipid-derived eicosanoids, leukotrienes, prostaglandins, histamines, 
proteases and a multitude of cytokines (IL-4, IL-6, IL-13 and TNFα).176 This degranulation 
causes bronchoconstriction, mucus secretion and vasodilation176 and is followed by Th2 
eosinophilic inflammation with recent studies suggesting that Th1177 and Th17178, 179 cells may 
also play an important role in airway inflammation. Eosinophilic and in certain patients 
neutrophilic,175 inflammation further exacerbates the allergic response through the release of 
similar pro-inflammatory cytokines (IL-4 and IL-13) and oxidized lipid signaling molecules 
(prostaglandins, leukotrienes and lipoxins).180 Additionally, release of reactive oxygen species 
(ROS) and oxidizing proteins, such as eosinophil peroxidase, are proposed to induce further lipid 
peroxidation within the airway throughout the asthmatic response.181 
 This model is further supported by the clinical impact of leukotriene receptor antagonists 
in asthmatic patients.182 Inhibition of 5-lipoxygenase (5-LOX) by the clinically approved 
medication, zileuton, showed significant improvements in lung function as measured by 
increased forced expiratory volume during the first second (FEV1), decreased rescue inhaler use 
and decreased asthma related hospitalizations.183 Additionally, the direct leukotriene receptor 
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antagonists: zafirlukast,184 montelukast,185 and pranlukast186 have shown significant 
improvements in the symptoms of asthmatic patients. These medications inhibit activation of the 
CysLT1 receptor within the airway thereby inhibiting eosinophilic inflammation.187  
 Non-enzymatic lipid peroxidation is proposed to exaggerate the acute asthmatic 
inflammatory response by mimicking pro-inflammatory lipid mediators and binding to 
promiscuous receptors present in the asthmatic airway.188 These oxidized lipids may upregulate 
bronchoconstriction and mucus production analogous to the structurally similar prostaglandins 
and leukotrienes produced by inflammatory eosinophils. However, there is little experimental 
data to support this lipid oxidation hypothesis. Studies in human bronchial epithelial cell lines 
have shown that administration of lipids exposed to ozone will induce upregulation of pro-
inflammatory cytokines (IL-6 and IL-8).189-191 Animals studies have shown that α-tocopherol 
administration attenuates the asthmatic response in mouse models of asthma.192-194 In contrast, 
recent observational studies in asthmatic patients have shown no correlation between β-carotene 
or vitamin-E levels and the presence or severity of asthma.195-197 Finally, in a single randomized 
controlled clinical trial, supplementation with vitamin E showed no effect in patients with mild 
or moderate asthma.198 However, as described previously (chapter 1 – 2), these compounds have 
significant limitations making it difficult to definitively conclude whether lipid peroxidation is a 
key driver of asthma pathophysiology. Therefore, we hypothesized that a potent small molecule 
inhibitor of lipid peroxidation would be able to probe the role of lipid peroxidation in the acute 





1 – 4 MECHANISM OF LIPID PEROXIDATION 
 Mammalian cell membranes contain polyunsaturated fatty acids (PUFAs) that are prone 
to oxidation and the formation of a plethora of oxidized lipid byproducts. PUFAs contain labile 
bis-allyic C-H bonds (LH)199 which upon exposure to reactive oxygen species (ROS) can be 
homolytically cleaved to form a lipid centered radical (L!).200  These lipid centered radicals react 
with oxygen at a diffusion limited rate to form a lipid peroxy radical (LOO!).201 The newly 
formed LOO! is the chain carrying species of lipid peroxidation and propagates this radical 
chain reaction by abstracting a hydrogen from LH to form LOOH and a lipid radical (L!) which 
is rapidly converted to LOO! thereby forming two equivalents of lipid peroxide. This process 
can be terminated in a variety of ways including decomposition of LOO!, reduction by 
antilipoperoxidant proteins or the formation of covalent adducts with biological 
macromolecules.81, 200 In the case of decomposition, LOO! will either undergo an intramolecular 
substitution reaction to form lipid epoxides202 or undergo intramolecular radical cyclization to 
form unstable endoperoxides which further breakdown to a variety of molecular species 
including potent electrophiles such as malondialdehyde (MDA) and pro-inflammatory signaling 
molecules such as 8-iso PGF2α.203, 204 In biological systems multiple protein families have evolved 
to reduce lipid peroxides and remove oxidized lipid byproducts with the most important and 
prevalent of these being the glutathione peroxidase,205 peroxiredoxin206 and glutathione-S-
transferase207 families of enzymes. Finally, lipid peroxy radicals and the radical containing 
breakdown products can react with DNA and proteins thereby terminating lipid peroxidation but 
forming carcinogenic adducts in the process.22, 208-211  
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Figure 1-3. Mechanism of lipid peroxidation. 
 Due to biological significance of lipid peroxidation, there has been extensive work 
towards discovering potent antilipoperoxidants. The target in this case is control of a bilayer 
localized non-enzymatic chemical reaction, rather than binding and inhibition of a functional 
enzyme or other macromolecule. Thus, finding a potent small molecule that performs this 
higher-order function represents a unique and challenging objective. Carotenoids represent an 
interesting starting point as they have been shown to possess antilipoperoxidant activity without 
the concomitant off-target effects observed for the tocopherols. There are two key proposed 
mechanisms by which carotenoids are able to quench lipid peroxidation. In the first, 
stoichiometric, mechanism, an inhibitor can undergo a stoichiometric reaction with a lipid 
peroxy radical (LOO!) thereby forming an oxygenated carotenoid byproduct which now 
contains a radical delocalized through the carotenoid polyene.212-214 This radical may have a 
higher barrier to propagation and therefore slows the rate of lipid peroxidation.  
 In the second, electron shuttle mechanism of inhibition of lipid peroxidation, the 
antilipoperoxidant carotenoid can act as an electron shuttle to catalytically quench the chain 
carrying species, LOO!. In this mechanism, the antilipoperoxidant will donate an electron to 
LOO! thereby forming LOO- and carot!+.212-214 The LOO- will rapidly pickup a proton at 
physiological pH to reform LOOH and thereby inhibit lipid peroxidation. Additionally, the 














FADH,217 or ascorbic acid218 thereby reforming the original carotenoid. This is analogous to the 
proposed mechanism by which α-tocopherol inhibits lipid peroxidation. In this cycle, the phenol 
on α-tocopherol donates a hydrogen atom to LOO! radical forming LOOH and the stabilized α-
tocopherol phenoxy radical.219 Finally, ascorbic acid will reduce the α-tocopherol phenoxy 
radical reforming α-tocopherol leading to a non-destructive quenching mechanism.220 We 
hypothesized that a small molecule capable of performing primarily the electron shuttle 
mechanism of radical quenching would act as a self-preserving quencher of lipid peroxidation. 
 
1 – 5 ATYPICAL CAROTENOIDS AS POTENTIAL ANTILIPOPEROXIDANTS  
 We sought to identify a highly effective small molecule inhibitor of non-enzymatic lipid 
bilayer peroxidation to advance our understanding of the specific role(s) this process plays in the 
pathogenesis of atherosclerosis and asthma, and potentially serve as a starting point for the 
development of small molecule replacements for missing or dysfunctional antilipoperoxidant 
proteins.221, 222 
We proposed that context-specific selective pressures may have driven the evolution of 
natural products with potent antilipoperoxidant activity in microorganisms that thrive in 
environments of extreme oxidative stress. We selected three atypical carotenoids to study as 
potential antilipoperoxidants: peridinin, synechoxanthin and di[(6-O-oleoyl-β-D-
glucopyranosyl)oxy]-astaxanthin (chlamydaxanthin) (Fig. 1 – 4). 
! 14!
 
Figure 1-4. Atypical carotenoid structures. 
Peridinin is an allenic norcarotenoid produced by the photosynthetic dinoflagellate 
Amphidinium carerae. Peridinin is localized to the peridinin-chlorophyll-protein (PCP) complex 
in dinoflagelletes223 and is thought to play two critical roles in the organism: light harvesting224 
and protection from photo-mediated oxidation.225  
 
Figure 1-5. Diagram showing Dexter energy transfer in A. carterae either from excited state peridinin to ground state chlorophyll 
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In light harvesting, peridinin within the PCP complex absorbs light in the 470 to 550 nm 
range, above the absorption spectrum of chlorophyll. Peridinin will absorb a photon thereby 
forming the singlet excited state (S2*) which will rapidly relax to the S1/SICT* excited state.226 
This excited state is able to transfer energy to chlorophyll held within the PCP complex by a 
Dexter energy exchange mechanism (Fig. 1 – 5, left).227 This mechanism can be thought of as a 
simultaneous double electron exchange228 whereby peridinin donates an excited state electron 
from the S1/SICT orbital and simultaneously accepts an electron from the ground state of 
chlorophyll.229 This process results in the formation of ground state peridinin (S0) and excited 
state chlorophyll (S1*).230 The excited state chlorophyll goes onto perform photosynthesis while 
peridinin can absorb a second photon and repeat the process.  
In the case of photo-protection, peridinin is proposed to quench the triplet excited state of 
chlorophyll through a similar mechanism.230 Occasionally, excited state chlorophyll (S1*) can 
undergo intersystem crossing to form the non-productive triplet excited state (T1*).231 This long-
lived triplet excited state can transfer energy to oxygen thereby forming ROS and leading to 
decomposition of the PCP complex.232 However, the PCP complex has evolved to prevent 
decomposition by positioning a single peridinin (peridinin-614) close to chlorophyll where it can 
quench the excited state triplet species via a similar Dexter energy transfer mechanism (Fig. 1 – 
5, right).226-229 Peridinin can accept the excited state electron from the T1* orbital on chlorophyll 
and donate a ground state electron to chlorophyll.225 This process results in the formation of 
ground state chlorophyll (S0) and excited state peridinin (T1*).225 The excited state peridinin can 
thermally relax back to the ground state (S0)233 thereby preventing the decomposition of the PCP 
complex. This suggests that peridinin may have evolved to readily undergo this electron shuttling 
without concomitant decomposition or photobleaching and perhaps this mechanism may enable 
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peridinin to preferentially undergo the non-self destructive electron shuttle mechanism of 
quenching lipid peroxy radicals. 
Synechoxanthin, which possess atypical aromatic dicarboxylate termini, is produced by 
the marine cyanobacterium Synechococcus sp. PCC 7002 found in the photic zone of the ocean 
where it is exposed to high light conditions.234, 235 Synechoxanthin was the primary carotenoid 
isolated from this organism and hypothesized to be responsible for its tolerance to these high 
light conditions.234, 235 Genetic studies found that by knocking-out the enzymes which aromatizes 
the terminal rings and oxidize the C-18 methyl groups to the carboxylic acids results in a greatly 
diminished tolerance for high light conditions.236 We hypothesized that the aromatic termini 
found in synechoxanthin may endow it with superior antilipoperoxidant activity as has been 
found with other aromatic carotenoids.237, 238 
The final target is the bis-glycolipidated carotenoid di[(6-O-oleoyl-β-D-
glucopyranosyl)oxy]-astaxanthin (chlamydaxanthin) first isolated in 2007 from the snow algae 
Chlamydomonas nivalis.239 This organism is responsible for the “watermelon snow” 
phenomenon in which patches of snow turn dark red due to increased carotenoid production 
during times of peak light intensity.240 Chlamydaxanthin represents one member of a growing 
class of glycolipidated carotenoids.241, 242 High elevation snow-capped mountains are exposed to 
high levels of ultraviolet light243, 244 and are proposed to have evolved high levels of carotenoid 
production to prevent oxidative damage from the increased incidence of UV radiation.245 
Chlamydomonus nivalis produces lipid globules containing both esterified (i.e. chlamydaxanthin) 
and non-esterified carotenoids thought to absorb incoming UV radiation allowing the organism 
to survive in this extreme environment.246-248 Specifically, glycolipidation is proposed to be 
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necessary to localize the carotenoid pigements within the lipid vesicles and to stabilize the high 
torsional forces within the small and highly curved lipid vesicles.245, 249  
We hypothesized that the glycolipidated tails, analogous to isoprene tails added to 
peptides and proteins,250 would act to direct and localize the carotenoid core within the 
hydrophobic core of a lipid membrane. In this model, the hydrophilic sugars would hydrogen 
bond to the carbonyls of the phospholipids while the hydrophobic tail would reach back and 
insert within the lipid bilayer. Furthermore, previous studies of astaxanthin provide contradictory 
conclusions regarding the localization and aggregation behavior of this carotenoid. Spectroscopic 
studies of astaxanthin in aqueous solution have shown its propensity to form large aggregates 
depending on the water to organic solvent ratio.251, 252 However, linear dichroism,253 UV-visible 
absorbance spectroscopy,254 differential scanning calorimetry,255 computational modeling256 and 
X-ray diffraction257 of lipid bilayers have been utilized to support a model of intramembranous 
localization. The specific localization of astaxanthin within the lipid bilayer remains unclear as 
each of these methods is limited to a resolution on the order of nanometers and these techniques 
are unable to differentiation between membrane bound and membrane inserted. We hypothesized 
that the glycolipidated appendages on chlamydaxanthin may disfavor extra-membranous 
aggregation and increase the effective molarity within the hydrophobic core of the lipid bilayer.  
For all three of these natural products, isolation from the producing organism is 
inefficient and represents a major barrier towards studying their antilipoperoxidant potential.234, 
235, 239, 258 In theory, chemical synthesis represents an alternative means of accessing such 
molecules and their derivatives, but the large size and high degree of complexity of these 
compounds presents a host of challenges.239, 259-262 With the goal of eliminating such synthesis 
bottlenecks, the Burke group recently developed a strategy, analogous to peptide coupling, in 
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which a single reaction is employed iteratively to assemble a collection of bifunctional 
haloboronic acid building blocks protected as the corresponding N-methyliminodiacetic acid 
(MIDA) boronates,263-266 A key feature of this platform is that all of the required functional 
groups, oxidation states, and stereochemistry are pre-installed into the building blocks, and then 
faithfully translated into the growing product due to the mild and stereospecific nature of the 
cross-coupling-based assembly. This approach was recently employed by my colleagues Dr. Eric 
Woerly and Dr. Seiko Fujii to complete the first stereocontrolled total syntheses of peridinin267 
and synechoxanthin,268 respectively.  
 In conclusion, we hypothesized that identification of a potent antilipoperoxidant isolated 
from an organism that thrives in environments of extreme oxidative stress would be a powerful 
probe to study the role of lipid peroxidation in human disease. Towards this objective, I have 
synthesized the atypical carotenoid chlamydaxanthin utilizing a new convergent building block 
based synthetic strategy (Chapter 2). In collaboration with Hannah M.S. Haley, we discovered 
that of the three atypical carotenoids synthesized in the Burke lab peridinin is an exceptionally 
potent small molecule antilipoperoxidant (Chapter 3). Finally, we utilized peridinin to probe the 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































TOTAL SYNTHESIS OF CHLAMYDAXANTHIN 
Adam G. Hill and Martin D. Burke 
 We targeted the synthesis and study of three structurally atypical carotenoid natural 
products isolated from microorganisms that thrive in environments of extreme oxidative stress. 
My colleagues had previously synthesized two of the tree atypical carotenoids, peridinin and 
synechoxanthin. We sought to complete the synthesis of the third and final atypical carotenoid, 
chlamydaxanthin. This molecule contains the astaxanthin core with a glycolipid appendage upon 
each alcohol of the terminal cyclohexane rings. Initial attempts to install the β-D-glucose 
followed by esterification with oleoyl chloride were unsuccessful. Therefore, we switched to a 
convergent synthetic route using a pre-functionalized glycolipid appendage containing the 
desired lipid tail and the protecting group (TDMBA; 4-(tert-butyl-dimethyl-silyl)oxy-2,2-
dimethyl-butyric acid). Optimization of the glycosylation reaction and development of mild 
anhydrous conditions for TDMBA removal completed the synthesis of chlamydaxanthin. This 
route provided the requisite material for biophysical assays. Additionally, this strategy would be 
amenable for the building block based synthesis of other glycolipid containing natural products. 
 The synthetic route was designed by Adam Hill and Marty Burke and chlamydaxanthin 







2 – 1 1st GENERATION SYNTHESIS OF CHLAMYDAXANTHION 
The Burke group had previously synthesized peridinin and synechoxanthin and I sought 
to synthesize the third and final atypical carotenoid, chlamydaxanthin. The isolation paper for 
chlamydaxanthin included the synthesis of a mass spectrometry standard and was the basis for 
my initial synthetic efforts.1 This route relied on initial glycosylation of astaxanthin with the 
tetrabenzoate protected α-glucosyl-bromide (2.1). This was followed by saponification of the 
benzoate groups and selective acylation of both C6 hydroxyl groups to yield chlamydaxanthin as 
a mass spectrometry standard (Fig. 2-1). 
 
Figure 2-1. Rezanka route to chlamydaxanthin. 
 
Repeating the reported conditions resulted in poor conversion (<5%) to the protected 
glycoside (2.2) and necessitated semi-prep HPLC purification (Table 2-1, entry 1). Increasing 
equivalents of sugar donor (2.1) and activator (AgOTf) were added to push the reaction to 
completion and provided a marginal increase in conversion (Table 2-1: entry 2-4).  Increasing 
temperature and recharging the reaction with both sugar donor and activator (Table 2-1: entries 











































utilized 8 equivalents of sugar donor and activator at 0 oC for 3 hours (Table 2-1: entry 3) 
giving a 15% yield of 2.2 and 50% yield of the intermediate mono-glycosylated product (2.3).  
These conditions required semi-preparative HPLC purification and were not amenable to 
isolation of useful quantities of compound 2.2. The poor reactivity was most likely caused by 
significant byproduct formation and possible decomposition of both astaxanthin and product in 
the presence of trifluoromethanesulfonic acid formed in the reaction. However, more extensive 
characterization of this reaction would be required to confirm this hypothesis. In contrast to the 
Renzaka report, we required milligram quantities of material for biological testing and we were 
never obtain sufficient quantities of 2.2 to perform the methanolysis and lipid acylation 
reactions.  Therefore, we developed a convergent building block based synthesis of 
chlamydaxanthin requiring a single glycosylation and deprotection reaction. 
 
Table 2-1. Optimization of astaxanthin glycosylation. Equal equivalents of 2.2 and AgOTf were added to each 
reaction. aIsolated off HPLC for 15% yield of 2.3 and 50% yield of 2.2. bAdded sugar donor over 40 min. cReaction 




entry temp. equiv. of 2.1
results
(astx. : 2.2 : 2.3)
1 0 oC 2 5:5:1
2 0 oC 4 0.5:5:1
3 0 oC 8 0:6:1a
4 0 oC 18 0:6:1
5 23 oC 8 0:13:1
6 40 oC 8 0:12:1
7 0 oC 8b 30:6:1
8 0 oC 8 + 8c 0:6:1
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2 – 2 CONVERGENT SYNTHESIS OF CHLAMYDAXANTHIN 
 We developed a convergent synthetic strategy in which the sugar donor is 
prefunctionalized with the requisite fatty acid at the C6 hydroxyl and a directing group on the C2 
hydroxyl capable of forming the desired β-glycosidic linkage (Fig. 2-2a).  
 
Figure 2-2. (a) Retrosynthesis of chlamydaxanthin. (b) Anchimeric assistance to form β-glycosides. (c) Potential 
directing groups for astaxanthin glycosylation.  
 
 Classically, pivolate protecting groups (2.4) are used to provide anchimeric assistance in 
which the steric bulk of the t-butyl group prevents both the formation of the α-linkage and 
undesired orthoester formation (Fig. 2-2b).2 However, in the subsequent step, the selective 
removal of a pivolate group in the presence of a fatty acid ester represents a challenging 
problem. 
Searching the literature revealed an interesting set of potential directing groups (Fig. 2-
2c). The Carreira group reported the use 2-chloro-2-methyl propanoate (2.5) in the synthesis of 
























































































conditions utilizing two equivalents of K2CO3.4 We were inspired by two reports from Kahne 
group in which the C2 hydroxyl of glucose was acylated with a tethered β-ketoester (2.6)5 or 
azide (2.7)6 both of which are capable of providing anchimeric assistance and were subsequently 
removed under oxidative or reductive conditions, respectively. The Codée group7 subsequently 
expanded this strategy through the development of 2.8 and 2.9 both of which contain a masked 
tethered nucleophile. Staudinger reduction of the azide (2.8) or oxidative removal of the PMP 
group (2.9) revealed a tethered nucleophile and induced an intramolecular cyclization giving rise 
to the free alcohol. The final example of this tethered nucleophile strategy was developed by the 
Ensley group8 utilizing a tethered acetoxy group (2.10) which upon mild hydrolysis reveals the 
alcohol. However, none of these protecting groups were amenable to chlamydaxanthin due to the 
requirement for non-hydrolytic deprotection conditions and the redox sensitive nature of the 
polyene. Finally, the Trost group9 reported the use of 4-(tert-butyl-dimethyl-silyl)oxy-2,2-
dimethyl-butyric acid (TDMBA, 2.11) for the selective protection and deprotection of a single 
secondary alcohol in the total synthesis of conduritol. We chose to base the synthetic strategy on 
this protecting group which has been previously utilized in the Burke group for the synthesis of 
the Eastern half of Amphotericin B.10 The quaternary alpha carbon acts as a steric block leading 
to exclusive formation of the desired β-linkage without concomitant orthoester formation. We 
hypothesized that removal of the t-butyl-dimethyl silyl ether (TBS) under buffered basic 
conditions followed by base catalyzed cyclization would allow for selective TDMB removal 
under mild anhydrous conditions.  
 


























TDMB was prepared from γ-butyrolactone starting with double methylation to give α,α-
dimethyl-γ-butyrolactone (2.12) followed by hydrolysis to open the lactone ring forming 2.13. 
Simultaneous protection of the carboxylic acid and alcohol utilizing TBSCl and subsequent 
methanolysis gave TDMB (2.11) on multi-gram scale (Fig. 2-3).10 
 
Figure 2-4. Synthesis of sugar donor for chlamydaxanthin. 
 
Synthesis of the desired sugar donor  (Fig. 2-4) commenced from D-glucose, which 
underwent peracylation, thiophenol formation and hydrolysis gave rise to the known 
intermediate 2.16.11 Selective acylation of the primary and most nucleophilic hydroxyl group 
(C6) utilizing freshly prepared oleoyl chloride proceeded in good yield to give 2.17. After 
extensive investigation, peracylation with TDMB utilizing EDC and DMAP as coupling reagents 
proceeded in 46% yield of the desired product (2.18). Initial attempts to oxidize the C1 thioether 
to the sulfoxide were unsuccessful leading to no conversion or decomposition. Mercury mediated 
conversion of the C1 thioether to the hemiacetal proceeded in 45% yield to a mixture of 
anomeric alcohols, but direct coupling of the anomeric alcohol to astaxanthin was unsuccessful. 
Finally, we formed the anomeric 2,2,2-trichloroacetimidate (2.20) anticipating a double Schmidt 




















































































Figure 2-5. Glycosylation of astaxanthin. 
 
 
Table 2-2. Optimization of glycosylation conditions. aprimarily formed the silyl transfer product. bisolated yield by 
HPLC 
 
Glycosylation of astaxanthin (Fig. 2-5) utilizing a buffered 2-chloro-6-methyl pyridinium 
triflate in hexanes10 gave no conversion (Table 2-2, entry 1). This was most likely due to 
astaxanthin being insoluble in hexanes. However, switching solvents to methylene chloride gave 
rise almost exclusively to the undesired silyl transfer product in which one alcohol on 
astaxanthin formed the expected glycoside while the second alcohol formed the unreactive TBS 
ether (Table 2-2; entry 2). Screening solvent mixtures, time and temperature (Table 2-2; entry 
3-6), I found that a 1:1 mixture of hexanes and methylene chloride at 0 oC for three hours 
entry& 'me&(h)& temp.& solvent& result&
1" 3"h" 23"oC" hexanes" 0%"conversion"
2" 1"h" 23"oC" CH2Cl2" <5%"yielda"
3" 3"h" 23"oC" 9:1"hexanes:CH2Cl2" 0%"conversion"
4" 3"h" 23"oC" 4:1"Hexanes:CH2Cl2" 0%"conversion"
5" 1"h" 23"oC" 1:1"Hexanes:CH2Cl2" 37%"yieldb"




































2.5 equiv. 1.25 equiv.
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sufficiently suppressed silyl transfer and gave the double glycosylated product (2.21) in 60% 
yield. 
 
Table 2-3. Optimization of TDMB deprotection conditions. atrace product observed by MS boleic acid hydrolysis was 
the only product observed cyield over 2 steps after HPLC purification 
 
 Conditions previously used to remove the TDMBA directing group relied on the use of a 
protic acid to both remove the TBS group and promote cyclization to the lactone.9, 10 However, 
anticipating acid mediated decomposition of the polyene, we investigated base mediate 
deprotection conditions (Table 2-3). Buffered HF•pyridine readily removed all 6 TBS groups, 
but induced only minimal cyclization and ester hydrolysis (Table 2-3, entry 1). Therefore, we 
switched to a two-step protocol in which the TBS groups were removed using HF•pyridine 
followed by a simple aqueous workup and subjecting the crude product to base mediated 
cyclization conditions at room temperature for 24 hours. Initial screening of amine bases showed 
no significant conversion (Table 2-3, entries 2-4) but switching to KHMDS lead to trace 
product formation and significant decomposition (Table 2-3 entries 5 – 7). Finally, utilizing 
DBU as a strong non-nucleophilic base in methylene chloride gave rise to chlamydaxanthin in 
entry base solvent result
1 pyridine CH2Cl2 trace product
2 pyridine MeOH no conversion
3 2,6-lutidine CH2Cl2 no conversion
4 Et3N CH2Cl2 no conversion
5 KHMDS CH2Cl2 decompositiona
6 KHMDS THF decomposition
7 KHMDS THF decomposition
8 DBU MeOH lipid hydrolysisb
9 DBU CH2Cl2 27% yieldc
2.21
1) HF•pyridine (1:5)
2) base (36 equiv.)
    solvent, 24 h
chlamydaxanthin
! 66!
27% yield over two steps (Table 2-3, entry 9). Further screening of solvent, time and 
temperature did not give to significant improvements in yield (data not shown).  
 
2 – 3 SUMMARY AND CONCLUSION 
 We successfully synthesized chlamydaxanthin in the quantities required to test its 
antilipoperoxidant activity. The convergent synthetic strategy developed in this synthesis is 
amenable to the synthesis of other glycolipidated natural products (Fig. 2-6).13-18 Additionally, 
due to its building block nature this synthetic strategy could be utilized for the efficient synthesis 
of derivatives of chlamydaxanthin such as isotopologues or derivatives containing other sugars 
or fatty acids to further probe its biological activity 
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Materials. Commercially available materials were purchased from Sigma-Aldrich, Alfa-Aesar, 
TCI America or Fisher Scientific and were used without further purification unless stated 
otherwise. Natural abundance astaxanthin was a gift from BASF. TDMBA1 and phenyl β-D-
thioglucopyranoside2 were synthesized as previously described. Unless stated otherwise, all of 
the solvents were dispensed from a solvent purification system that passes solvents through 
packed columns according to the method described by Pangborn and coworkers (THF, Et2O, 
CH3CN, CH2Cl2: dry neutral alumina; hexanes, toluene: dry neutral alumina and Q5 reactant; 
DMSO, DMF, CH3OH: activated molecular sieves).3 Triethylamine, diisopropylamine, pyridine, 
and 2,6-lutidine were freshly distilled under an atmosphere of nitrogen over CaH2. Water was 
dispensed from a MilliQ water purification system (Millipore Corporation) unless stated 
otherwise. 
 
General experimental procedures. Unless noted, all reactions were performed in flame dried 
round bottom flasks, Schlenk flasks fitted with rubber septa, or glass vials under a positive 
pressure of argon. Organic solutions were concentrated via rotary evaporation under reduced 
pressure with a bath temperature of 35-40 °C unless otherwise noted. Reactions were monitored 
by analytical thin layer chromatography (TLC) performed using the indicated solvent on E. 
Merck silica gel 60 F254 plates (0.25mm). Compounds were visualized by exposure to a UV 
lamp (λ = 254 nm) and/or a solution of stain (KMnO4, CAM = ceric ammonium molybdate or 
PMA = phosphomolybdic acid) followed by brief heating using a Varitemp heat gun. Column 
chromatography was performed using standard methods4 or on a TeledyneIsco CombiFlash Rf 
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purification system using Merck silica gel grade 9385 60Å (230-400 mesh). Unless otherwise 
noted, compounds were adsorbed onto non acid-washed Celite in vacuo which was then loaded 
on top of a silica gel column or into a CombiFlash cartridge. 1H NMR spectra were recorded at 
23 °C on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity 
Inova 500NB, Varian VXR 500. Chemical shifts (δ) are reported in parts per million (ppm) 
downfield from tetramethylsilane and referenced to residual protium in the NMR solvent 
(CHCl3, δ = 7.26; acetone-d6, δ = 2.05, center line). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration. 13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500. Chemical shifts (δ) are reported in ppm downfield from 
tetramethylsilane and referenced to carbon resonances in the NMR solvent (CDCl3, δ = 77.0, 
center line; acetone-d6, δ = 29.80, center line) or to added tetramethylsilane (δ = 0.00). Carbons 
bearing boron substituents were typically not observed (quadrupolar relaxation). High resolution 
mass spectra (HRMS) were performed by Furong Sun, Haijun Yao and Kevin Tucker at the 
University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory.  
 
HPLC Purification and analysis. Preparative-scale HPLC purification was performed using an 
Agilent 1260 series instrument equipped with a multiple wavelength detector and a Waters 
SunFire Prep C18 OBD 5 µm 30 × 150 mm column at a flow rate of 25 ml/min. Semi-
preparative scale HPLC purification was performed using an Agilent 1200 series instrument and 
a Waters SunFire Prep C18, 5 µm, 10 x 250 mm. All analytical HPLC analysis was performed 
using an Agilent 1200 series instrument equipped with a variable wavelength detector and 
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analytical Agilent Eclipse XDB-C18, 5 µm, 4.6 x 150 mm column. All HPLC solvents were 
filtered through 0.2-µm Millipore filters before use.  
 
I. SYNTHESIS AND CHARACTERIZATION 
 
2.17. To an oven dried 3-neck 3L round bottom flask equipped with a thermometer and charged 
with a stir bar and phenyl β-D-thioglucopyranoside 2.162 (5.79 g, 21 mmols) was added MeCN 
(1.5 L). The solution was heated to 40 – 50 oC and swirled to fully dissolve SI-1. The solution 
was stirred and cooled to 0 oC under Ar. To the stirring solution was added 2,6-lutidine (7.4 mL, 
63 mmols) followed by dropwise addition of oleoyl chloride (6.4 g, 21 mmols). The reaction was 
stirred at 0 oC for 14 h. To the reaction was added MeOH (50 mL) and solvent was removed in 
vacuo. The resulting mixture was azeotroped with toluene (5 x 100 mL) and concentrated in 
vacuo. The crude solid was loaded onto celite and purified by column chromatography on silica 
gel (95:5 DCM:MeOH) to afford 2.17 as an off-white solid (8.50 g, 75%).  
 
TLC (DCM:MeOH 95:5) 
 Rf = 0.31, stained by CAM 
1H NMR (500 MHz, CDCl3) 
δ 7.56 – 7.52 (m, 2H), 7.32 – 7.28 (m, 3H), 5.39 – 5.32 (m, 2H), 4.53 (app d, J = 9.5 Hz, 
1H), 4.46 (m, 1H), 4.34 (d, J = 12.5 Hz, 1H), 3.59 (t, J = 9 Hz, 1H) 3.50 (ddd, J = 2, 4.5, 
9.5 Hz, 1H), 3.34 (t, J = 9.5 Hz, 2H) 2.37 (t, J = 7 Hz, 2H) 2.01 (q, J = 6 Hz, 4H), 1.63 


















13C NMR (125 MHz, CDCl3) 
δ!174.6,132.5, 132.3, 130.1, 129.8, 129.1, 128.1, 87.9, 77.8, 77.6, 72.0, 70.0, 63.6, 34.3, 
32.0, 29.91, 29.88, 29.87, 29.67, 29.66, 29.48, 29.47, 29.4, 29.3, 27.4, 27.3, 25.0, 22.8, 
14.3  
HRMS (ESI+) 
Calculated for C30H48O6S (M+H)+:  537.3250 
Found:      537.3258 
 
 
2.18. To a 40 mL flame-dried vial was added 2.17 (0.536 g, 1.0 mmols), EDC!HCl (2.9 g, 15 
mmols), N,N-dimethyl-4-aminopyridine (1.8 g, 15 mmols) and 2,2-dimethyl-(tButyl-dimethyl-
silyl)-4-oxy butanoic acid1 (TDMBA, 3.7 g, 15 mmols) and the vial was placed under an Ar 
atmosphere. To the vial was added DCM (10 mL), it was then sealed with a PTFE-lined cap, 
placed in a 40 oC heating block and stirred for 4 weeks. Two identical reactions were setup in 
parallel following the same procedure. Both reactions were poured into hexanes (1L) and washed 
with 1M HCl (3 x 250 mL) followed by brine (3 x 250 mL). The organic layer was dried with 
MgSO4, filtered and concentrated in vacuo. The resulting oil was loaded onto celite and purified 
by column chromatography on silica gel (100:0 " 90:10 hexanes:EtOAc) to afford 2.18 as a 
colorless oil (1.12 g, 46% yield). 
 
TLC (90:10 hexanes:EtOAc) 




















1H NMR (500 MHz, CDCl3) 
 δ 7.52 – 7.48 (m, 2H) 7.32 – 7.27 (m, 3H) 5.39 – 5.32 (m, 2H) 5.08 (t, J = 10 Hz, 1H) 
 5.03 (t, J = 9.5, 1H) 4.71 (t, J = 10 Hz, 1H) 4.22 (dd, J = 2 Hz, 12 Hz, 1H) 4.07 (dd, J = 
 6.5 Hz, 12 Hz, 1H) 3.76 – 3.70 (m, 1H) 3.73 (t, J = 7.5 Hz, 2H), 3.66 – 3.57 (m, 4H) 2.33 
 (t, J = 7 Hz, 2H) 2.01 (q, J = 5.5 Hz, 4H) 1.88 – 1.68 (m, 6H), 1.62 (t, J = 7 Hz, 2H), 1.33 
 – 1.24 (m, 22H) 1.20 (s, 3H) 1.19 (s, 3H) 1.15 (s, 3H) 1.14 (s, 6H) 1.11 (s, 6H) 0.88 – 
 0.85 (m, 27H) 0.88 – 0.85 (m, 3H) 0.04 – 0.01 (m, 18H) 
13C NMR (125 MHz, CDCl3) 
 δ 176.7, 176.1, 176.0, 173.4, 132.9, 132.7, 130.2, 130.0, 129.1, 128.5, 86.7, 76.4, 73.6, 70
 .2, 68.4, 62.4, 60.0, 59.84, 59.77, 53.7, 42.5, 42.1, 41.8, 41.4, 41.29, 41.28, 34.3, 32.2, 30.
 02, 29.99, 29.8, 29.6, 29.5, 29.4, 29.2, 26.2, 26.1, 25.6, 25.5, 25.31, 25.27, 25.1, 25.0, −5.
 0, −5.09, −5.11, −5.2 
HRMS (ESI+) 
 Calculated for C66H120O12Si3S (M+H)+: 1221.7887 
 Found:      1221.7853 
 
 
2.19.  A 7 mL flame-dried vial with stir bar was brought into the glovebox and charged with 
Hg(OCOCF3)2 (75 mg, 0.176 mmols) and a stir bar and removed from the glovebox. The vial 
was cooled to 0 oC under Ar. To the vial was added a solution of 2.18 in DCM (150 mg, 0.123 

















under Ar at 0 oC for 1 h. The reaction was diluted with DCM (50 mL) and transferred to a 
separatory funnel with saturated aqueous KI (50 mL). The layers were separated and the organic 
layer was washed with saturated aqueous KI (50 mL) followed by washing with H2O (50 mL). 
The organic layer was dried with MgSO4, filtered and solvent removed in vacuo. The crude 
material was adsorbed onto celite and purified by column chromatography on silica gel (100:0 " 
90:10 hexanes:EtOAc) to afford SI – 4 as a 1.4:1 mixture of α:β anomers (62.5 mg, 45%). 
TLC (90:10 hexanes:EtOAc) 
 2.19α ,  Rf =0.34, stained by PMA 
 2.19β ,  Rf = 0.19, stained by PMA 
1H NMR (500 MHz, CDCl3) 
 2.19α:  δ 6.21 (d, J = 3.5 Hz, 1H) 5.37 – 5.31 (m, 2H) 5.28 (t, J = 9.5 Hz, 1H) 5.13 (t, J = 
 10 Hz, 1H) 4.14 – 4.07 (m, 2H) 3.98 (dd, J = 2 Hz, 10 Hz, 1H) 3.84 (brs, 1H) 3.75 – 3.59 
 (m, 6H) 2.88 (d, J = 8 Hz, 1H) 2.31 (dt, J = 2.5 Hz, 8 Hz, 2H), 2.00 (q, J =10.5 Hz, 4H) 
 2.13 – 2.05 (m, 1H) 1.98 – 1.92 (m, 1H) 1.81 – 1.65 (m, 2H), 1.59 (app brs, 2H) 1.35 – 
 1.25 (m, 22H) 1.16 – 1.11 (m, 18H), 0.88 – 0.83 (m, 27H) 0.88 – 0.83 (m, 27H) 0.05 – 
 0.03 (m, 18H) 
 2.19β  :δ 5.62 (t, J = 10 Hz, 1H) 5.45 (d, J = 2.5 Hz, 1) 5.37 – 5.30 (m, 2H) 5.14 (t, J = 
 10.5 Hz, 1H) 4.78 (dt, J = 4 Hz, 9.5 Hz, 1H) 4.26 – 4.22 (m, 1H) 4.19 – 4.08 (m, 2H) 
 3.76 – 3.56 (m, 6H) 2.36 (t, J = 8 Hz, 1H), 2.04 – 1.96 (m, 4H) 1.78 – 1.69 (m, 6H) 1.69 
 – 1.57 (m, 2H) 1.35 – 1.25 (m, 22H) 1.16 – 1.11 (m, 18H) 0.88 – 0.83 (m, 27H) 0.88 – 
 0.83 (m, 3H) 0.05 – 0.03 (m, 18H) 
13C NMR (125 MHz, CDCl3) 
 2.19α: δ177.5, 176.1, 175.7, 173.4, 130.1, 129.9, 91.0, 73.2, 70.5, 70.3, 67.1, 61.7, 60.20
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 , 60.17, 59.8, 42.8, 42.6, 42.0, 41.3, 41.2, 41.1, 34.1, 32.1, 29.92, 29.89, 29.86, 29.7, 29.5,
  29.4, 29.30, 29.25, 27.4, 27.3, 26.6, 26.4, 26.21, 26.15, 26.0, 25.5, 25.2, 24.9, 24.5, 24.4, 
 22.8, 18.7, 18.5, 18.4, 14.3, −5.0, −5.16, −5.20, −5.22, −5.25, −5.4 
 2.19β:  δ 176.8, 176.5, 176.1, 173.5, 130.1, 129.9, 89.6, 72.3, 69.7, 68.0, 67.7, 61.8, 60.4,
 59.79, 59.75, 42.8, 42.0, 41.9, 41.8, 41.3, 41.2, 30.9, 34.1, 32.1, 29.93, 29.89, 29.7, 29.5, 
 29.4, 29.32, 29.26, 27.37, 27.35, 26.4, 26.2, 26.1, 26.0, 25.4, 25.3, 25.2, 25.1, 24.9, 24.2, 
 22.8, 18.7, 18.4, 18.3, 14.3, −5.08, −5.10, −5.17, −5.20, −5.23, −5.3 
HRMS (ESI+) 
 Calculated for C60H116O13Si3 (M+H)+: 1129.7802 
 Found:      1129.7784 
 
 
2.20. Compound 2.19, (105 mg, 0.093 mmols, 1.4:1 α:β) was added to a flame-dried 7 mL vial 
and azeotroped with benzene (3x1 mL). The vial was taken into the glove box and Cs2CO3 (60 
mg, 2.0 mmols) and a stir bar were added. The vial was taken out of the glove box, placed under 
Ar and DCM (1 mL) was added followed by Cl3CCN (0.2 mL, 2.0 mmols). The solution was 
stirred for 20 hours under Ar. The reaction was then loaded directly onto a silica gel column and 
purified by column chromatography (90:10 hexanes:EtOAc) to give a light yellow oil (85.5 mg, 





















1H NMR (500 MHz, CDCl3) 
 δ 8.69 (s, 0.63H) 8.57 (s, 0.37H) 6.55 (d, J = 3.5 Hz, 1H) 5.62 (t, J =10 Hz, 1H) 5.36 – 
 5.28 (m, 2H) 5.21 (t, J = 10 Hz, 1H) 5.14 (dd, J = 3.5 Hz, 10 Hz, 1H), 4.20 – 4.06 (m, 
 4H) 3.68 – 3.59 (m, 4H) 3.56 (t, J = 7 Hz, 1H), 2.30 (dt, J = 2 Hz, 8 Hz, 2H) 2.00 – 1.98 
 (m, 4H) 1.84 – 1.66 (m, 4H) 1.62 – 1.53 (m, 2H) 1.34 – 1.22 (m, 22H) 1.18 (s, 3H) 1.16 
 (s, 3H) 1.14 (brs, 6H) 1.12 (brs, 6H) 0.9 – 0.82 (m, 27H) 0.9 – 0.82 (m, 3H) 0.04 – -0.02 
 (m, 18H)  
13C NMR (125 MHz, CDCl3) 
 δ 176.6, 176.5, 176.0, 173.2, 160.6, 130.1, 129.9, 92.8, 92.7, 90.9, 70.4, 69.7, 61.5, 59.8, 
 59.7, 42.4, 42.0, 41.9, 41.8, 41.3, 41.24, 41.18, 34.1, 32.0, 29.90, 29.86, 29.7, 29.4, 29.32, 








































2.21: To a flame-dried 7 mL vial with stir bar was added astaxanthin (19.9 mg, 0.0333 mmols) 
and 2.20 (105 mg, 0.083 mmols, 1.6:1 α:β) and the vial was put under Ar. To the vial was added 
hexanes (2 mL) and 2-chloro-6-methyl pyridine buffer (1 mL, 0.082 mmols 2-chloro-6-methyl 
pyridine, 0.041 mmols 2-chloro-6-methyl pyridinium triflate). The reaction was stirred under Ar 
for 3 hours at 23 oC. The reaction was diluted with Et2O (3 mL) and poured into saturated 
NaHCO3 (50 mL). The aqueous layer was then extracted with Et2O (3x50 mL), organic layers 
combined, dried with MgSO4, filtered and solvent removed in vacuo to give a red solid. The 
crude solid was loaded onto celite and purified by column chromatography on silica gel (95:5 " 
85:15 hexanes:EtOAc) to give a red solid (53.3 mg, 57%). 
 
1H NMR (500 MHz, CDCl3) 
 δ 6.68 – 6.60 (m, 4H) 6.46 – 6.33 (m, 4H) 6.32 – 6.23 (m, 4H) 6.23 – 6.19 (m, 2H) 5.38 – 
 5.27 (m, 4H) 5.21 (d, J = 8 Hz, 1H) 5.12 (q, J = 10 Hz, 4H) 5.07 (t, J = 10.5 Hz, 2H) 5.03 
 (t, J = 8 Hz, 2H) 4.77 (d, J = 8 Hz, 2H) 4.42 (dd, J = 13, 5 Hz, 2H) 4.29 (t, J = 8 Hz, 2H) 
 4.21 – 4.15 (m, 4H) 4.09 (dd, J = 12.5, 5 Hz, 2H) 4.04 (dd, J = 12, 5.5 Hz, 2H) 3.74 – 
 3.59 (m, 18H) 3.56 (t, J = 7.5 Hz, 2H) 2.32 (q, J = 7.5 Hz, 4H) 1.99 – 1.97 (m, 20H) 1.88 
 (s, 6H) 1.82 – 1.56 (m, 12H) 1.35 – 1.24 (m, 44H) 1.24 – 1.10 (m, 36H) 0.89 – 0.83 (m, 
 60H) 0.05 – 0.00 (m, 36H) 
13C NMR (125 MHz, CDCl3) 
 δ 197.2, 195.5, 176.7, 176.6, 176.3, 176.1, 176.0, 175.9, 173.5, 173.4, 160.8, 159.6, 
 142.1, 139.7, 139.6, 136.8, 135.0, 134.9, 134.80, 134.77, 134.75, 134.0, 133.90, 133.88, 
 133.84, 133.82, 130.8, 130.13, 130.10, 129.91, 129.88, 128.8, 128.5, 124.8, 123.59, 
 123.56, 99.8, 98.9, 76.5, 72.8, 72.6, 72.4, 72.3, 72.2, 71.82, 71.77, 68.7, 68.5, 62.1, 60.1, 
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 59.9, 59.78, 59.77, 59.75, 59.73, 44.3, 43.4, 42.5, 42.4, 42.0, 41.8, 41.4, 41.3, 41.19, 
 41.17, 37.04, 36.8, 34.2, 34.1, 32.1, 30.5, 30.4, 29.92, 29.89, 29.7, 29.5, 29.38, 29.36, 
 29.30, 29.28, 27.8, 27.4, 27.0, 26.10, 26.08, 25.5, 25.41, 25.37, 25.3, 25.21, 25.18, 25.17, 
 25.05, 24.95, 24.90, 22.8, 20.9, 20.5, 18.3, 14.4, 14.3, 14.1, 13.0, 12.7, -5.10, -5.12, -5.18, 
 -5.20, -5.23 
MS (MALDI): 
 Calculated for C160H280O28Si6 (M+Na)+:  2840.899 







Chlamydaxanthin: To an oven-dried 2.5 mL Teflon vial, under Ar, was added SI – 6 (30 mg, 
0.0106 mmols) by transferring in Et2O and blowing off the Et2O under a gentle stream of Ar. 
The vial was placed under Ar, THF was added (0.75 mL) and cooled to 0 oC. To the vial was 
added the HF!py stock solution (0.75 mL, 1:5 HF:pyridine (v/v)). The vial was removed from 
the ice bath and allowed to warm to 23 oC. The reaction was stirred for 3 h under Ar. It was then 
quenched by addition to a separatory funnel with saturated NaHCO3 (50 mL) and EtOAc (50 













































organic layers were combined, dried with MgSO4, filtered and solvent removed in vacuo to give 
a crude red solid. This material was used directly in the next step without further purification. 
 The crude material was transferred to a flame-dried 7 mL vial with stir bar and DBU 
stock solution (1.5 mL, 0.40 mmols DBU, 267 mM in THF) was added. The dark red solution 
was stirred for 24 h under Ar. The reaction was then transferred to a separatory funnel with 
saturated NH4Cl (50 mL) and EtOAc (50 mL). The layers were separated and the organic layer 
was washed with NH4Cl (2x50 mL) followed by washing with brine (2x50 mL). The organic 
layer was then dried with Na2SO4, filtered and solvent removed in vacuo.  
 The crude red solid was dissolved in DMSO (1 mL), filtered through a 0.2 µM PTFE 
filter and purified by preparative HPLC to give 4.1 mg (0.00283 mmols, 27%) of a red solid.  
 
HPLC Method: 
Column: Sunfire Prep C18, 5 µm, 10 x 250 mm 
Flow Rate: 25 mL/min 
Solvent: 90:10 MeOH:acetone 
Elution Time: 13.5 min. 
1H NMR (500 MHz, CD3OD) 
 δ 6.78 – 6.69 (m, 4H) 6.54 – 6.46 (m, 4H) 6.38 – 6.28 (m, 6) 5.37 – 5.29 (m, 4H) 4.55 (d, 
 J = 5 Hz, 2H) 4.51 (dd, J = 12, 2 Hz, 2H) 4.46 (d, J = 7.5 Hz, 2H) 4.42 (dd, J = 11.5, 2 
 Hz, 2H) 4.20 (dd, J = 12, 6.5 Hz) 4.14 (dd, J = 11.5, 6.5 Hz, 2H) 3.50 – 3.44 (m, 2H) 
 3.43 – 3.38 (m, 2H) 2.37 – 2.30 (m, 4H) 2.23 (dd, J = 13, 5 Hz, 2H) 2.06 – 1.97 (m, 20H) 
 1.93 (t, J = 13.5 Hz, 2H) 1.90 (s, 6H) 1.66 – 1.56 (m, 4H) 1.36 – 1.23 (m, 52H) 0.89, (t, J 
 = 7 Hz, 6H) 
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HRMS (ESI): 
 Calculated for C88H137O16 (M+Na)+:  1471.9726 
 Found:     1471.9698  
 Calculated for C88H137O16 (M+H)+:  1449.9907 

















Acq. Operator   : JTH                          
Acq. Instrument : Instrument 1                    Location : Vial 84
Injection Date  : 11/5/2015 2:33:06 PM         
                                                Inj Volume : 100.000 µl
Acq. Method     : C:\CHEM32\1\METHODS\AGH\AGH_C--B_10MIN.M
Last changed    : 11/5/2015 2:22:14 PM by JTH
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\HMSH_CHOLESTEROL.M
Last changed    : 2/3/2016 11:28:05 AM by JWL























































































































































































































































































































                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: DAD1 A, Sig=478,4 Ref=off
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.711 BB    0.1363 1314.82092  134.21048  87.6243
   2  11.055 BB    0.1673   26.22366    2.19655   1.7476
   3  11.427 BB    0.2560  159.47705    9.30426  10.6281
 
Totals :                  1500.52163  145.71129
 
 
Data File C:\CHEM32\1\DATA\AGH\AGH 2015\AGH_120C_PREP-HPLC-6.D
Sample Name: AGH_120C_prep-HPLC-6.D
















 CHAPTER 3 
 
PERIDININ IS A POTENT AND MEMBRANE-EMBEDDED INHIBITOR OF 
 BILAYER LIPID PEROXIDATION 
 
Adam G. Hill, Hannah M. S. Haley, Alexander I. Greenwood, Eric M. Woerly, 
Chad M. Rienstra and Martin D. Burke 
 
Antilipoperoxidant protein dysfunction is associated with many human diseases, 
suggesting that bilayer lipid peroxidation may contribute broadly to pathogenesis. Small 
molecule inhibitors of this membrane-localized chemistry could in theory promote better 
understanding and/or treatment of such diseases, but currently available compounds have 
important limitations and clinical trials have repeatedly shown neutral or even adverse effects of 
antilipoperoxidant supplementation. Enabled by efficient, modular syntheses of natural products 
produced by microorganisms that thrive in environments of extreme oxidative stress, we found 
that the atypical carotenoid peridinin is an exceptionally potent inhibitor of non-enzymatic 
bilayer lipid peroxidation. SSNMR experiments with a synthesized isotopologue further linked 
this potency to heightened effective molarity within the lipid bilayer. That is, in contrast to the 
primarily extramembranous localization of the widely used but much less potent 
antilipoperoxidant astaxanthin, peridinin is completely embedded within and physically spans 
the hydrophobic core of POPC membranes, maximizing its concentration at the site of the 
targeted lipid peroxidation reactions.  
 Portion of this chapter were adapted from Hannah M. S. Haley,* Adam G. Hill,* Alex 
Greenwood, Eric M. Woerly, Chad M. Rienstra, and Martin D. Burke Manuscript in Preparation 
(*these authors contributed equally to this work). Adam Hill and Hannah Haley developed and 
performed the biophysical and cellular assays and synthesized 13C labeled carotenoids. 
Preliminary results for peridinin antilipoperoxidant activity were obtained by Eric Woerly. Alex 
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Greenwood performed and analyzed the SSNMR experiments. The experiments in this chapter 
were designed by Adam G. Hill, Hannah M. S. Haley, Alexander I. Greenwood, Chad M. 
Rienstra and Martin D. Burke. 
 
3 – 1 ANTILIPOPEROXIDANT ACTIVITY OF ATYPICAL CAROTENOIDS IN 
CHEMICALY DEFINED LIPOSOMES 
 The disappointing results of clinical trials applying β-carotene, α-tocopherol and 
astaxanthin for the prevention of atherosclerosis suggest either the lack of a key causative 
connection between bilayer lipid peroxidation and atherosclerosis, or a failure of these small 
molecules to potently and selectively inhibit lipid membrane oxidation (Chapter 1). Importantly, 
significant evidence for the latter hypothesis exists. Experiments have shown that β-carotene can 
act as a prolipoperoxidant under certain conditions.1 α-tocopherol has been shown to have 
significant off-target effects,2-5 as it can inhibit physiological lipid oxidation enzymes 12/15-
LOX,6-10 bind to protein kinase C and inhibit the expression of the key transcription factors AP-1 
and NF-κβ.11-14 Finally, astaxanthin has demonstrated a lack of potency, as high doses are 
required both in vitro and in vivo to exert a biologically significant effect.15-20  
 To further understand these results, we aimed to characterize the antilipoperoxidant 
activity of atypical carotenoids in chemically defined liposomes. We selected this simplified 
system to directly study a cell-free chemical reaction in which we could directly quantify the 
inhibition of lipid peroxidation. Previous work has relied on a variety of methods to measure 
antilipoperoxidant activity,21, 22 including measuring cellular redox potential by fluorescent dyes, 
most commonly BODIPY and its derivatives,23-25 measuring a mixture of electrophiles by the 
thiobarbituric acid reactive substances (TBARS) assay,26 and measuring lipid hydroperoxides 
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(LOOH) in liposomes27 and cells28 by fluorescent reducing agents. However, relatively few 
reports directly quantify the end products of lipid peroxidation as a method to measure inhibition 
of lipid peroxidation.  
  
 
Figure 3-1. (a) Mechanism of MDA formation. (b) Scheme of liposome assay. (c) CuCl2 is required to initiate lipid peroxidation 
and MDA formation. 
 
 We combined 75 mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 
25 mol% 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PUFA) and formed large 
unilamellar vesicles (LUVs) 200 nm in diameter. These PUFAs contain a small amount of 
LOOH derived from spontaneous autoxidation. Exposure of these pre-existing LOOH to CuCl2 
initiates lipid peroxidation, via oxidation of LOOH to the corresponding lipid peroxyl radical 
(LOO!), the chain-carrying species in this reaction.29-32 We choose to measure malondialdehyde 
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with thiobarbituric acid (TBA) under acidic conditions and the MDA-TBA adduct was 
specifically quantified by HPLC analysis (Fig. 3-1a,b). Consistent with the proposed 
mechanism, we observed significant formation of MDA in the presence of Cu(II) chloride over 
the course of ten hours (Fig. 3-1c). We further observed no significant MDA formation in the 
absence of Cu(II) chloride (Fig. 3-1c). Additional experiments showed that PPh3 mediated 
reduction of LOOH prevents MDA formation and that running the liposome assay in the absence 
of O2 prevents MDA formation.34 
 
Figure 3-2. β-carotene is a prolipoperoxidant as shown by increase in MDA formation over the course of 7.5 hours. Error bars 
represent std. dev.; n = 3. 
 
 We first tested the three antilipoperoxidants which have failed in clinical trials: β-
carotene, α-tocopherol and astaxanthin. Analysis of β-carotene in the liposome system confirmed 
the prolipoperoxidant activity of this carotenoid as evidenced by increased MDA formation 
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Figure 3-3. (a) Lipid protection for three atypical carotenoids and two typical antilipoperoxidants in chemically defined 
liposomes containing 75:25 POPC:PUFA. Inhibition of MDA formation (b) and PUFA consumption (c) versus time for 
astaxanthin and peridinin in chemically defined liposomes. Lipid protection = [(1-MDAcarot/MDAvehicle)*100]; error bars = SEM; 
n = 3 – 9; *p < 0.05, **p < 0.01, ***p < 0.001, NS = not significant, * = comparison to vehicle and # = comparison to 
astaxanthin. 
 
 We next tested α-tocopherol and found poor antilipoperoxidant activity in the liposome 
assay (Fig. 3-3a) with α-tocopherol activity plateauing at ~80% inhibition of lipid peroxidation 
and 6.2 mol% α-tocopherol relative to lipid. We did not observe any improvement in inhibition 
of MDA formation up to 37 mol% α-tocopherol. Finally, astaxanthin showed weak 
antilipoperoxidant activity in the liposome assay with an EC90 of 5.2 mol% astaxanthin relative 
to lipid in the model membrane assay (Figs. 3-3a).  
 We tested the antilipoperoxidant activity of the three atypical carotenoids in the same 
model membrane assay (Fig. 3-3a). Chlamydaxanthin showed no improvement relative to 












































































0.5% peridinin ** 
*** ## 
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lipid. Synechoxanthin was approximately two times more effective than astaxanthin with 1.9 
mol% relative to lipid reaching 90% inhibition of lipid peroxidation. Peridinin demonstrated 
exceptionally potent antilipoperoxidant activity. Only 0.5 mol% relative to lipid reached 90% 
inhibition of lipid peroxidation demonstrating that peridinin is an order of magnitude more 
potent than astaxanthin. Analysis of both MDA formation and PUFA consumption (Figs. 3-3b,c), 
further confirmed that while 0.5 mol% astaxanthin minimally inhibited this process over the 
course of 10 hours, 0.5 mol% peridinin was sufficient for almost complete inhibition. 
 
Figure 3-4. Inhibition of MDA formation by peridinin (20 µM, red) and astaxanthin (20 µM, blue) in HeLa cells exposed to 
FeCl
3
. Error bars = std. dev.; n = 3 
 
 Based upon the results in the model membrane assay, we choose to focus on the atypical 
carotenoid peridinin. We hypothesized that if peridinin demonstrated potent antilipoperoxidant 
activity in human cells, it could be a valuable tool to understand the role of non-enzymatic lipid 
peroxidation in human diseases. We first developed a HeLa cell assay in which exposure to 
FeCl3 induces lipid peroxidation. Lipid peroxidation was monitored by MDA formation, as 
previously described. In this experiment, 20 µM astaxanthin showed a moderate decrease in 
MDA formation while 20 µM peridinin lead to a more significant decrease in MDA formation 






















opposed to CuCl2 to initiate lipid peroxidation and using a human cell line as opposed to 
chemically defined liposomes. 
 We next developed a more physiologically relevant assay in primary human umbilical 
vein endothelial cells (HUVECs). We found that cellular stress caused by incubating HUVECs in 
serum-free basal media leads to the reproducible onset of spontaneous endogenous lipid 
peroxidation (Fig. 3-5a). This experiment represents a third method of initiation of lipid 
peroxidation. Lipid peroxidation was monitored by MDA quantification, as previously described, 
and cell counts were measured at the beginning and end of the assay to confirm differences in 
MDA were not the result of differences in cell number (Fig. 3-5b).  
 
Figure 3-5: (a) Inhibition of MDA formation by astaxanthin and peridinin in primary HUVECs over the course of 2 hours. (b) 
Cell counts for HUVECs at 0 and 120 minutes. (c) Dose-response for astaxanthin, α-tocopherol and peridinin in primary 
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 We first confirmed that peridinin showed similarly potent antilipoperoxidant activity in 
human cells. We found that 2 µM peridinin added to the media led to significant inhibition of 
lipid peroxidation whereas 2 µM astaxanthin showed no effect on MDA formation over the 
course of two hours (Fig. 3-5a). Analysis of the dose-response curve for peridinin gave an EC50 
of 140 nM (Fig. 3-5c). Astaxanthin, in contrast, gave an EC50 of >40 µM and its exact 
determination was limited by poor solubility in the DMSO vehicle (Fig. 3-5c). Interestingly, α-
tocopherol demonstrated significantly improved antilipoperoxidant activity in the cellular system 
with an EC50 of 200 nM (Fig. 3-5c). This divergence suggests that the antilipoperoxidant activity 
of α-tocopherol in vivo is primarily due to mechanisms other than direct inhibition of non-
enzymatic lipid bilayer peroxidation. This is consistent with previous studies suggesting a 
diverse range of mechanisms of action for α-tocopherol.2-5 Finally, we showed Peridinin to be an 
order of magnitude more potent than the recently reported antilipoperoxidant OH-pen35 (EC50 = 
2.6 µM, data not shown). In conclusion, peridinin has now demonstrated significant 
improvement in antilipoperoxidant activity over astaxanthin in both chemically defined 
liposomes and human cells as well in assays using three different methods for initiation of lipid 
peroxidation. 
 
3 – 2 PERIDININ IS NOT MORE EFFECTIVE IN ATTENUATING LIPID LATERAL 
DIFFUSION 
 We next aimed to understand the mechanistic underpinnings of the exceptional potency 
of peridinin in contrast to the structurally similar but much less potent carotenoid astaxanthin. 
We considered three specific hypotheses (Fig. 3-6): (i) Peridinin is more effective at slowing the 
rate of lateral lipid diffusion and thereby attenuates the propagation of lipid peroxidation. (ii) 
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Peridinin is able to more rapidly quench lipid peroxyl radicals. (iii) Peridinin is preferentially 
localized within the lipid bilayer and therefore has a higher effective molarity at the site where 
lipid peroxidation occurs.  
 
 
Figure 3-6. Three hypotheses to explain the increased potency of peridinin over astaxanthin. 
 
 The first hypothesis predicts that peridinin more effectively attenuates the rate of lipid 
lateral diffusion than astaxanthin, thereby slowing the rate of free-radical propagation of lipid 
peroxidation. This correlation has been suggested for other carotenoids36-38 and more extensively 
characterized in the context of the membrane-embedded sterol cholesterol.39-42 Magic angle 
spinning solid-state NMR (MAS-SSNMR) and solution NMR were applied to quantify the 
effects of carotenoid incorporation on lipid diffusion by measurement of lipid methylene 1H R2 
relaxation rates. The relaxation rate (R2) is dependent on the rate of lateral diffusion of the lipid 
tails as decreased motion leads to an increase in the relative rate of dipole-dipole relaxation.43 
Therefore, samples with a higher rate of relaxation have a slower rate of lipid lateral diffusion. 
 

































Figure 3-7. Lipid lateral diffusion as determined by -CH2- line width in both solid-state NMR (a) and solution phase NMR (b). 
(c) Effect of peridinin, astaxanthin and cholesterol on MDA formation in chemically defined liposomes. Error bars = SEM; n = 3; 
***p < 0.001; NS = not; * = comparison to vehicle 
 
 Liposomes containing a range of carotenoid concentrations for which antilipoperoxidant 
activity is observed (0.5-5% carotenoid relative to lipid) or cholesterol44 as a positive control 
were prepared. Increasing concentrations of peridinin, astaxanthin and cholesterol each resulted 
in similar, concentration-dependent increases in lipid R2, indicative of a decrease in the rate of 
lipid lateral diffusion. This was observed in both the solution phase NMR and solid-state NMR 
studies (Figs. 3-7a,b). Alternatively, the antilipoperoxidant activity of these three molecules 
diverged. Astaxanthin and peridinin showed substantial inhibition of lipid peroxidation at 3 
mol%, while 3 mol% cholesterol showed no inhibition of lipid peroxidation (Fig. 3-7c). A 
significantly higher concentration of cholesterol (24 mol%), which caused a significantly greater 
reduction in lateral lipid diffusion (Figs. 3-7a,b,c), was required to achieve a similar level of 
antilipoperoxidant activity (Fig. 3-7c). This divergence of concentration dependence for 
inhibition of lipid lateral diffusion and inhibition of lipid peroxidation demonstrates that the 
attenuation of lipid lateral diffusion is not the primary driver for the exceptional 
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3 – 3 PERIDININ IS NOT A MORE RAPID QUENCHER OF PEROXY RADICALS 
  The second mechanistic hypothesis suggests that peridinin is a more potent 
antilipoperoxidant than astaxanthin because it more rapidly quenches lipid peroxyl radicals, the 
chain carrying species in the propagation of lipid peroxidation (Fig. 3-6). To test this, we 
investigated two important modes of radical quenching reactivity: (i) single electron transfer 
from the carotenoid to a radical species and (ii) stoichiometric reactivity of the carotenoid with 
an oxygen-centered radical.45-49 Solution phase assays in which all species are fully soluble were 
utilized to specifically isolate carotenoid chemical reactivity from the complicating factors of 
membrane dynamics and localization.  
To probe the capacity of astaxanthin and peridinin to perform single electron transfer, we 
utilized a decolorization assay based on electron donation to the preformed radical cation derived 
from oxidation of 2,2’-azino-bis(3-ethylbenzothioazoline-6-sulfonic acid) (ABTS).50 Both 
astaxanthin and peridinin were able to rapidly perform single electron donation, as indicated by 
loss of the ABTS!+ signal upon carotenoid addition.  Surprisingly, we observed a faster rate of 
electron transfer from astaxanthin. The half-life of ABTS!+ was 2.3 ± 0.1 minutes with 
astaxanthin and 8.3 ± 0.1 minutes with peridinin (Fig. 3-8a).  
 
Figure 3-8. (a) Ability of peridinin and astaxanthin to donate an electron to the stable ABTS radical cation. (b) Carotenoid 
consumption in the presence of 1 equiv. tBuOOH and 1 equiv. CuCl
2
 in separate solution phase experiments. (c) Carotenoid 
consumption when peridinin and astaxanthin are co-incorporated in the same solution phase experiment with 1 equiv. each of 
peridinin, astaxanthin, tBuOOH and CuCl
2





































































 We then probed the stoichiometric reactivity of astaxanthin and peridinin towards 
oxygen-centered radical species. To mirror the conditions of the liposome-based lipid 
peroxidation assay, we assessed the stability of each carotenoid in solution with tert-butyl 
hydroperoxide and the initiator CuCl2. Remarkably, whereas astaxanthin was fully consumed 
over the course of 2 hours, peridinin underwent limited degradation under the same conditions 
(Fig. 3-8b). These data are consistent with a much faster rate of self-destructive peroxyl radical 
quenching for astaxanthin.  
We hypothesized that peridinin may undergo a non-destructive electron shuttle 
mechanism of quenching lipid peroxidation. In this mechanism, peridinin would donate an 
electron to a radical thereby forming the corresponding anion and peridinin radical cation. The 
relatively stable peridinin radical cation could now accept an electron from an appropriate 
reductant, such as Cu(I) formed in this assay, thereby reforming ground state peridinin and 
inhibiting propagation of lipid peroxidation (see chapter 1 – 5). To probe this hypothesis, we 
performed a co-incorporation assay in which peridinin and astaxanthin were combined in the 
tBuOOH solution phase assay. The inclusion of peridinin protected astaxanthin from 
decomposition and significantly decreased the rate of astaxanthin consumption (Fig. 3-8c). 
Collectively, these experiments are consistent with the hypothesis that astaxanthin exerts 
antilipoperoxidant activity via both self-consumptive and potentially self-preserving electron 
transfer mechanisms, while peridinin quenches radicals primarily via a non-self-destructive 
single-electron transfer mechanism. 
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Figure 3-9. (a) MDA formation and (b) carotenoid consumption in chemically defined liposomes containing either astaxanthin 
alone, peridinin alone, or co-incorporated astaxanthin and peridinin in the same liposomes. Error bars = std. dev.; n = 3. 
 
 Additional experiments in the model liposome assay revealed that peridinin is only 
minimally consumed as it protects against lipid peroxidation (Fig. 3-9a). Peridinin protects 
astaxanthin from consumption upon co-incorporation in the liposome assay (Fig. 3-9b) as was 
previously observed in the solution phase stoichiometric reactivity assay. Collectively, these 
results are consistent with peridinin undergoing a primarily non-destructive mechanism of 
radical quenching involving electron transfer from peridinin to the lipid peroxy radical. In 
conclusion, these results disprove the second hypothesis that peridinin has a faster inherent rate 
of reactivity than astaxanthin. Additionally, they suggest that a catalytic electron transfer 
mechanism of radical quenching may contribute to its potent antilipoperoxidant activity. 
 
3 – 4 PERIDININ HAS A HIGHER EFFECTIVE MOLARITY IN LIPID BILAYERS 
The third mechanistic hypothesis predicts that relative to astaxanthin peridinin has an 
increased propensity to insert into the hydrophobic core of lipid bilayers, thereby increasing its 
effective molarity at the site necessary to promote antilipoperoxidant activity. Interrogating this 
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angstrom-level resolution. Making these determinations is challenging due to limited high-
resolution methods for characterizing small molecule-membrane interactions.  
Previous studies of astaxanthin provide contradictory conclusions regarding the 
localization and aggregation behavior of this carotenoid.51, 52 Linear dichroism,53 UV-visible 
absorbance spectroscopy,54 differential scanning calorimetry55, computational modeling56 and X-
ray diffraction38 of lipid bilayers have been utilized to support a model of intramembranous 
localization, however these methods are limited in the resolution necessary to precisely 
determine the location of a small molecule relative to lipid bilayers. The aggregation behavior of 
peridinin in the presence of lipid bilayers has to the best of our knowledge not been previously 
studied. 
We thus applied a paramagnetic relaxation enhancement (PRE)-based MAS SSNMR 
experiment57-61 recently extended in collaboration with the Rienstra group62 to characterize small 
molecule-membrane interactions with exceptional levels of spatial resolution (Fig. 3-10). 
 
Figure 3-10. PRE experiment to determine carotenoid localization utilizing 16-DOXYL-PC (red spheres) and 
13
C labeled 
carotenoids (green spheres). 
 
In this experiment, the PRE of a 13C nuclei proximal to a lipid-appended stable radical 
spin label, such as 4,4-dimethyloxazolidine-N-oxyl (DOXYL), can be quantified by measuring 
the longitudinal relaxation rate (R1 = 1/T1) of the 13C nuclei. This PRE effect can be detected for 
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distances up to ~20 Å and allows for direct measurement of the intramembranous carotenoid 
population.  
This experiment required access to highly 13C-enriched astaxanthin and peridinin. 
Uniformly 13C-enriched astaxanthin was produced via biosynthesis utilizing the red yeast X. 
dendrorhous strain UBV-AX263 with fully 13C-labeled glucose as the primary carbon source. 
Optimization of media composition, fermentation time and light conditions yielded 65% 13C 
incorporation and represents the first known report of 13C-astaxanthin (Fig. 3-11).  
 
Figure 3-11. Biosynthesis of astaxanthin utilizing 13C labeled glucose and the astaxanthin over-producing yeast X. dendrorhous. 
 
Due to the challenges associated with the production and isolation of peridinin from its 
producing organism, this compound is not amenable to a biosynthetic strategy for isotopologue 
generation.64, 65 However, given the inherent efficiency and flexibility of our MIDA boronate 
building block-based total synthesis, we were in the unique position to access site-specifically 
13C-labeled derivatives simply by incorporating the corresponding site-selectively labeled 
building blocks (BBs) into our synthetic route. As representative positions spanning the polyene 
core and having resolved carbon signals in the 13C spectrum, we selected the C7 and C7’, 
polyene carbons near the terminal rings contained in BB1 and BB4, and C15, and C15’ carbons at 





























 The synthesis of 13C labeled BB1 and BB4 (Fig. 3-12) utilized >99% 13C enriched 
paraformaldehyde which was reacted with vinyl lithium species 3.1 to give the 13C labeled 
alcohol 3.2. Sharpless asymmetric epoxidation gave 3.3 in 7:1 dr and 94% yield. 66 Installation of 
the requisite alkyne commenced with alcohol oxidation to the aldehyde followed by Colvin 
rearrangement to give 3.5.67 This compound gave rise to both 13C labeled BB1 and BB4. 13C 
labeled BB1 was synthesized by cyclohexyl borane catalyzed hydroboration68 to give the vinyl 
pin-ester followed by transesterification with free MIDA ligand to give 13C labeled BB1. 
Synthesis of BB4 began by TBAF mediated TBS deprotection followed by Cu mediated alkyne-
epoxy rearrangement to give the desired iodoallene 3.8. 13C labeled BB4 was completed by 
































































































The synthesis of 13C labeled BB3 (Fig. 3-13) utilized >99% 13C enriched TMS-acetylene 
which after lithiation and trapping with triethylgermanium chloride gave 3.10. Removal of the 
TMS group followed by hydrostannylation gave the bis-metalated olefin 3.11. This compound 
underwent a selective stille coupling with the MIDA boronate protected diene 3.1269 to yield the 
germanium protected triene 3.13. 13C BB3 was stored as the germanium species (3.13) and 
underwent a stereospecific iodo-degermylation to reveal 13C labeled BB3 immediately prior to 
cross-coupling with the requisite 13C labeled peridinin fragment.  
 


































































1) NaOH, THF, 95%
2) 13C BB3, PdCl2(PPh3)2
Ag2O, DMSO, 39%













































Iterative building block assembly to afford 13C labeled peridinin (Fig. 3-14) began with 
the hydrolysis of 13C-labeled BB1 and cross-coupling to natural abundance BB2 to afford 
tetraenyl MIDA boronate 3.14. MIDA deprotection via transesterification to the corresponding 
pinacol boronic ester and coupling to 13C-labeled BB3 yielded heptaene 3.15. In situ MIDA 
hydrolysis to the heptaenyl boronic acid and coupling to 13C-labeled allenyl halide BB4 yielded 
protected peridinin (3.16). Global desilylation utilizing buffered HF!pyridine yielded C7, C7’, 
C15, C15’ 13C-labeled peridinin (13C-peridinin).  
We prepared samples of 13C-astaxanthin in POPC bilayers (MLVs) and used a series of 
13C chemical shift correlation experiments (including 2D 13C-13C with POST-C7 mixing and 3D 
13C-13C-13C with SPC7 and DARR mixing in the first and second indirect dimensions) to de novo 
assign the 13C resonances of astaxanthin (data now shown). The 13C-astaxanthin samples showed 
a mixture of a major and a minor state (Fig. 3-15a). A second group of samples were prepared 
with 13C-peridinin in POPC bilayers (MLVs), and we assigned 13C resonances from the 
corresponding solution phase 13C shifts. The 13C-peridinin samples showed only a single set of 




Figure 3-15. Representative DARR NMR spectra for astaxanthin (a) and peridinin (b). Dark blue peaks represent major 
astaxanthin population, light blue peaks represent minor astaxanthin population and red peaks represent the single peridinin 
population. 
 
PRE measurements were performed for a POPC only control, the 13C-astaxanthin-POPC 
sample, and the 13C-peridinin-POPC sample in the presence of 5 mol% 16-DOXYL-PC. 
Measurement of the PRE effect in the POPC carbons shows a maximum value on carbons 16 and 
17 and a steady decrease in PRE value for carbons approaching the phosphatidylcholine head 
group, consistent with a well-formed membrane in all samples where the 16-DOXYL spin label 






Figure 3-16. PRE values for POPC carbons in the MLVs containing 5 mol% 16-DOXYL-PC and requisite 13C labeled 
carotenoid (black = POPC only; blue = 4 mol% astaxanthin; red = 4 mol% peridinin). Samples were 25:1 POPC:carotenoid. Error 
bars = std. error. 
Analysis of the T1 relaxation curves for astaxanthin carbons 1-4 in the 13C-astaxanthin 
sample yielded a two component fit, with the major component corresponding to 78 ± 2% and a 
minor component corresponding to 22 ± 2% of the total signal (Fig. 3-17a). The major 
astaxanthin population exhibited no observable PRE effect, while the minor astaxanthin 
population exhibited a significant PRE effect (Fig. 3-17b). Thus, the majority of astaxanthin 
resides outside the hydrophobic core of the lipid bilayer. When we alternatively analyzed the 
13C-peridinin sample, we observed a large PRE effect for all four labeled carbons (Fig. 3-17c). 
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Figure 3-17. PRE results for the major (dark blue) and minor (light blue) populations of astaxanthin (b) and the single population 
of peridinin (c). Error bars = SEM 
 
 We also noted in the 13C-peridinin sample containing the 16-DOXYL spin label that 
carbons 15 and 15’ of peridinin showed a much larger PRE effect (8-10 s-1) than the 7 and 7’ 
carbons (3-4 s-1). This suggested that peridinin might be oriented parallel to the bilayer normal 
and thus span the hydrophobic core (Fig. 3-18a). Spin-diffusion experiments provided a second 
line of evidence in support of such an orientation. Specifically, strong water-peridinin and lipid-
peridinin correlations were observed for the 7 and 7’ carbons, but only lipid-peridinin 
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Figure 3-18. (a) Peridinin spin diffusion data from water and POPC to the 15, 15’, 7 and 7’ carbons. (b) Schematic showing the 
proposed localization of peridinin within the lipid bilayer and DOXYL-PC label locations. (c) PRE effect from [7,7’,15,15’]-13C 
peridinin to the 5-, 7-, 10, 12-, 14- and 16-DOXYL PC spin labels. Error bars = SEM. 
 
 To further probe this putative orientation of peridinin in the bilayer, we performed a 
series of PRE experiments employing different PC lipids bearing DOXYL spin labels on carbons 
5, 7, 10, 12, 14 and 16 (Fig. 3-18c).  The relative magnitude of PRE observed for carbons 7 and 
15 across this series of experiments confirmed that peridinin is oriented parallel to the bilayer 
normal (Fig. 3-18c). Specifically, for 5-DOXYL-PC and 7-DOXYL-PC probes, a significantly 
larger PRE was observed for C7 relative to C15. The exact opposite was observed for the 14-
DOXYL-PC and 16-DOXYL-PC lipids, and a transition between these two extremes was 
observed with the intervening 10-DOXY-PC and 12-DOXYL-PC probes.  
 
3 – 5 SUMMARY AND CONCLUSIONS 
We have shown that peridinin is a potent inhibitor of lipid peroxidation in both 
chemically defined liposomes and primary human endothelial cells. The increased potency of 
a. 
















































































































































































































peridinin over astaxanthin cannot be attributed to either a greater inhibition of lipid lateral 
diffusion or an increased inherent rate of radical quenching. We have found that in contrast to the 
primarily extramembranous localization of astaxanthin, peridinin is fully embedded in the lipid 
bilayers and spans the hydrophobic core of the lipid bilayer. We conclude that the corresponding 
maximization of effective molarity at the site of the targeted hydrocarbon oxidation chemistry is 
responsible for the exceptional capacity for peridinin to act as a potent inhibitor of non-
enzymatic bilayer lipid peroxidation. Finally, peridinin is minimally consumed upon exposure to 
peroxy radicals both in solution and in liposomes. These results are consistent peridinin primarily 
quenching peroxy radicals via a non-destructive electron shuttle type mechanism. These 
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Materials. Commercially available materials were purchased from Sigma-Aldrich, Alfa-Aesar, 
Avanti Polar Lipids, Cambridge Isotope Laboratories, TCI America, Fisher Scientific, Lonza, 
ATCC, Corning, or Gibco and were used without further purification unless stated otherwise. 
Natural abundance astaxanthin was a gift from BASF. Peridinin was synthesized as reported by 
Woerly and coworkers.1 Synechoxanthin was synthesized as reported by Fujii and coworkers.2 
Unless stated otherwise, all of the solvents were dispensed from a solvent purification system 
that passes solvents through packed columns according to the method described by Pangborn and 
coworkers (THF, Et2O, CH3CN, CH2Cl2: dry neutral alumina; hexanes, toluene: dry neutral 
alumina and Q5 reactant; DMSO, DMF, CH3OH: activated molecular sieves).3 Triethylamine, 
diisopropylamine, pyridine, and 2,6-lutidine were freshly distilled under an atmosphere of 
nitrogen over CaH2. Water was dispensed from a MilliQ water purification system (Millipore 
Corporation) unless stated otherwise. All lipids were purchased from Avanti Polar Lipids as 25 
mg/mL or 10 mg/mL solutions in CHCl3, were stored at -20 oC under an atmosphere of dry 
argon, and were used within 1 month of opening. The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (16:0-18:1 PC, POPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine 
(18:0-20:4 PC, PUFA) and 1-palmitoyl-2-stearoyl-(X-DOXYL)-sn-glycero-3-phosphocholine 
(X-DOXYL-PC, where X = 5, 7, 10, 12, 14, 16) were used.  
 
General experimental procedures. Unless noted, all reactions were performed in flame dried 
round bottom flasks, Schlenk flasks fitted with rubber septa, or glass vials under a positive 
pressure of argon or nitrogen. Organic solutions were concentrated via rotary evaporation under 
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reduced pressure with a bath temperature of 35-40 °C. Reactions were monitored by analytical 
thin layer chromatography (TLC) performed using the indicated solvent on E. Merck silica gel 
60 F254 plates (0.25mm). Compounds were visualized by exposure to a UV lamp (λ = 254 nm) 
and/or a solution of stain (KMnO4, CAM = ceric ammonium molybdate or PMA = 
phosphomolybdic acid) followed by brief heating using a Varitemp heat gun. Column 
chromatography was performed using standard methods4 or on a TeledyneIsco CombiFlash Rf 
purification system using Merck silica gel grade 9385 60Å (230-400 mesh). Unless otherwise 
noted, compounds were adsorbed onto non acid-washed Celite in vacuo which was then loaded 
on top of a silica gel column or into a CombiFlash cartridge. 1H NMR spectra were recorded at 
23 °C on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity 
Inova 500NB, Varian VXR 500. Chemical shifts (δ) are reported in parts per million (ppm) 
downfield from tetramethylsilane and referenced to residual protium in the NMR solvent 
(CHCl3, δ = 7.26; acetone-d6, δ = 2.05, center line). Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration. 13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500. Chemical shifts (δ) are reported in ppm downfield from 
tetramethylsilane and referenced to carbon resonances in the NMR solvent (CDCl3, δ = 77.0, 
center line; acetone-d6, δ = 29.80, center line) or to added tetramethylsilane (δ = 0.00). Carbons 
bearing boron substituents were typically not observed (quadrupolar relaxation). High resolution 
mass spectra (HRMS) were performed by Furong Sun, Haijun Yao and Kevin Tucker at the 
University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory. UV-Vis 
analyses were performed on a Shimadzu PharmaSpec UV-1700 spectrophotometer or a BioTek 
Synergy H1 Hybrid Reader. 
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HPLC Purification and analysis. Preparative-scale HPLC purification was performed using an 
Agilent 1260 series instrument equipped with a multiple wavelength detector and a Waters 
SunFire Prep C18 OBD 5 µm 30 × 150 mm column at a flow rate of 25 ml/min. Semi-
preparative scale HPLC purification was performed using an Agilent 1200 series instrument and 
a Waters SunFire Prep C18, 5 µm, 10 x 250 mm. All analytical HPLC analysis was performed 
using an Agilent 1200 series instrument equipped with a variable wavelength detector and 
analytical Agilent Eclipse XDB-C18, 5 µm, 4.6 x 150 mm column. All HPLC solvents were 
filtered through 0.2-µm Millipore filters before use.  
 
HPLC methods. The methods below were used for small molecule analysis by analytical HPLC.   
Astaxanthin - Isocratic 90:10 MeOH:H2O, detect at 478 nm, 2 mL/min, tR ~ 5.7 min 
Peridinin - Isocratic 90:10 MeOH:H2O, detect at 468 nm, 2 mL/min, tR ~ 1.9 min 
Chlamydaxanthin - Isocratic 85:15 MeOH:acetone, detect at 478 nm, 2 mL/min, tR ~ 6.1 min  
Synechoxanthin - 70:30 MeOH:25 mM NH4OAc to100 MeOH over 10 min, detect at 478 nm,  
1.75 mL/min, tR ~ 6.2 min 
α-Tocopherol - Isocratic 90:10 MeCN:MeOH, detect at 208 nm, 2 mL/min, tR ~ 10.8 min 
Cholesterol - Isocratic 90:10 MeCN:MeOH, detect at 212 nm, 2 mL/min, tR ~ 13 min 
MDA-TBA adduct - Isocratic 67:20:13 MeCN:MeOH:50mM KH2PO4, detect at 533 nm, 1.5 






I. ASSAY PROCEDURES 
Preparation of small molecule solutions. Solutions of the small molecules were prepared in the 
indicated solvents directly prior to use. Peridinin was dissolved in THF at a concentration of 3.8 
or 5.5 mg/mL. Astaxanthin was dissolved in THF at a concentration of 3.8 or 7.7 mg/mL. 
Synechoxanthin was prepared in 5% NEt3 in DMSO at a concentration of 5.1 mg/mL. 
Chlamydaxanthin was prepared in THF at a concentration of 2.9 mg/mL. β-Carotene was 
dissolved in THF at a concentration of 13.4 mg/mL. Cholesterol (recrystallized from EtOH) was 
prepared in deacidified CHCl3 (passed through plug of basic alumina) at a concentration of 5.25 
mg/mL. α-tocopherol was prepared in deacidified CHCl3 (passed through plug of basic alumina) 
at a concentration of 1.5, 4.5, or 22.4 mg/mL.  
 
Preparation of Large Unilamellar Vesicles (LUVs). For α-tocopherol and cholesterol containing 
LUVs, a solution of the small molecule was added to the lipid solution prior to liposome 
formation. For peridinin, astaxanthin, synechoxanthin, chlamydaxanthin (note exceptions), and 
β-carotene containing LUVs, the carotenoid was added directly following liposome formation.5 
To 12x75 mm test tubes was added 150 ml POPC and 50 ml PUFA via Hamilton syringe. 
For alpha-tocopherol, cholesterol, and chlamydaxanthin (3.4, 4.2, and 6.8% incorporation only) 
containing liposomes, small molecule solution (2-180 mL) was added to the lipid solution. The 
CHCl3 was removed under a gentle stream of nitrogen and the resulting lipid film was stored 
under high vacuum for at least 4 hours prior to use to remove any residual solvent.  
The lipid film was hydrated with 300 ml 150 mM KCl/0.5 mM HEPES pH 7.4 aqueous 
buffer (K buffer) and vortexed vigorously for approximately 2 minutes (until the film was fully 
removed from the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs). 
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The resulting lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe 
was placed in an Avanti Polar Lipids Mini-Extruder with a second collection syringe on the 
opposite side. The lipid solution was then passed through a 0.20 µm Whatman polycarbonate 
filter (supported on both sides by a 10 mm Whatman drain disk) 21 times. The resulting LUV 
suspension was collected in the syringe that did not contain the original suspension of MLVs to 
prevent the carryover of MLVs into the LUV solution. All LUV suspensions were added to 
separate clean 12x75 mm test tubes.   
For peridinin, astaxanthin, synechoxanthin, chlamydaxanthin (0.1-2.6, 3.6% 
incorporations), and β-carotene containing liposomes, carotenoid solution (2-100 µL) was added 
dropwise to a gently vortexing suspension of LUVs under a stream of nitrogen. For the control, 
vehicle was added to a suspension of LUVs in the same manner (volume of vehicle added was 
equivalent to the largest volume used for carotenoid delivery for a given set of liposomes).  
    LUVs were purified by gel size exclusion chromatography with a Sephadex G50-150 
(Sigma-Aldrich) column (1 cm column, 1.0 g unswelled resin, resin swelled with K buffer, 
eluted with K buffer). Purified LUVs were collected in 13x100 mm test tubes, transferred to 20 
mL vials with a syringe for volume determination, and analyzed for total phosphorous 
concentration.  
 
Determination of Phosphorous Content. Determination of total phosphorus was adapted from the 
report of Chen and coworkers.6 10 µL aliquots of the purified LUV suspension were added to 7 
mL vials. To each vial and a vial containing no lipids that was used as a blank, was added 450 
µL of 8.9 M H2SO4 (Fisher Chemical). The four samples were incubated open to ambient 
atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 23 °C and 
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cooled for 5 minutes. After cooling, 150 µL of 30% w/v aqueous hydrogen peroxide (Fisher 
Chemical) was added to each sample, and the vials were returned to the 225 °C heating block for 
30 minutes. The samples were then removed to 23 °C and cooled for 5 minutes before the 
addition of 4 mL water. Then 500 µL of 2.5% w/v ammonium molybdate (Sigma-Aldrich) was 
added to each vial and the resulting mixtures were then vortexed briefly and vigorously. 
Subsequently, 500 µL of 10% w/v ascorbic acid (Sigma-Aldrich or Fisher Chemical) was added 
to each vial and the resulting mixtures were then vortexed briefly and vigorously. The vials were 
capped with a PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 
minutes. The samples were removed to 23 °C and cooled for approximately 15 minutes prior to 
analysis by UV/Vis spectroscopy (UV-Vis or plate reader). Total phosphorus concentration was 
determined by observing the absorbance at 820 nm and comparing this value to a standard curve 
obtained through this method and a phosphorus standard solution (0.65 mM phosphorous as 
KH2PO4, Sigma-Aldrich). LUVs were diluted with K buffer to a final concentration of 1 mM 
total phosphorous, which is equivalent to 1 mM lipid. An aliquot of LUV suspension was 
removed for analysis of small molecule concentration, and the LUVs were stored under N2 
overnight at 4 °C.   
 
Determination of Small Molecule Concentration in LUVs. To HPLC vials were added 100 mL of 
1 mM LUV suspension and 200 mL of 4:1:1 acetone:MeOH:0.2M BHT in EtOH or DMSO. The 
mixtures were vortexed to give clear solutions. The samples were analyzed by analytical HPLC 
(75 or 100 µL injections, see methods above) and the small molecule concentration was 
determined by comparing the peak area to standard curves prepared from small molecule 
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solutions of known concentrations. Small molecule content was reported as mol% relative to 
total lipid concentration.  
 
MDA-TBA Lipid Peroxidation Time Course Assay. Assay was adapted from Rengel and 
coworkers.5 To 7 mL vials was added 1 mL of the 1 mM LUV suspension.  To each sample was 
added 10 µL of 11 mM CuCl2 (Sigma-Aldrich) in DI H2O.  The vials were capped with a PTFE 
lined cap, gently inverted 5-10x to mix, and incubated in a 37 oC aluminum heating block. At 2.5 
hour intervals for 10 hours (including an initial timepoint directly following CuCl2 addition), the 
vials were gently inverted 3x to mix the suspensions an aliquot was removed from each sample 
and analyzed for MDA content. A 100 µL aliquot was removed from each liposome sample to a 
1.5 mL HPLC vial containing 500 µL of TBA solution (0.4% w/v thiobarbituric acid in 0.1 M 
NaOAc, pH 3.5).  The vials were capped and incubated in a 100 oC aluminum heating block for 
15 minutes.  The samples were removed to 23 oC and cooled for approximately 10 min to 23 oC 
prior to MDA-TBA adduct quantification by HPLC (75 µL injection, see method above). For 
experiments in which carotenoid consumption was concomitantly analyzed, a second aliquot was 
removed from each sample and assayed for small molecule concentration as described above. 
 
Lipid Protection Assay in Liposomes. LUVs containing increasing concentrations of the small 
molecules (astaxanthin, peridinin, synechoxanthin, chlamydaxanthin, and alpha-tocopherol) were 
prepared as described above and subjected to the lipid peroxidation assay. At 2.5 hour intervals, 
the vials were inverted 3x and opened to atmosphere for approximately 10 seconds to simulate 
the experimental conditions for the time course assay. After 10 hours, a 100 µL aliquot was 
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removed from each sample for TBA analysis as described above. The percent protection afforded 
by the small molecule relative to a vehicle control run concurrently was calculated as follows: 
 
The compiled data set for each small molecule was plotted as % incorporation vs. % protection 
and fit in OriginPro using the Exponential function (y = y0 + AeR0x). This function was solved 
for x at y=90 to determine the % incorporation necessary for 90% protection from lipid 
oxidation. Standard error in the fit was propagated to determine standard error in the 90% 
protection value.  
 
PUFA Consumption Assay. LUVs containing astaxanthin and peridinin were prepared as 
described above and subjected to the lipid peroxidation assay. Following CuCl2 addition and 
every 2.5 hours thereafter for 10 hours, 100 mL aliquots of liposome suspension were removed 
to 7 mL vials containing 1.5 mL MeOH and 300 uL 20% v/v HCl in MeOH. Vials were capped 
with PTFE lined caps and heated in a 100 oC aluminum heating block for 45 min. The samples 
were removed to 23 oC and cooled for approximately 10 min prior to the addition of 1 mL brine 
and 1 mL hexanes. The vials were vortexed briefly and vigorously and the hexanes layer 
containing the resulting lipid methyl esters was removed to 7 mL vials. The aqueous layer was 
extracted with hexanes (2 x 1 mL). The combined organic layers were concentrated in a 
lyophilizer jar in vacuo for 45 min to remove all hexanes, redissolved in 300 µL decane, and 
analyzed by GC (7890A Series, Agilent Technologies). The PUFA peak (methyl arachidonate) 
was confirmed via comparison to the known compound (Sigma, catalog number A9298). PUFA 
remaining at each time point was calculated as a percent relative to PUFA at t=0 for the same 
sample. 
% protection = 100− peak area of carotenoid sample









GC Method: Agilent HP-5 capillary column, 2 µL injection, 2:1 split, 250 oC inlet 
temperature, 6 mL/min flow  
Oven program: 170 oC initial temperature, 20 oC/min ramp to 210 oC, 0.5 min hold, 25 
oC/min ramp to 275 oC, 0.5 min hold.     
 
Solution NMR Lipid Diffusion Assay. LUVs containing increasing concentrations of the small 
molecules (astaxanthin, peridinin, and cholesterol) were prepared as described above with the 
following modifications. The lipid films were hydrated with D2O (99.9 atom % D, Sigma-
Aldrich or Cambridge Isotope Laboratories). Sephadex was hydrated and the column eluted with 
D2O. Only the most concentrated 10-14 drops of purified LUV solution were collected from the 
Sephadex size exclusion column (concentrated solution desired for maximized NMR signal). 
Following determination of total phosphorous content as described above, liposomes were 
diluted to a uniform concentration of 3.8 mM with D2O and added to NMR tubes for immediate 
analysis. Experiments were performed at 37 °C using a 750 MHz Varian NMR System Narrow 
Bore spectrometer.  
For each sample, a 1H spectra was recorded and T1 and T2 values were measured for the 
lipid methylene (-CH2) signal. T1 values were measured using standard T1 inversion recovery 
pulse sequence. T2 values were measured using a Carr-Purcell Meiboom-Gill T2 measurement. 
The following big tau (bτ) array was used: bτ = 0.0025, 0.005, 0.01, 0.015, 0.02, 0.03, 0.04, 0.06, 
0.08, 0.1, 0.15, 0.2. After NMR analysis, LUV suspensions were diluted to 1 mM lipid with 
water and analyzed for small molecule concentration as described above. 
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ABTS!+ Electron Transfer Assay. Assay was adapted from Re and co-workers.7 Solutions of 10 
mM 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (Sigma-
Aldrich) and 4 mM potassium persulfate (Sigma-Aldrich) were prepared in MilliQ water. These 
solutions were mixed in equal volume, resulting in concentrations of 5 mM ABTS and 2 mM 
potassium persulfate. ABTS and potassium persulfate react with a stoichiometry of 2:1, therefore 
this results in incomplete oxidation of ABTS to ABTS!+. This solution was allowed to react 
protected from light for 12-17 hours prior to use.  
An aliquot of the ABTS!+ solution was diluted with ethanol to an absorbance of 0.7±0.02 
at 734 nm (typical dilution was 50 µL ABTS!+ into 4 mL ethanol). The concentration of ABTS!+ 
was calculated utilizing the extinction coefficient 1.6 x104 L mol-1 cm-1.7  
Solutions of astaxanthin and peridinin were prepared in dichloromethane, each at an 
approximate concentration of 2 mM. The resulting carotenoid concentration was quantified by 
HPLC analysis (diluted aliquot of carotenoid solution in DMSO for analysis) and diluted to a 
final concentration of 1.1 mM. The analytical HPLC methods described in General Experimental 
Procedures were utilized. This is the concentration necessary to deliver 1 equivalent carotenoid 
relative to ABTS!+ when 20 µL carotenoid solution is added to 500 µL ABTS!+. 
The UV-Vis (Shimadzu PharmaSpec UV-1700) was baselined at 734 nm. To a quartz 
cuvette fitted with a stopper was added 500 µL ABTS!+ and the absorbance at 734 nm was 
recorded for 30-35 seconds. The cuvette was removed from instrument, a 20 µL aliquot of 
carotenoid solution was added and mixed thoroughly by bubbling air through solution with a 
glass pipette, and the cuvette was replaced in the spectrometer to continue absorbance readings 
for 1 hour. For the vehicle control, a 20 µL aliquot of dichloromethane was added in place of the 
carotenoid solution. 
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Data points were plotted every 60 seconds from t=30-3570 seconds, normalizing time to 
t=0. Data were fit in OriginPro using the exponential function ExpDec1 (y = y0 + Ae-x/t), where 
output “tau” is the half life (tau = t*ln(2)). For statistical analysis, absorbance at the final 
timepoint for astaxanthin and peridinin were compared by 2-tailed homoscedastic t-test in Excel.    
 
Solution Phase Carotenoid Consumption Assay. Solutions of astaxanthin or peridinin were 
prepared at 500 µM in dichloromethane and diluted to 50 µM with ethanol. Carotenoid 
concentration was then quantified by HPLC analysis (see above for analytical HPLC method) for 
more precise determination and diluted to a final concentration of 33 µM. A solution of CuCl2 
(Sigma-Aldrich) was prepared at 0.82 mM in ethanol. A solution of tBuOOH (70 wt% in H2O, 
Sigma-Aldrich) was prepared at 413 mM in ethanol.  
To a 2 mL glass vial equipped with a stir bar was added 20 mL CuCl2 solution, 20 µL 
tBuOOH solution, and 500 µL carotenoid solution (resulting mixture contains 1 equivalent 
carotenoid, 1 equivalent CuCl2, 500 equivalents tBuOOH). Vial was vortexed to mix and placed 
in a room temperature aluminum block with stirring at 350 RPM. A 50 µL aliquot was 
immediately removed (t=0 timepoint) and worked up to quench the reaction. The aliquot was 
added to a 7 mL vial containing 3 mL EDTA/HEPES buffer (5.5 mM EDTA tetrasodium salt 
hydrate/10 mM HEPES in half-saturated brine, pH adjusted to 7.0 with HCl/NaOH) and 1 mL 
methyl tert-butyl ether and vortexed to mix. The organic layer was transferred to a second 7 mL 
vial and the aqueous layer was extracted with methyl tert-butyl ether (2 x 1 mL). The combined 
organics were extracted with 1 mL EDTA/HEPES buffer and the layers separated. The final 
aqueous wash was extracted with methyl tert-butyl ether (2 x 0.5 mL). All organics were 
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combined. Aliquots were taken at t=0, 10, 20, 30, 45, 60, 90, and 120 minutes and worked up as 
described.  
All combined organics were concentrated in a lyophilizer jar in vacuo for 2-3 hours. Each 
sample was resuspended in 500 µl DMSO and analyzed for carotenoid content by HPLC (35 µL 
injection, methods described above.) Carotenoid remaining at each time point was calculated as a 
percent relative to carotenoid at t=0. For the controls, either the CuCl2 solution or the tBuOOH 
solution was omitted and 20 µL EtOH was added in place of the missing reagent. 
 
Cell Culture Conditions. HeLa cells were kindly donated by the Hergenrother lab at UIUC. HeLa 
cells were cultured in RPMI 1640 with 10% FBS and 50 µg/mL PEN-STREP (Corning, 30-002-
Cl). Media was changed every other day and upon confluence cells were split 1:6.  
 Primary human umbilical vein endothelial cells (HUVECs, Lonza C2517A) were 
obtained from Lonza and cultured according to manufacturer’s instructions. Briefly, cells were 
maintained in EGM-2 (Lonza CC-3162 BulletKit) comprised of EBM-2 (Lonza, CC-3156), 
EGM-2 SingleQuot Kit Suppl. & Growth Factors (CC-4176 containing FBS, hydrocortisone, 
hFGF, VEGF, R3-IGF-1, ascorbic acid, hEGF and heparin; GA-1000 aliquot was not used), 50 
µg/mL PEN-STREP (Corning, 30-002-Cl), 50 µg/mL gentamycin (Sigma-Aldrich, G1522) and 2 
µg/mL fluconazole (10 mg/mL stock in DMSO, Sigma-Aldrich, F8929). Primary HUVECs at 
passage one were received as frozen stocks and stored in liquid N2 cryo-storage. One vial from 
cryo-storage was split into three T-75 flasks with 15 mL warm media per flask. The cells were 
grown to confluence over 5 days changing media the day after seeding and every other day there 
after. The confluent cells were trypsinized (5 mL, 0.25% trypsin EDTA, Lonza 17-602E), 
quenched with 10% FBS (HI, Gibco 16000-036) in HEPES buffered saline (Lonza, CC-5024), 
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centrifuged (1500 RPM, 5 min) supernatant removed and cells resuspended in warm EGM-2. 
The cell pellet from each flask was then split 1:4 into T-75 flasks with 15 mL warm media/flask. 
The media was changed the next day and every other day there after until the cells were 
confluent on day 5. The cells were then trypsinized (5 mL, 0.25% trypsin EDTA), spun down 
(1500 RPM, 5 min) and resuspended in freezing media (10% DMSO Sigma-Aldrich, D2438, 
10% FBS and 80% EGM-2). The cells were stored at -80 oC for 24 hours and then moved into 
liquid N2 storage. Each experiment used a new cryo-vial of HUVEC cells at passage four. 
 
Preparation of Carotenoid Solutions for Cellular Assays. Fresh DMSO stock solutions of each 
small molecule (peridinin, astaxanthin, a-tocopherol and OH-pen) were prepared (1 – 2.5 mM) 
and concentrations of carotenoid solutions (peridinin and astaxanthin) were checked by HPLC 
(average of 3 runs) prior to each experiment. DMSO stock solutions were then added to EGM-2 
(0.1 – 0.5% DMSO) or basal media (0.1 – 0.5%) as required at the appropriate final 
concentration. 
 
Antilipoperoxidant Assay in HeLa Cells. Confluent HeLa cells were seeded into 24-well plates  
with 100,000 cells/well and allowed to attach overnight. The media was aspirated and RPMI 
1640 with the appropriate carotenoid solution was added to each well (1 mL/well). The cells 
were incubated with carotenoid or DMSO vehicle for 24 hours. The media was aspirated, the 
cells washed with PBS (3 x 1 mL), and RPMI 1640 with 200 µM FeCl3 and without FBS or 
antibiotics was added (0.75 mL/well). MDA was measured every 12 hours for 96 hours. 
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Antilipoperoxidant Assay in Primary HUVECs. HUVECs were taken out of cryo-storage and 
seeded into two T-75 flasks with 15 mL warm media. The media was changed the next day and 
then every other day there after until the cells were confluent on days 4 or 5. The cells were 
trypsinized (5 mL, 0.25% trypsin EDTA), trypsin quenched with 10% FBS in HEPES buffered 
saline, centrifuged (1500 RPM, 5 min), supernatant removed and cells resuspended in warm 
EGM-2. The cells were counted by hemocytometer and diluted to between 35,000 and 50,000 
cells/mL. The cells were seeded onto 24-well plates with 1 mL cell suspension per well and cells 
incubated at 37 oC. All experiments were run with 3 – 6 wells per condition per time point. The 
cells were allowed to attach for 24 – 36 hours, media aspirated and replaced with media 
containing either DMSO alone or the appropriate small molecule. HUVECs were incubated at 37 
oC for 12 hours with the appropriate small molecule. Lipid oxidation was initiated by switching 
to basal media (EBM-2, Lonza CC-3156 supplemented with hydrocortisone, hFGF, VEGF, R3-
IGF-1, hEGF and heparin from EGM-2 SingleQuot Kit Suppl. & Growth Factors; FBS, ascorbic 
acid and antibiotics were not added). HUVECs were washed (1 x 0.75 mL) with basal media. In 
the time course assay (Fig. 3 – 5a), basal media without small molecule was added to the 
HUVECs to initiate lipid peroxidation. In this assay, time points were taken every 30 minutes for 
2. Identical 24-well plates were setup in parallel to measure cell counts (see Cell Counting 
Workup). In the dose-response assay (Fig. 3 – 5c), basal media containing the appropriate small 
molecule was added to the HUVECs to initiate lipid peroxidation. In this assay, time points were 
taken at initiation of lipid peroxidation and again after 2 hours. 
 
MDA Workup. For each well, the media was transferred to a 1.7 mL eppendorf tube containing 
20 µL 0.2 M BHT in EtOH. The cells were scraped (United Biosystems, MCS-200) and the well 
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washed with the initially removed media, which was then returned to the eppendorf tube. The 
well was washed a final time with 200 mL PBS which was added to the same eppendorf. The 
media/PBS mixture in the tube was flash frozen in liquid N2 and stored at -80 oC until the end of 
the experiment. All samples from a single time point were then thawed (37 oC for 2 minutes) and 
800 mL added to an HPLC vial containing 10 mL 0.25 M trichloroacetic acid, 50 mL acetate 
buffer (pH 3.5, 2 M) and 20 mL 1 M thiobarbituric acid in DMSO. The vial was capped, 
vortexed and heated in an aluminum heat block at 100 oC for 15 minutes. The samples were 
cooled to room temperature, filtered through a 0.2 um PTFE syringe filter (Fisher, 9720002) and 
MDA-TBA adduct quantified by HPLC (100 µL injection, 67% KH2PO4, 20% MeOH, 13% 
MeCN, 1.5 mL/min isocratic, Eclipse XDB-C18, 5 mm, 4.6 x 150 mm column Agilent, 993967-
902). Lipid protection (%) was calculated as before (see Lipid Protection Assay). 
 
Cell Counting Workup. Media was aspirated, cells washed with HEPES buffered saline (500 mL) 
and trypsin (250 mL, 0.25 mg/mL with EDTA) was added. Cells were trypsinized at 37 oC for 5 
– 7 minutes. The trypsizined cell suspension was added to a BD TrucountTM Tubes (catalog # 
340334) containing trypsin neutralizing solution (300 mL, 10% FBS in HEPES buffered saline). 
Trypsin protocol was repeated and cell suspension added to the same BD TrucountTM Tube. Each 
well was then washed with trypsin neutralizing solution (2 x 300 mL, 10% FBS in HEPES 
buffered saline) with each wash being added to the same BD Trucount Tube. Cell counts were 
immediately measured on a BD LSR II Flow Cytometry Analyzer recording 3000 total bead 
events per tube.  
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Preparation of MLVs for SSNMR.8 [U-13C]-Astaxanthin or [7,7’,15,15’-13C]Peri was dissolved in 
THF and concentration determined by HPLC. Carotenoid solutions were diluted to between 0.5-
3.0 mM in THF. To a 7 mL vial for each required sample was added the carotenoid THF solution 
and solvent removed in vacuo. To each vial was added POPC (673 mL) and in the DOXYL 
containing samples, 5 mol% of the appropriate DOXYL-PC lipid (84 mL) was added. Solvent 
was removed in vacuo and samples placed under high vacuum for ~24 hours. To each vial was 
added H2O (565 mL) and HEPES buffer (18 mL, 10 mM, pH 7.0). The samples were sonicated 
and vortexed to form MLVs. The MLVs were subjected to five freeze/thaw cycles by 
submerging in liquid N2 and warm water. The samples were then frozen in liquid N2 and water 
removed by lyophilization. The samples were stored as a dry powder at -20 oC under Ar. 
Samples were then packed into 3.2 mm diameter SSNMR rotors (Agilent Technologies, 
Santa Clara, CA, and Loveland, CO, and Revolution NMR, Fort Collins, CO) and rehydrated 
with MilliQ water (~ 6 µl). Hydration of 21-30% (by 1H NMR) was maintained by custom-made 
Kel-F and rubber spacers. Four astaxanthin samples were produced: two with a molar ratio of 
10:1 POPC:Astaxanthin, and two with a ratio of 25:1. At each ratio, one sample contained 5% 
16-DOXYL-POPC in place of POPC. Seven peridinin samples were produced, at a ratio of 25:1 
POPC:peridinin, containing either 5% 5-DOXYL-POPC, 7-DOXYL-POPC, 10-DOXYL-POPC, 
12-DOXYL-POPC, 14-DOXYL-POPC, 16-DOXYL-POPC, or no spin label.  
 
SSNMR Experiments. All NMR experiments were performed on a 600 MHz InfinityPlus 
spectrometer (Agilent Technologies, Inc.) with either a 3.2 mm Agilent Balun 1H-13C-15N MAS 
probe or a 3.2-mm T3 HXY MAS probe tuned to 1H-31P-13C. All experiments were acquired at 
12.5 kHz MAS and at a VT temperature set point of 20 oC, with the exception of the astaxanthin 
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2D 13C -13C correlation experiments which were acquired at a VT temperature of 0 oC. SPINAL-
64 1H decoupling9 was employed during acquisition and evolution periods with ~80 kHz field 
strength. Tangent ramped cross polarization10 was utilized for 2D experiments, while 1D spectra, 
including T1 measurements, were acquired using direct 13C polarization. Chemical shifts were 
externally referenced to the downfield 13C peak of adamantane (40.48 relative to DSS).11  
 Processing and integrations of 1D spectra, including those for T1 measurements, were 
performed with Varian Spinsight software 4.3.2, and spectra were subsequently visualized using 
MestReNova 8.1 software (Mestrelab Research SL). Multidimensional spectra were processed in 
NMRPipe12 and peaks were picked using the Gaussian fit method in Sparky 
(https://www.cgl.ucsf.edu/home/sparky/; Goddard, T.D. & Kneller, D.G. Sparky 3. University of 
California, San Francisco). In all cases data was processed using back linear prediction in the 
direct dimension and Lorentzian-to-Gaussian apodization in all dimensions prior to zero filling 
and Fourier transformation.  
 
Assignments and Spectra. Astaxanthin assignments were achieved collecting 13C-13C POST-C7 
spectra13 with either 28, 42, or 56 post-cycles of 10:1 POPC:[U-13C]-astaxanthin to obtain one- 
and two-bond correlations. Solid-state 13C assignments of peridinin were achieved by collecting 
a 13C-13C dipolar-assisted rotational resonance (DARR) spectrum14 of 25:1 POPC:[7,7’,15,15’-
13C]-peridinin (500 ms mixing) and comparing to previously published assignments in CD3OD.15 
Two-dimensional spectra were collected with pulse delays of 1.5 and 2.0 s for astaxanthin and 
peridinin, respectively. Directly-polarized 1D spectra of astaxanthin and peridinin samples were 
obtained with pulse delays of 25 and 30 s, respectively, to achieve nearly complete relaxation of 
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all spins. Proton spin diffusion experiments16, 17 were carried out with a pulse delay of 2 s and 
with mixing times of 1, 4, 16, 64, 100, 225, 400, and 625 ms.  
 
 









































































































Fully Assigned MAS-SSNMR 1D spectrum of POPC:13C-peridinin (25:1) 
 
PRE Measurements. 13C T1 values were measured using a standard T1 inversion recovery pulse 
sequence with 20 randomized delay times (τ) of 0.001, 0.01, 0.015, 0.02, 0.03, 0.05, 0.075, 0.1, 
0.15, 0.25, 0.4, 0.6, 0.9, 1.2, 2, 3, 4, 6, 8, and 10 s. Data was collected in 8 replicates for 
statistical analysis, and each time point was averaged over 96 scans with 8 dummy scans. The 
astaxanthin experiments employed a pulse delay of 7 s, while the peridinin experiments used 2 s. 
POPC peak integration boundaries were set as the linewidth at half height, while the entirety of 
astaxanthin and peridinin peaks (when resolved) were integrated to avoid bias towards one 






















































large integrations (“a” and “b”) because of insufficient resolution to isolate full sets of four peaks 
for a given carbon. T1 curves were fit using the interior-point method in Matlab R2014a (The 
MathWorks, Inc.), or the generalized reduced gradient method in the Solver function in Excel 
(Microsoft Office 2011) in the case of global fits of the ratio of astaxanthin populations, I0,A/I0,B. 
POPC and peridinin relaxation curves were fit to a single exponential decay of the form:  
!!(1− (2− !!!!!!"!#$)!!!!!)       (1) 
where τ is the delay time, R1 = 1/T1 is the longitudinal relaxation rate, I0 is the integration 
intensity at full relaxation, and tcycle is the time in between acquisitions, given by the sum of the 
acquisition and pulse delay, 7.03072 s and 2.03072 s in astaxanthin and peridinin T1 
experiments, respectively. Astaxanthin relaxation curves were fit to a double exponential decay 
of the form:  
!!,! 1− 2− !!!!,!!!"!#$ !!!!,!! + !!,!(1− (2− !!!!,!!!"!#$)!!!!,!!)  (2) 
where subscripts A and B refer to the major and minor components of the fit. All astaxanthin 
curves were globally fit, with the ratio of A and B treated as a global fit parameter. Longitudinal 
13C PREs were determined by calculating the difference in R1 values in the presence and absence 
of the DOXYL spin label. We report as uncertainty the propagated standard error in R1 fits 
across 8 replicate datasets. We report as uncertainty of I0,A/I0,B the propagated standard error of 
this parameter across global fits to 8 replicate datasets. 
 
II. SYNTHESIS AND CHARACTERIZATION 
Biosynthesis of [U-13C]Astaxanthin. [U-13C]Astaxanthin was prepared from the red yeast 
Xanthophyllomyces dendrorhous (strain UBV-AX2, ATCC strain #74219). The ampule of X. 
dedrorhous obtained from ATCC was grown to confluency in custom yeast media (see below). 
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Back stocks were prepared via the addition of 0.5 mL yeast in media and 0.5 mL of 40% glycerol 
into 2 mL cryovials. Vials were frozen and stored at -80 oC.  
 Fermentation: To six baffled flasks (500 mL) was added 100 mL media, 1 mL of a 40% 
[U-13C] glucose solution and 1 mL of thawed yeast back stock. The flasks were shaken at 20 oC, 
250 RPM under continuous light for 7 days. Yeast cultures were fed once per day with 1 mL of a 
40% [U-13C]glucose solution for the first 5 days. On the 7th day, the cultures were spun down 
(3000g x 10 min), supernatant discarded, and the pellets combined into 6 50 mL conical tubes. 
The yeast pellets were washed with water (3 x 40 mL), frozen, and lyophilized to yield a dry red 
powder.  
 Isolation: To each conical tube was added 3 g of glass beads (Sigma-Aldrich, 425-600 
µm acid-washed) and 25 mL of warm DMSO (55 oC). The tubes were vortexed (3 x 30 sec.), 
centrifuged (3000g x 5 min) and supernatant removed. The extraction was repeated 5 – 7 times 
until no significant color remained in the supernatant. The supernatants from all the extractions 
were combined and divided into three aliquots. The first aliquot was added to a 4 L separatory 
funnel containing 2 L of brine and was extracted with 500 mL EtOAc. The extraction was 
repeated with 500 mL EtOAc 8 -12 times until no significant color remained in the aqueous 
layer. The combined organic layers were dried with Na2SO4 and solvent removed in vacuo to 
give a red oil. This procedure was repeated with the remaining DMSO extracts.  
 Purification: The crude [U-13C]Astaxanthin was combined and half the material was 
loaded onto Celite, purified by reverse phase chromatography on C18 silica gel (12g) (90:10 " 
100:0 MeOH:H2O) and solvent removed in vacuo to give a red solid. Purification was repeated 
on the second half of the crude [U-13C]Astaxanthin. The combined [U-13C]Astaxanthin was 
dissolved in DMSO (15 mL) and purified by preparative HPLC to give 15.8 mg of red solid. 
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This red solid was dissolved in DMSO and repurified by semi-prep HPLC to give 8.5 mg of pure 
[U-13C]Astaxanthin (0.0142 mmols, 14.2 mg/mL) with 65% 13C incorporation as determined by 
1H NMR. 
Preparative HPLC Method: 
 Column: Sunfire Prep C18, 5 mm, 30 x 150 mm 
 Flow Rate: 25 mL/min. 
 Solvent A: 92.5:7.5 MeOH:H2O 
 Solvent B: Acetone 
 Method: 100% A (0 – 14 min.), 100% A " 100% B (14 – 14.5 min.), 100% B (14.5 – 
 19.5 min.) 
 Elution Time: 12.9 min. 
Semi-preparative HPLC Method: 
 Column: Sunfire Prep C18, 5 mm, 10 x 250 mm 
 Flow Rate: 25 mL/min. 
 Solvent: 95:5 MeOH:H2O 
 Elution Time: 6.9 min. 
Media Composition:18 
 Yeast Extract (22.5 g), NH4SO4 (7.5 g), KH2PO4 (4.5 g), MgSO4 (1.5 g) inositol (195 
mg) pyridoxine!HCl (105 mg), ZnSO4 (45 mg), thiamine HCl (30 mg) and Cu pantothenate (24 
mg) were combined in a 2 liter culture bottle and H2O was added to a total volume of 1.5 L. To 
the liquid media was added FeNH4SO4 (15 mg, 0.750 mL of a 200 mg/mL stock solution in 
H2O), CuSO4 (3 mg, 0.150 mL of a 20 mg/mL stock solution) and biotin (0.15 mg, 0.075 mL of 
! 139!
a 2 mg/mL stock solution). The media was set to pH 5.5 with 1M citric acid and 15% KOH. The 
media was autoclaved prior to use. 
 
Synthesis of 13C labeled Peridinin 
 
3.2. To a flame-dried 100 mL Schlenk flask equipped with a stir bar was added vinyl iodide 3.119 
(3.10 g, 8.2 mmol, 1 equiv.). The flask was vac-filled with argon (x 3). THF (9.3 mL) was added 
via syringe and the solution was cooled to -78 °C in a dry ice/isopropanol bath with stirring for 
20 minutes. To this solution was added tert-butyllithium (1.7 M in pentane, 11 mL, 18.7 mmol, 
2.3 equiv.) dropwise over 30 minutes. The resulting solution was stirred at -78 °C for 10 
minutes. To a flame-dried 20 mL vial was added 13C paraformaldehyde 99 atom % (0.51 g, 16.3 
mmol, 2 equiv.). The flask was vac-filled with argon (x 3) and THF (4 mL) was added to form a 
suspension. The paraformaldehyde suspension was added via syringe to the prepared solution of 
lithiated vinyl iodide, rinsing the vial with an additional 4 mL THF. The reaction was stirred at -
78 °C for 1 hour, then allowed to gradually warm to room temperature and stir for another 17 
hours under argon. The reaction was quenched with H2O (20 mL) and transferred to a separatory 
funnel containing brine (30 mL) and Et2O (30 mL). The layers were separated and the aqueous 
layer was extracted with Et2O (3 x 30 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo to afford a clear, colorless oil. The crude material 
was purified via silica gel chromatography (hexanes:EtOAc 85:15) to afford the product 3.2 as a 












TLC (hexanes:EtOAc 4:1)  
 Rf = 0.34, stained by KMnO4  
1H-NMR (500 MHz, CDCl3) 
δ 4.17 (dd, J = 142.3, 11.5, Hz, 1H, H7’), 4.09 (dd, J = 141.0, 11.5 Hz, 1H, H7’), 3.95-3.90 
(m, 1H, H3’), 2.18 (m, 1H, H4’), 2.05 (dd, J = 17.1, 9.3 Hz, 1H, H4’), 1.76 (s, 3H, C5’-
Me), 1.64 (m, 1H, H2’), 1.46 (t, J = 12.0 Hz, 1H, H2’), 1.10 (s, 3H, C1’-Me), 1.05 (s, 3H, 
C1’-Me), 0.90 (s, 9H, Si-tBu), 0.07 (s, 6H, Si-Me2) 
13C-NMR (125 MHz, CDCl3) 
δ 137.3 (d, J = 46.7 Hz), 131.4 (C5’), 65.7, 58.3, 48.7, 42.9, 36.9, 29.5, 28.7, 26.1, 19.7, 
18.4, -4.5, -4.5 
HRMS (ES+) 
 Calculated for 12C1513CH33O2Si (M+H)+: 286.2283  
 Found:      286.2285  
 
 
3.3. To a flame-dried 40 mL vial equipped with a stirbar was added (-)-diethyl D-tartrate (1.05 
mL, 6.13 mmol, 1.2 equiv.). The vial was sealed with a septum cap and vac-filled with argon (x 
3). CH2Cl2 (8 mL) was added via syringe and the vial was cooled to -20 °C using an immersion 
cooler. To the solution was added Ti(OiPr)4 (1.5 mL, 5.11 mmol, 1 equiv.) which was 
maintained at -20 °C with stirring for 20 minutes. tBuOOH (5 M in decane, 2.0 mL, 10.22 mmol, 
2 equiv.) was then added and the resulting solution was stirred at -20 °C for 30 minutes. To a 50 














added activated 4 Å molecular sieves and vac-filled with argon (x 3). CH2Cl2 (11 mL) was added 
via syringe and the solution was cooled to -20 °C. The Ti(OiPr)4 solution was cannulated to the 
flask containing the allylic alcohol over 7 minutes, and the resulting reaction mixture was 
maintained at -20 °C with stirring for 12.5 hours. The reaction was quenched with the addition of 
Et2O (7.5 mL), 30% aq NaOH (0.3 mL), and brine (0.3 mL) and allowed to warm to room 
temperature with stirring. Celite and Na2SO4 were added and the resulting slurry was filtered 
over a pad of Celite with Et2O. The crude material was adsorbed onto Celite from an Et2O slurry 
and purified by silica gel chromatography (hexanes:EtOAc 90:10) to yield the product 3.3 (1.44 
g, 94% yield, 7:1 dr) 
 
TLC (hexanes:EtOAc 4:1)  
 Rf = 0.37, stained by KMnO4  
1H-NMR (500 MHz, CDCl3) 
δ 3.85 (dd, J = 144.5, 11.5 Hz, 1H, H7’), 3.79 (m, 1H, H3’), 3.72 (dd, J = 143.0, 11.5 Hz, 
1H, H7’), 2.22 (dd, J = 14.5, 5.0, 1H), 1.63 (dd, J = 14.5, 8.5, 1H), 1.44 (m, 1H), 1.40 (s, 
3H), 1.24 (m, 1H), 1.13 (s, 3H), 1.06 (s, 3H), 0.87 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H) 
13C-NMR (125 MHz, CDCl3)  
δ 68.3 (d, J = 46.2 Hz), 65.8, 64.4, 60.5, 48.3, 42.4, 34.2, 27.3, 25.9, 25.0, 19.9, 18.2, -
 4.7, -4.7 
HRMS (ES+) 
 Calculated for 12C1513CH33O3Si (M+H)+: 302.2233  




3.4. To a flame-dried 50 mL Schlenk flask equipped with a stir bar and purged with argon was 
added oxalyl chloride (0.35 mL, 4.13 mmol, 1.4 equiv.) and CH2Cl2 (10 mL). The solution was 
cooled to -78 °C in a dry ice/isopropanol bath. DMSO (0.5 mL, 7.08 mmol, 2.4 equiv.) was 
added and the solution was stirred at -78 °C for 5 minutes. A solution of epoxy alcohol 3.3 (0.89 
g, 2.95 mmol, 1.0 equiv.) in CH2Cl2 (9.5 mL) was added via syringe and the resulting mixture 
was stirred for 15 minutes. NEt3 (2.7 mL, 19.5 mmol, 6.6 equiv.) was added via syringe. The 
reaction was stirred at -78 °C for 10 minutes, after which the cooling bath was removed and the 
reaction was allowed to warm to room temperature. After 1 hour, the reaction was transferred to 
a separatory funnel containing H2O (20 mL) and CH2Cl2 (20 mL). The layers were separated and 
the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified via silica 
gel chromatography (3.5% EtOAc in hexanes) to afford the product 3.4 (0.75 g, 85% yield). 
Note: The aldehyde was used immediately in the next reaction without characterization. 
 
 
3.5 To a flame-dried 100 mL Schlenk flask purged with argon was added diisopropylamine (0.5 
mL, 3.5 mmol, 1.4 equiv.) and THF (20 mL). The solution was cooled to 0 °C in an ice bath. n-
Butyllithium (2.5 M in hexanes, 1.4 mL, 3.5 mmol, 1.4 equiv.) was added dropwise and the 
resulting solution stirred for 30 minutes. The 0 °C bath was replaced with a -78 °C dry 





























Trimethylsilyldiazomethane (2 M in Et2O, 1.8 mL, 3.5 mmol, 1.4 equiv.) was added and the 
solution was stirred for 30 minutes. A solution of aldehyde 3.4 (0.75 g, 2.5 mmol, 1 equiv.) in 
THF (6.2 mL) was added to the reaction. The mixture was stirred at -78 °C for 1 hour, after 
which the cold bath was removed and the reaction was stirred at room temperature for an 
additional 2 hours. The reaction was again cooled to 0 °C, quenched with 15% acetic acid in 
EtOAc (7 mL), and allowed to warm to room temperature with stirring over 15 minutes. The 
solution was transferred to a separatory funnel with H2O (30 mL) and Et2O (30 mL). The layers 
were separated and the aqueous layer was extracted with Et2O (2 x 30 mL). The combined 
organic layers were washed with brine (2 x 30 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude material was purified via silica gel chromatography (3% 
EtOAc in hexanes) to afford the product 3.5 (0.48 g, 66% yield). Note: We did not observe a 
peak in the 13C NMR for the quaternary carbon adjacent to the 13C labeled carbon.  
 
TLC (hexanes:EtOAc 9:1)  
 Rf = 0.66, stained by KMnO4  
1H-NMR (500 MHz, CDCl3) 
δ 3.77 (m, 1H), 2.39 (d, J = 49.5 Hz, 1H), 2.21 (dd, J = 14.5, 4.7 Hz, 1H), 1.65 (dd, J = 
14.5, 8.0 Hz, 1H), 1.49 (s, 3H), 1.48-1.45 (m, 1H), 1.25 (s, 3H), 1.23-1.16 (m, 1H), 1.10 
(s, 3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H)   
13C-NMR (125 MHz, CDCl3)  
δ 81.0, 74.0 (d, J = 173.6 Hz), 66.1, 64.4, 45.7, 40.4, 34.0, 29.7, 26.0, 25.7, 21.8, 18.2, -




 Calculated for 12C1613CH30O2Si (M)+: 295.2049  
 Found:      295.2045  
 
 
3.6. To a flame dried 7 mL vial equipped with a stir bar was added alkyne 3.5 (416.5 mg, 1.4 
mmol, 1 equiv.), sealed with a septum cap, purged with argon, and taken into the glovebox. To 
the vial was added dicyclohexylborane (27.4 mg, 0.154 mmol, 0.11 equiv.) sealed, and removed 
from the glovebox. To the reaction vial was added pinacolborane (0.3 mL, 2.1 mmol, 1.5 equiv.) 
via syringe to yield a yellow/white slurry. The vial was sealed with Teflon tape and parafilm and 
the reaction was allowed to stir 14 hours at room temperature. The resulting solid was dissolved 
in Et2O, adsorbed onto Celite, and purified by silica gel chromatography (hexanes:EtOAc 95:5) 
to afford the product 3.6 (520 mg, 87% yield). 
 
TLC (95:5 hexanes:EtOAc)  
 Rf = 0.50, stained with cerium ammonium molybdate  
1H-NMR (500 MHz, CDCl3) 
δ 6.79 (dd, J = 155.6, 17.9 Hz, 1H), 5.63 (dd, J = 17.9, 7.2 Hz, 1H), 3.81 (m, 1H), 2.19, 
(ddd, J = 14.6, 5.1, 1.7 Hz, 1H), 1.59 (dd, J = 14.5, 8.2 Hz, 1H), 1.45 (ddd, J = 13.1, 3.4, 
1.7, 1H), 1.24 (s, 12H), 1.22-1.15 (m, 1H), 1.12 (s, 3H), 1.11 (s, 3H), 0.90 (s, 3H), 0.83 
(s, 9H), 0.00 (s, 3H), 0.00 (s, 3H)    













13C-NMR (125 MHz, CDCl3) 
δ 148.2, 83.3, 71.2 (d, J = 53.3 Hz), 66.5, 64.8, 47.2, 41.4, 34.9, 29.6, 26.0, 25.0, 24.9, 
20.3, 18.2, -4.6, -4.6  
HRMS (ES+) 
 Calculated for 12C2213CH44BO4Si (M+H)+: 424.3135  
 Found:      424.3139  
 
 
13C BB1. Pinacol boronic ester 3.6 (185 mg, 0.44 mmol, 1 equiv.) was concentrated in a 40 mL 
vial. To the vial was added methyliminodiacetic acid (387 mg, 2.63 mmol, 6 equiv.) and DMSO 
(4.4 mL). The vial was sealed with a PTFE-lined cap, placed in a 65 °C aluminum heating block, 
and stirred for 17 hours. The vial was removed from the heating block and allowed to cool to 
room temperature. The reaction mixture was transferred to a separatory funnel with H2O (100 
mL) and EtOAc (40 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 30 mL). The combined organic layers were washed with half-saturated brine (2 x 30 
mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude material was adsorbed 
onto Celite from an acetone slurry and purified via silica gel chromatography (Et2O to 3:2 
acetone:Et2O) to afford the product 13C BB1 as a white solid (86 mg, 44% yield) with recovered 
pinacol boronic ester 3.6 starting material (84 mg).  
 
TLC (Et2O:MeCN 4:1)  

















1H-NMR (500 MHz, d6-acetone) 
δ 6.38 (dd, J = 154.0, 17.5 Hz, 1H), 5.71 (dd, J = 18.0, 7.0 Hz, 1H), 4.23 (dd, J = 17.0, 
2.0 Hz, 2H), 4.06 (dd, J = 17.0, 4.5 Hz, 2H), 3.87 (m, 1H), 3.02 (s, 3H), 2.21 (ddd, J = 
14.5, 5.0, 1.5 Hz, 1H), 1.66 (dd, J = 8.0, 14.5 Hz, 1H), 1.49 (ddd, J = 12.5, 3.0, 1.5 Hz, 
1H), 1.20-1.28 (m, 1H), 1.15 (s, 3H), 1.14 (s, 3H), 0.93 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 
0.05 (s, 3H) 
13C-NMR (125 MHz, d6-acetone)  
δ 169.0, 140.8, 118.6 (d, J = 70.4 Hz), 71.4 (d, J = 53.8 Hz), 66.5, 65.7, 62.4, 47.9, 47.6, 
42.1, 35.5, 29.8, 26.2, 25.4, 20.5, 18.6, -4.5, -4.5 
HRMS (ES+) 
 Calculated for 12C2113CH39BNO6Si (M+H)+: 453.2673  
 Found:      453.2677  
 
 
3.10. A flame dried 25 mL Schlenk flask equipped with a stir bar was charged with 13C labeled 
ethynyltrimethylsilane 99 atom% (0.4 mL, 2.83 mmols, 1.0 equiv.) and THF (5 mL). The flask 
was cooled in a -78 oC IPA/dry ice bath for 15 minutes and n-butyllithium (1.8 mL, 1.6 M in 
hexanes, 2.88 mmols, 1.02 equiv.) was added dropwise. The reaction was placed in a 0 oC ice 
bath and stirred for 25 minutes. The -78 oC IPA/dry ice bath was replaced and the flask was 
cooled at -78 oC for 15 minutes. To the flask, triethylgermanium chloride (0.47 mL, 2.84 mmols, 
1.0 equiv.) was added dropwise. The reaction was allowed to warm to room temperature and 
stirred for 14 hours. To the flask was added saturated NH4Cl (2 mL) and the solution was poured 







separated, dried over MgSO4, filtered and solvent removed in vacuo to give a yellow oil. The 
crude product was purified by silica gel chromatography (hexanes) to give the product 3.10 as a 
colorless oil (602 mg, 82% yield). 
 
1H-NMR (400 MHz, CDCl3) 
 δ 1.08 (t, J = 7.8 Hz, 9H), 0.84 (qd, J = 7.8, 2.1 Hz, 6H), 0.16 (d, J = 2.4, 9H)  
13C-NMR (100 MHz, CDCl3) 
 δ 114.4 (d, J = 98.9 Hz), 111.5 (d, J = 98.9 Hz), 9.1, 5.8, 0.4 
LRMS (EI+) 
 Calculated for 12C913C2H25GeSi (M+H)+:   261.1 
 Found:       261.1 
 
 
3.11. A flame dried 7 mL vial equipped with a stir bar was charged in order with 13C labeled 
alkyne 3.10 (600 mg, 2.08 mmols, 1.0 equiv.), MeOH (3.9 mL) and 3M NaOH (0.777 mL, 2.33 
mmols, 1.1 equiv.). The vial was stirred for 20 minutes at room temperature and then poured into 
a separatory funnel containing 1M HCl (2.4 mL), brine (20 mL) and Et2O (20 mL). The aqueous 
layer was extracted with Et2O (3 x 20 mL) and the combined organics were washed with brine (1 
x 50 mL). The organic layer was separated, dried with MgSO4, filtered and solvent removed in 
vacuo to give the product as a colorless oil. The crude product was used in the subsequent 
reaction without further purification. (Note: The water bath for the rotatory evaporator was 










 A 20 mL vial equipped with a stir bar was charged with the crude 13C alkyne and AIBN 
(38 mg, 0.231 mmols, 0.1 equiv.) and purged with Ar for 10 minutes. To the vial was added 
HSnBu3 (0.81 mL, 3.00 mmols, 1.45 equiv.) and toluene (5 mL). The vial was sealed and heated 
with stirring to 100 oC for 22 hours. Solvent was removed in vacuo, CCl4 (5 mL) was added and 
the solution was stirred for 30 minutes. To the vial, saturated KF (2.5 mL) and H2O (2.5 mL) 
were added and the solution was stirred for 2 hours. The reaction was poured in brine (50 mL) 
and extracted with petroleum ether (3 x 50 mL). The combined organics were washed with brine 
(1 x 50 mL), dried with MgSO4, filtered and solvent removed in vacuo. The crude product was 
purified by silica gel chromatography (petroleum ether) to give 3.11 as a colorless oil (639 mg, 
64% yield). 
 
TLC (hexanes)  
 Rf = 0.79, visualized by short wave UV and stained with KMnO4  
1H-NMR (500 MHz, CDCl3) 
δ 6.80 (ddd, J = 145.5, 22.3, 3.1 Hz, 1H), 6.61 (ddd, J = 145.1, 22.3, 3.0 Hz, 1H), 1.52-
1.47 (m, 6H), 1.34-1.27 (m, 6H),1.01 (t, J = 7.9 Hz, 9H), 0.91-0.88 (m, 15 H), 0.77 (qd, J 
= 8.0, 1.5 Hz, 6H)  
13C-NMR (125 MHz, CDCl3)  







3.13. A flame dried 40 mL vial equipped with a stir bar was charged with MIDA boronate 3.121  
(203 mg, 0.582 mmols, 1.0 equiv.) and taken into the glovebox. To the vial was added CuTC 
(167 mg, 0.876 mmols, 1.5 equiv.) and Pd(PPh3)4 (36 mg, 0.031 mmols, 0.05 equiv.). The vial 
was taken out of the glovebox and DMF (6 mL) and SI – 14 (340 mg, 0.714 mmols, 1.2 equiv.) 
were added. The reaction was sealed and stirred at room temperature for 5 hours. The reaction 
was poured into brine (100 mL) and extracted with EtOAc (3 x 75 mL). The combined organics 
were washed with brine (2 x 50 mL), dried with MgSO4, filtered and concentrated in vacuo. The 
crude product was purified by silica gel chromatography (100:0 to 90:10 Et2O:MeCN) to give 
3.13 as a yellow solid (143 mg, 51% yield). 
 
TLC (Et2O:MeCN 4:1)  
 Rf = 0.65, visualized by short wave UV and stained by KMnO4 
1H NMR (500 MHz, d6-acetone) 
δ 6.67 (dddd, J = 151, 18, 10, 3 Hz, 1H), 6.67 (ddd, J = 14.5, 11, 7 Hz, 1H), 6.43 (d, J = 
11 Hz, 1H), 6.29 (dd, J = 14.5, 10.5, 1H), 6.08 (ddd, J = 143, 18, 5 Hz, 1H), 4.23 (d, J = 
16.5 Hz, 2H), 4.06 (d, J = 17 Hz, 2H), 2.97 (s, 3H), 1.82 (s, 3H), 1.04 (t, J = 8 Hz, 9H), 
0.83 (qd, J = 8, 1.5 Hz, 6H) 
 
13C NMR (125 MHz, d6-acetone)  
δ 169.2, 145.7 (d, J = 61 Hz), 137.0 (d, J = 7.625 Hz), 136.6 (d, J = 53.75 Hz) 129.5 (d, J 






















 Calculated for 12C1613C2H31BGeNO4 (M+H)+:  412.1625 
 Found:        412.1626 
 
 
3.7. To a flame-dried 7 mL vial equipped with a stir bar and charged with alkyne 3.5 (209 mg, 
0.71 mmols, 1.0 equiv) was added THF (1.4 mL) and TBAF (1M in THF, 1.4 mL, 1.4 mmols, 
2.0 equiv). The vial was stirred for 24 hours at room temperature. To the vial was added 
saturated NaHCO3 (1 mL) and the reaction mixture was transferred to a separatory funnel 
containing NaHCO3 (30 mL) and Et2O (30 mL). The aqueous layer was extracted with Et2O (3 x 
20 mL), organics combined and washed with brine (2 x 20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by silica gel chromatography (80:20 
hexanes:EtOAc) to give 3.7 a white solid (102 mg, 79% yield). Note: We did not observe a peak 
in the 13C NMR for the quaternary carbon adjacent to the 13C labeled carbon. 
 
1H-NMR (500 MHz, CDCl3) 
d 3.80 (m, 1H), 2.40 (d, J = 49.6 Hz, 1H), 2.33 (ddd, J = 14.5, 5.1, 1.8 Hz, 1H), 1.63 (dd, 
J = 14.3, 8.7 Hz, 1H), 1.60-1.56 (m, 1H), 1.51 (s, 3H), 1.26 (s, 3H), 1.24-1.18 (m, 1H), 
1.11 (s, 3H)  
13C-NMR (125 MHz, CDCl3)  















 Calculated for 12C1013CH16O2 (M)+: 181.11839   
 Found:     181.11886  
 
 
3.8. A flame-dried 10 mL Schlenk flask equipped with a stir bar and charged with 3.7 (102 mg, 
0.562 mmols, 1.0 equiv) was cooled in an IPA bath held at -12 oC via cryo-cool. To the flask was 
added Et2O (3.25 mL) followed by CuI (105 mg, 0.55 mmols, 0.98 equiv) and NH4I (39 mg, 0.27 
mmols, 0.48 equiv) under a stream of Ar and HI (57% solution, distilled and stabilized, 0.11 mL, 
0.83 mmols, 1.5 equiv) was added. The reaction was stirred at -10 to -12 oC for 1 hour and 45 
minutes. While at -12 to -10 oC, to the flask was added 1.5 mL NH4OH and 1.5 mL saturated 
NH4Cl. The blue reaction mixture was then poured into a separatory funnel containing brine (30 
mL) and Et2O (30 mL). The organic layer was extracted with Et2O (3 x 20 mL), organics 
combined, washed with brine (2 x 20 mL), dried over MgSO4, filtered and solvent removed in 
vacuo. The crude material was purified by silica gel chromatography (70:30 " 50:50 
hexanes:EtOAc) to give 3.7 as a white solid (112 mg, 65% yield). Note: Product contained 10% 




TLC (Et2O)  
 Rf = 0.41, visualized by short wave UV  
















δ 5.74 (d, J = 5.6 Hz, 1H), 4.29-4.23 (m, 1H), 2.20 (ddd, J = 13.1, 4.2, 2.3 Hz, 1H), 1.89 
(ddd, J = 12.6, 4.2, 2.4 Hz, 1H), 1.41 (s, 3H), 1.39-1.29 (m, 2H), 1.31 (s, 3H), 1.15 (s, 
3H) 
13C-NMR (125 MHz, CDCl3) 
δ 201.9, 119.6 (d, J = 102.5 Hz), 72.2, 64.1, 48.8, 48.4, 38.3 (d, J = 110.3 Hz), 35.4, 31.2, 
30.8, 29.9 
HRMS (EI+) 
 Calculated for 12C1013CH17O2I (M)+: 309.0307   
 Found:     309.0315  
 
 
3.9. To a flame-dried 7 mL vial equipped with a stir bar and charged with 13C allene 3.8 (110 mg, 
0.356 mmols, 1.0 equiv) was added pyridine (1.2 mL, freshly distilled) and acetic anhydride 
(0.17 mL, 1.8 mmols, 5.0 equiv.). The reaction was stirred at room temperature for 10 hours. The 
reaction was poured into a separatory funnel containing Et2O (10 mL) and saturated NaHCO3 (10 
mL) and extracted with Et2O (2 x 10 mL). The organics were combined, dried with MgSO4, 
filtered and solvent removed in vacuo. The crude material was purified by silica gel 
chromatography (80:20 to 70:30 hexanes:EtOAc) to give 3.9 as a white solid (88.5 mg, 71% 
yield).  
TLC (60:40 hexanes:EtOAc) 
 Rf = 0.53, stained by KMnO4  


















δ 5.75 (d, J = 5.6 Hz, 1H), 5.29 (m, 1H), 2.21 (ddd, J = 13.0, 4.3, 2.3 Hz, 1H), 2.01 (s, 
3H), 1.90 (ddd, J = 12.4, 4.3, 2.3 Hz, 1H), 1.50-1.33 (m, 2H), 1.40 (s, 3H), 1.34 (s, 3H), 
1.13 (s, 3H)  
13C-NMR (125 MHz, CDCl3)  
δ 201.8, 170.6, 119.2 (d, J = 102.5 Hz), 71.7, 67.7, 44.8, 44.8, 38.6 (d, J = 110.6), 35.4, 
31.2, 30.7, 29.8, 21.6  
HRMS (EI+) 
 Calculated for 12C1213CH19IO3 (M)+: 351.0413   
 Found:     351.0416 
 
 
13C BB4. To a flame-dried 7 mL vial charged with 3.9 (85 mg, 0.242 mmols, 1.0 equiv) was 
added methylene chloride (1.2 mL), 2,6-lutidine (freshly distilled, 0.34 mL). The vial was cooled 
to 0 oC and TMSOTf (0.35 mL, 1.93 mmols, 8.0 equiv) was added dropwise. The reaction was 
allowed to warm to room temperature and stirred for 2 hours. The reaction was cooled to 0 oC 
and H2O (1 mL) was added dropwise. The reaction was poured into a separatory funnel 
containing Et2O (10 mL) and brine (10 mL) and extracted with Et2O (3 x 10 mL). The combined 
organics were washed with brine (2 x 10 mL), dried with MgSO4, filtered and solvent removed 
in vacuo. The crude material was purified by reverse phase chromatography on C18 silica gel 
(40:60 to 0:100 H2O:MeCN) to give 13C BB4 as an off-white solid (68 mg, 66% yield).  
 



















 Rf = 0.79, visualized by short wave UV 
1H-NMR (500 MHz, CDCl3) 
δ 5.68 (d, J = 5.6 Hz, 1H), 5.26 (m, 1H), 2.19 (ddd, J = 12.6, 4.1, 2.3 Hz, 1H), 2.01 (s, 
3H), 1.90 (ddd, J = 12.3, 4.2, 2.3 Hz, 1H), 1.42 (s, 3H), 1.41-1.30 (m, 2H), 1.30 (s, 3H), 
1.11 (s, 3H), 0.09 (s, 9H) 
13C-NMR (125 MHz, CDCl3)  
δ 201.8, 170.5, 119.1 (d, J = 103.0 Hz), 73.9, 68.0, 46.9, 44.9, 37.9 (d, J = 110.8 Hz), 
35.3, 31.4, 29.8, 29.5, 21.6, 2.3 
HRMS (EI+) 
 Calculated for 12C1513CH27IO3Si (M)+: 423.0808   
 Found:      423.0791  
 
 
3.14. To a 7 mL vial equipped with a stir bar was added 13C BB1 (88.3 mg, 0.195 mmols, 1.0 
equiv.). The starting material was dissolved in THF (2.0 mL), stirred vigorously and 1M NaOH 
(0.60 mL, 0.60 mmols, 3.0 equiv.) was added. The reaction was stirred for 25 minutes until no 
more MIDA boronate remained by TLC. The reaction was poured into phosphate buffer (25 mL, 
0.5 M, pH 7.0) and extracted with Et2O (3 x 10 mL). The organics were combined, dried over 
MgSO4, filtered and solvent removed in vacuo to give a white solid (55 mg, 83% yield). The 


































 To a flame-dried 7 mL vial was added BB21 (45.5 mg, 0.133 mmols, 1.0 equiv.) and the 
vial was taken into the glovebox. In the glovebox, a 7 mL vial was charged with Pd(OAc)2 (2.25 
mg, 0.010 mmols, 0.08 equiv.) and XPhos (10.5 mg, 0.022 mmols, 0.18 equiv.) and THF (0.4 
mL) was added. The vial was stirred in the glovebox at room temperature for 15 min. To the vial 
containing BB2 was added K3PO4 (76 mg, 0.357 mmols, 2.9 equiv.) followed by 13C BB1 boronic 
acid as a solution in THF:toluene (1:2, 2 x 0.9 mL). The catalyst solution was added to the 
reaction. The reaction vial was taken out of the glovebox, sealed and stirred at 45 oC for 24 
hours. The reaction was cooled to room temperature, diluted with EtOAc and filtered over celite. 
The solvent was removed in vacuo and purified by flash chromatography on florosil 
(Et2O:MeCN 100:0 to 80:20) to give 3.14 as a yellow solid (41.2 mg, 57% yield). 
 
TLC (4:1 Et2O:MeCN) 
 Rf = 0.61, stained by KMnO  
1H-NMR (500 MHz, d6-acetone) 
δ 7.52 (s, 1H), 7.19 (dd, J = 159.0, 15.7 Hz, 1H), 6.40 (dd, J = 15.6, 3.7 Hz, 1H), 5.93 (s, 
1H), 5.82 (s, 1H), 4.26 (d, J = 17.0 Hz, 2H), 4.09 (d, J = 16.9 Hz, 2H), 3.89 (m, 1H), 3.10 
(s, 3H), 2.27-2.22 (m, 4H), 1.72 (dd, J = 14.4, 8.3 Hz, 1H), 1.53 (ddd, J = 13.0, 3.4, 1.6 
Hz, 1H), 1.33-1.25 (m, 1H), 1.20 (s, 3H), 1.16 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 
3H), 0.07 (s, 3H)  
 
13C-NMR (125 MHz, d6-acetone) 
! 156!
δ 169.2, 168.9, 147.2, 146.4, 138.8 (d, J = 6.5 Hz), 135.0, 126.6, 122.3 (d, J = 72.5), 
121.0, 70.8 (d, J = 55.6 Hz), 67.8, 65.6, 62.6, 47.7, 47.2, 42.2, 35.7, 35.7, 26.2, 25.4, 
20.2, 18.7, 18.6, -4.6, -4.6 
HRMS (ESI+) 
 Calculated for 12C2913CH45BNO8Si (M)+: 587.3041   
 Found:      587.3039  
 
 
13C BB3. A flame dried 7 mL vial equipped with a stir bar was charged with 3.13 (64.4 mg, 0.16 
mmols, 1.0 equiv.), placed under Ar and MeOH (3 mL) was added. The vial was cooled (15 
min.) in an IPA/dry ice bath at -78 oC. In a second flame dried 7 mL vial charged with I2 (freshly 
sublimed, 123 mg, 0.485 mmols, 3.0 equiv.) was added MeOH (1.5 mL). The I2 solution was 
cooled in an IPA/dry ice bath at -78 oC for 10 minutes and then was added dropwise in three 
separate portions to the vial containing 3.13 while in the -78 oC IPA/dry ice bath. The reaction 
was stirred for 3 hours 20 minutes at -78 oC under Ar. The solution was then quickly transferred 
to a 125 mL Erlenmeyer flask equipped with a stir bar containing 50 mL sat. NaHSO3 and 25 mL 
EtOAc while vigorously stirring the solution. The vial was washed with EtOAc (2 x 10 mL) to 
ensure quantitative transfer. The solution was transferred to a separatory funnel and the aqueous 
layer was removed. The organic layer was then washed with sat. NaHSO3 (3 x 50 mL) and brine 
(2 x 50 mL), dried with MgSO4, filtered and solvent removed in vacuo. The remaining tan solid 


























3.15. A 7 mL vial equipped with a stir bar was charged with tetraene MIDA boronate 3.14 (61.4 
mg, 0.105 mmols, 1.0 equiv.), pinacol (23 mg, 0.195 mmols, 1.9 equiv.) and NaHCO3 (54 mg, 
0.643 mmols, 6.1 equiv.) and MeOH (1.1 mL) was added. The vial was sealed and stirred at 45 
oC for 3 hours. The reaction was cooled to room temperature, diluted with EtOAc and filtered 
through celite. The solvent was then removed in vacuo, crude material transferred to a 7 mL vial 
and azeotroped with toluene (3 x 1 mL). To the vial was added a stir bar, CaCl2 (58 mg, 0.523 
mmols, 5.0 equiv.), NaHCO3 (45 mg, 0.536 mmols, 5.1) and toluene (1.1 mL). The vial was 
stirred at room temperature for 3 hours. The solution was then diluted with EtOAc, filtered 
through celite and solvent removed in vacuo to give a yellow solid (59 mg). The product SI – 21 
was used in the subsequent coupling reaction without further purification. 
 
 
3.16. The two coupling partners 13C BB3  (50.1 mg, 0.133 mmols, 1.3 equiv.) and 3.15 (59 mg, 





















































vial containing BB3 was added PdCl2(PPh3)2 (6.0 mg, 0.0086 mmols, 0.08 equiv.) and Ag2O (78 
mg, 0.337 mmols, 3.2 equiv.). BB3 was transferred into the reaction vial by dissolving in three 
sequential portions of DMSO (0.4 mL, 0.4 mL and 0.3 mL). The vial was sealed, taken out of the 
glovebox, heated to 45 oC and stirred as a sealed vessel for 13 hours. The reaction was cooled to 
room temperature, diluted with EtOAc (10 mL) and transferred to a separatory funnel containing 
brine (25 mL). The aqueous layer was extracted with EtOAc (3 x 25 mL). The organics were 
combined, washed with brine (2 x 25 mL), dried with MgSO4, filtered and solvent removed in 
vacuo. The crude red solid was purified by reverse phase chromatography on C18 silica gel 
(40:60 to 5:95 H2O:MeCN) to give 3.16 as a red solid (28.1 mg, 39% yield). 
 
TLC (Et2O:MeCN 4:1) 
 Rf = 0.42, visualized by visible light (orange) 
1H-NMR (500 MHz, d6-acetone) 
δ 7.50 (s, 1H), 7.18 (dd, J = 158.5, 15.7 Hz, 1H), 6.86 – 6.76 (m, 2H), 6.66 – 6.56 (m, 
2H), 6.52 – 6.46 (m, 2H), 6.41 (dd, J = 16, 3.5 Hz, 1H), 6.00 (s, 1H), 4.24 (d, J = 17.0 
Hz, 2H), 4.07 (d, J = 16.9 Hz, 2H), 3.89 (m, 1H), 2.98 (s, 3H) 2.27-2.23 (m, 1H) 2.21 
(s,3H), 1.84 (s, 3H), 1.71 (dd, J = 14.4, 8.3 Hz, 1H), 1.53 (ddd, J = 13.0, 3.2, 1.6 Hz, 1H), 
1.31 (dd, J = 13.0, 10.0, 1H), 1.20 (s, 3H), 1.17 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 
3), 0.07 (s, 3H) 
13C-NMR (125 MHz, d6-acetone) 
 δ 169.2, 169.2, 148.0, 138.3 (d, J = 68.5 Hz), 138.2 (d, J = 68.5 Hz), 137.7, 137.0 (d, J = 
68.625), 134.9 134.53 (d, J = 2.875 Hz), 134.45, 130.3 (d, J = 68.5 Hz), 130.1, (d, J = 
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68.5 Hz), 125.4, 122.8, 119.6 (d, J = 7.5 Hz), 70.8 (d, J = 55.75 Hz), 67.8, 65.6, 62.7, 
47.7, 47.2, 42.0, 35.8, 27.6, 26.2, 25.5, 20.2, 18.6, 15.5, 15.4, -4.5, -4.6 
HRMS (ESI+) 
 Calculated for 12C3413C3H53BNO8Si (M+H)+: 681.3734   
 Found:       681.3730  
 
 
13C protected peridinin 3.17. Catalyst Solution: In the glovebox, a 7 mL vial equipped with a 
stir bar was charged with Pd(OAc)2 (2.5 mg, 0.011 mmols), Xphos (10.5 mg, 0.021 mmols) and 
THF (2 mL). Catalyst solution was stirred for 20 minutes at room temperature prior to use.  
 In the glovebox, a 7 mL vial equipped with a stir bar in the glovebox was charged with 
13C heptaene 3.16 (15 mg, 0.0220 mmols, 1.0 equiv.) and NaOH (oven dried, 7 mg, 0.175 
mmols, 8.0 equiv.). To the vial was added a THF (0.55 mL) solution of 13C BB4 (12.1 mg, 
0.0286 mmols, 1.3 equiv.) and 0.2 mL of the catalyst solution (see above). The vial was capped 
with a septum, removed from the glovebox, placed under Ar and H2O (purged with Ar for 30 
min., 0.15 mL) was added. The reaction was stirred at room temperature for 1.5 hours under Ar. 
The reaction was poured into phosphate buffer (10 mL, 0.5 M, pH 7.0) and extracted with Et2O 






































filtered and solvent removed in vacuo to give a red solid. The crude solid was purified by reverse 
phase chromatography on C18 silica gel (95:5 to 50:50 MeCN:EtOAc) to give 3.17 as a red solid 
(11.3 mg, 63% yield). 
 
TLC (hexanes:EtOAc) 
 Rf = 0.66, visualized by visible light (orange) 
1H-NMR (500 MHz, d6-acetone)  
 δ 7.51 (s, 1H), 7.17 (dd, J = 158.4, 15.8 Hz, 1H), 6.81-6.73 (m, 2H), 6.61-6.59 (m, 1H), 
 6.53-6.47 (m, 2H), 6.40 (dd, J = 15.5, 3.7 Hz, 1H), 6.22 (d, J = 11.6 Hz, 1H), 6.11 (d, J = 
 2.6 Hz, 1H), 6.00 (s, 1H), 5.32 (m, 1H), 3.90 (m, 1H), 2.27-2.23 (m, 1H), 2.21 (s, 3H), 
 2.17 (dt, J = 4.3, 2.1 Hz, 1H),1.98 (s, 3H), 1.93-1.91 (m, 1H), 1.85 (s, 3H), 1.72 (dd, J = 
 14.6, 8.3 Hz, 1H), 1.55-1.52 (m, 1H), 1.49-1.31 (m, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.20 
 (s, 3H), 1.17 (s, 3H), 1.07 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.13 (s, 9H), 0.08 (s, 3H), 
 0.07 (s, 3H). 
HRMS (ESI+) 
 Calculated for 12C4413C4H73O7Si2 (M+H)+:  821.5029   
































13C peridinin. HF!pyridine Stock Solution: To an oven dried 2.5 mL Teflon vial equipped with a 
stir bar was added pyridine (freshly distilled, 0.8 mL). The vial was cooled in a 0 oC ice bath and 
HF!pyridine (70% HF in pyridine, new bottle, 0.25 mL) was added. Note: Wet HF/pyridine 
solution leads to significant product decomposition. 
 To an oven dried 2.5 mL Teflon vial equipped with a stir bar under Ar was added 13C 
protected peridinin 3.17 (5.8 mg, 0.00705 mmols, 1.0 equiv.) by dissolving in Et2O and blowing 
off the solvent under a gentle stream of Ar. The vial was then placed back under Ar and THF 
(0.35 mL) was added. The vial was then cooled in a 0 oC ice bath and HF/pyridine stock solution 
(0.15 mL) was added dropwise. The ice bath was removed and the reaction was stirred at room 
temperature for 4 hours. The vial was diluted with Et2O (1 mL) and transferred to a separatory 
funnel containing Et2O (10 mL) and sat. NaHCO3 (20 mL). The aqueous layer was extracted 
with Et2O (4 x 20 mL). The combined organics were dried with MgSO4, filtered and solvent 
removed in vacuo to give a red solid. The crude product was purified by reverse phase semi-prep 




 Column: Sunfire Prep C18, 5 mm, 10 x 250 mm 
 Flow Rate: 5 mL/min 
 Solvent: 25:75 H2O:MeCN 
 Elution Time: 16.8 min. 
TLC (hexanes:acetone 7:3) 
 Rf = 0.27, visualized by visible light (orange) 
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1H-NMR (500 MHz, CDCl3) 
 δ 7.17 (dd, J = 160.2,15.6 Hz, 1H), 7.02 (s, 1H), 6.78-6.58 (m, 2H), 6.46-6.36 (m, 3H), 
 6.37 (dd, J = 15.4, 3.8 Hz, 1H), 6.11 (d, J = 11.6 Hz, 1H), 6.05 (d, J = 2.6 Hz, 1H). 5.73 
 (s, 1H), 5.38 (m, 1H), 3.90 (m, 1H), 2.40 (ddd, J = 14.4, 5.0, 1.6 Hz, 1H), 2.28 (ddd, J = 
 12.4, 4.0, 1.9 Hz, 1H), 2.23 (s, 3H), 2.04 (s, 3H), 1.99 (ddd, J = 12.8, 4.4, 2.4 Hz, 1H), 
 1.80 (s, 3H), 1.67-1.56 (m, 2H), 1.53-1.48 (m, 1H), 1.43-1.35 (m, 2H), 1.38 (s, 3H), 1.35 
 (s, 3H), 1.26 (m, 1H), 1.203 (s, 3H), 1.199 (s, 3H), 1.07 (s, 3H), 0.97 (s, 3H)  
13C NMR (125 MHz, CDCl3, 13C enriched signals only)   
δ 202.88, 137.44 (d, J = 69.2 Hz), 133.85, 129.14 (d, J = 69.3 Hz) 
HRMS (ESI+) 
 Calculated for 12C3513C4H51O7 (M+H)+:  635.3769   












































































PERIDININ TO PROBE THE ROLE OF LIPID PEROXIDATION IN ATHEROSCLEROSIS 
AND ASTHMA 
 
Adam G. Hill, Hannah M. S. Haley, Xin Ren, Kui My Huynh,  
Xiaozhu Huang and Martin D. Burke  
 
 Lipid peroxidation is widely cited as an important and addressable pathway to 
pathogenesis in many human diseases including atherosclerosis and asthma. Evidence for this 
comes primarily from correlating disease incidence and/or severity with oxidized lipids, missing 
or inactive antilipoperoxidant proteins and knockout animals missing antilipoperoxidant proteins. 
However, elucidating the potential causative relationship between oxidized lipids and human 
disease remains a challenge. We hypothesized that peridinin, a potent inhibitor of lipid 
peroxidation, would be a useful tool to probe the role of lipid peroxidation in atherosclerosis and 
asthma. 
 In the case of atherosclerosis, we showed that the oxidation of endogenous lipids present 
within primary human endothelial cells are capable of inducing monocyte-endothelial cell 
adhesion. Leveraging peridinin as a unique chemical probe of lipid bilayer peroxidation, we 
found that small molecule-mediated inhibition of bilayer lipid peroxidation blocks stress-induced 
monocyte-endothelial cell adhesion, a key step in atherogenesis. 
 In the case of asthma, we evaluated OVA and HDM mouse models of allergic asthma but 
were unable to definitively determine the role of lipid peroxidation in the acute asthmatic 
reaction. We observed inconsistent levels of lipid peroxidation between experiments and saw 
little reduction of lipid peroxidation upon intranasal administration of peridinin. Our preliminary 
results suggest that lipid peroxidation is not a key driver of the acute allergic asthmatic reaction 
as we always observed a strong asthmatic phenotype but did not consistently observe significant 
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lipid peroxidation.  Further studies are needed to evaluate the biodistribution of peridinin within 
the mouse airway and further investigate the presence of lipid peroxidation in mouse models of 
both acute and chronic asthma.  
 Monocyte binding assay was developed by Adam Hill. Peridinin for the mouse studies 
was synthesized by Adam Hill and Hannah Haley. Liposomal peridinin samples were prepared 
by Adam Hill. The mouse asthma studies were performed Xin Ren and Kui My Huynh in the 
laboratory of Xiaozhu Huang at the UCSF Sandler Asthma Basic Research Center. The 
asthmatic phenotype was analyzed by Xin Ren, Kui My Huynh and Xiaozhu Huang. The 8-iso 
PGF2α assays were developed by Adam Hill and the MDA assays were developed by Hannah 
Haley. The atherosclerosis experiments were designed by Adam Hill, Hannah Haley and Marty 
Burke. The asthma experiments were designed by Adam Hill, Hannah Haley, Xiaozhu Huang 
and Marty Burke. 
 
4 – 1 PERIDININ TO PROBE THE ROLE OF LIPID PEROXIDATION IN 
ATHEROSCLEROSIS 
 Lipid peroxidation is commonly cited as potentially modifiable risk factor for the 
development of atherosclerosis but there are currently no clinically relevant methods to address 
lipid peroxidation.1-6 Specifically, the oxidation of endogenous lipids within the endothelial wall 
has been proposed to initiate monocyte binding through the lipid whisker model (Fig. 1 – 1, 
chapter 1 – 2).7 However, no small molecules have been shown to successfully mitigate lipid 
peroxidation and thereby lead to a decrease in monocyte binding. We sought to use this system 




Figure 4-1. Peridinin inhibits monocyte binding to primary human endothelial cells (a) Binding of primary CD14+ monocytes to 
primary HUVECs and (b) representative images of bound monocytes. Growth media does not induce lipid peroxidation (a, left 
and b, top panels) and basal induces endogenous lipid peroxidation (a, left and b, bottom panels). Error bars = SEM; n = 16 (a); n 
= 16 (b), *p < 0.05, **p < 0.01, NS = not significant.  
 We developed an assay to study monocyte binding using primary HUVECs, as before 
(see chapter 3-2), in combination with primary CD14+ human monocytes. We first showed that 
under complete media conditions there is a baseline level of monocyte binding to the primary 
HUVECs and all results were normalized to this value. Consistent with prior reports,6, 8-26 the 
incubation of HUVECs with exogenously oxidized phospholipids (OxPUFA) under complete 
media conditions caused a significant increase in monocyte binding (Fig. 4-1a). Alternatively, 
induction of lipid peroxidation by switching to basal media caused a similar increase in bound 
monocytes as was observed upon addition of exogenous OxPUFA (Fig. 4-1a,b). Utilizing 
astaxanthin as a negative control, we added 2 µM astaxanthin and observed no reduction in lipid 
peroxidation and no change in monocyte binding (Figs. 4-1a,b). In stark contrast, the addition of 
2 µM peridinin caused a significant reduction in both lipid peroxidation and the number of bound 
monocytes (Figs. 4-1a,b). Microscopic analysis of these samples was consistent with the 
conclusion that the bilayer localization of the carotenoids in HUVECs mirrors that in liposomes 
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astaxanthin but not in the peridinin treated cells (Fig. 4-1c). Collectively, these results indicate 
that the small molecule-mediated attenuation of bilayer lipid peroxidation is able to mitigate 
monocyte-endothelial cell adhesion. Furthermore, this supports the hypothesis that a more potent 
and selective membrane embedded antilipoperoxidant is required to exert a meaningful impact 
on the lipid whisker model of atherogenesis. This study exemplifies the use of peridinin and 
astaxanthin as a pair of chemical probes to better understand the role of bilayer lipid peroxidation 
in human disease. 
 
4 – 2 PERIDININ TO PROBE THE ROLE OF LIPID PEROXIDATION IN ASTHMA 
 Lipid peroxidation is widely cited as an important and addressable pathway to 
pathogenesis in asthma (chapter 1 – 3). Evidence for this includes: a) Patients with asthma have 
increased lipid peroxidation products in breath condensate,27-35 b) Asthma risk is associated with 
genetic deficiencies of antilipoperoxidant proteins,36, 37 c) Knockout mice deficient in 
antilipoperoxidant proteins show a more severe asthma phenotype,38, 39 and d) Vitamin E 
treatment in mouse models of asthma reduces both lipid peroxidation and asthma severity.40-42 
The last line of evidence is confounded by reports that, in addition to antilipoperoxidant activity, 
vitamin E also possesses anti-inflammatory and enzyme inhibitory activities (chapter 1 – 2). It 
has thus remained unclear whether the increased lipid peroxidation associated with asthma plays 
a causative role or is simply correlated with this disease.  
 Asthma is a complex and heterogeneous disease that involves multiple organ systems and 
is not readily reproduced in its entirety in cell culture. Therefore, we choose to study the role of 
lipid peroxidation in the ovalbumin (OVA) and house dust mite (HDM) mouse models of 
asthma, in collaboration with Xiaozhu Huang at the UCSF Sandler Asthma Basic Research 
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Center.43-45 However, an animal model requires both significantly more compound than cellular 
assays and a suitable method of delivery into the mouse airway.  
 We utilized our ICC based synthesis of peridinin to synthesize sufficient quantities of this 
natural product for mouse studies. We prepared >50 mg of peridinin by scaling up and 
optimizing both the building block synthesis and cross-coupling reactions throughout the 
synthesis. Upon access to sufficient quantities of peridinin, we turned our attention to small 
molecule delivery to the mouse airway. 
 
Figure 4-2. Experimental scheme for determination of the maximum tolerated dose of peridinin. 
 
 Peridinin is not water soluble but we have previously shown that it readily incorporates 
into liposomes (chapter 3 – 4). We were able to prepare a liposomal formulation of peridinin in 
POPC for intranasal delivery directly to the mouse airway. In our first study, we dosed by 
intranasal delivery wild-type BALB/c mice with increasing concentrations of peridinin (0.2, 1, 5, 
and 25 mg/kg) on four consecutive days to identify the maximally tolerated dose of peridinin. 
Peridinin was well-tolerated up to 5 mg/kg but showed toxicity at 25 mg/kg (Fig. 4 – 3). The 
mice given 25 mg/kg developed a hunch back, loss of smooth and shiny fur and took longer to 
recover from anesthesia as well as showing increased lung inflammation and a significant drop in 



















morphological differences, no change in body weight or lung inflammation as compared to the 
POPC only treated mice (Fig. 4 – 3a-c).  
 
Figure 4-3. Peridinin is Well Tolerated in Wild-Type Mice. Intranasal delivery of peridinin POPC liposomes is well tolerated 
in wild-type mice up to 5 mg/kg as evidenced by (a) no change in body weight, (b,c) no increase in lung tissue inflammation as 
observed by H&E staining. (d) Quantification of peridinin by HPLC in the left lung lobe shows dose-dependent accumulation. (e) 
No peridinin was observed in the blood at doses up to 5 mg/kg. Error bars represent SEM, n = 5, *p <0.05, **p < 0.01, NS = p > 
0.05 
 We further quantified peridinin concentration in the lungs and the bloodstream 24 hours 
after the final intranasal administration. We found increasing concentrations of peridinin in the 
lungs (Fig. 4 – 4d) with a ten-fold increase between the 5 mg/kg and 25 mg/kg treatment groups. 
We did not observe any systemic exposure up to 5 mg/kg but did observe a significant 
accumulation peridinin in the blood stream at the 25 mg/kg dose (Fig. 4 – 4e). This suggests that 
high doses of peridinin given via intranasal delivery can enter the bloodstream and cause 
systemic toxicity. However, 5 mg/kg was well-tolerated and localized exclusively to the mouse 
airway. To avoid peridinin toxicity, all further experiments used 1 and 5 m/kg doses of peridinin 
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Figure 4-4. Experimental design for initial ovalbumin acute mouse asthma model. 
 
 We began with the acute OVA mouse model of asthma, which is reported in multiple 
prior studies to show both elevated levels of lipid peroxidation and a robust asthma phenotype.40-
42, 46-49 BALB/c mice were sensitized to OVA/alum via ip injection over 3 weeks and then 
challenged via intranasal OVA for 3 days (Fig. 4 – 4). Peridinin (1 or 5 mg/kg) was administered 
once a day beginning one day before and ending one day after the OVA challenge phase (Fig. 4 
– 4).  
 
Figure 4-5. (a) Airway lipid peroxidation as determined by quantification of 8-iso PGF
2α
 in the BALF. Intranasal delivery of 5 
mg/kg peridinin over 5 days does not effect the acute asthmatic phenotype as evidenced by no reduction in (b) airway 
hyperresponsiveness, (c) IgE in the BALF, (d) leukocytes in BALF, (e) lung tissue inflammation and (f) mucus production. 
Shaded data represents saline sensitized/challenged animals. Black data points represent vehicle, green data points represent 1 
mg/kg peridinin group and blue data points represent 5 mg/kg peridinin. Error bars represent SEM, n = 4(a) or n = 8(b-f), *p < 
0.05, **p < 0.01, ***p < 0.001, NS = p > 0.05 
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 We observed an increase in 8-iso PGF2α levels in the bronchoalveolar lavage fluid 
(BALF) upon OVA administration and a decrease in 8-iso PGF2α levels in the BALF upon 
peridinin administration (Fig. 4 – 5a). However, neither of these two effects reached statistical 
significance in this experiment with p-values of 0.179 and 0.0955, respectively (Fig. 4 – 5a). 
This experiment utilized 8 mice/group but due to technical difficulties 8-iso PGF2α was only 
measured in 4 animals/group and this experiment lacked the statistical power to differentiate 
between the observed levels of 8-iso PGF2α in each group. In contrast, OVA challenge caused a 
robust asthmatic phenotype as observed by an increase in airway hyperresponsiveness after 
acetylcholine challenge, increase in IgE titers, airway histopathology and PAS staining for 
mucus (Fig. 4 – 5b-f). However, peridinin administration at 1 or 5 mg/kg showed no change in 
any of these markers of airway constriction or inflammation (Fig. 4 – 5b-f). These initial results 
are in contrast to prior reports40-42, 46-49 and suggest that lipid peroxidation may not be a key 
driver of the asthmatic phenotype. 
  
Figure 4-6. Experimental design for second ovalbumin acute mouse asthma model. 
 
 We thus repeated the OVA mouse model with a greater number of mice (10/group) and 
measured two independent markers of lipid peroxidation (8-iso PGF2α and MDA) in both the 
BALF and airway tissue (Fig. 4 – 6). 
sensitization




















Figure 4-7. Lipid peroxidation was not observed in the OVA model as shown by no change in (a) 8-iso PGF
2α
 in the BALF, (b) 
MDA in the BALF, (c) 8-iso PGF
2α
in lung tissue and (d) MDA in the lung tissue. Acute asthmatic phenotype is observed as 
before in acute OVA model as shown by an increase in (e) Airway hypperresponsiveness, (f) leukocytes in BALF and (g) IgE in 
BALF. Error bars represent SEM, n = 10, *p < 0.05, **p < 0.01, ***p < 0.001, NS = p > 0.05 
 
 In this second experiment, no differences were observed in the level of oxidized lipids 
between the OVA and saline-treated groups (Fig. 4 – 7a-d). The OVA sensitized and challenged 
mice exhibited the same exaggerated AHR phenotype and airway inflammation as observed 
previously (Fig. 4 – 7e-g). Thus, we concluded that lipid peroxidation is not a key driver of the 
asthma phenotype in this OVA mouse model of acute asthma.  
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 The lack of lipid peroxidation in this OVA model is inconsistent with the increased levels 
of lipid peroxidation products observed in the breath condensate of asthmatic patients.27-35 With 
the goal of performing a more definitive experiment, we transitioned to the more clinically 
relevant HDM model of acute asthma (Fig. 4 – 8).50 HDM is a more complex mix of allergens 
containing environmentally relevant protein and non-protein immunogenic components to which 
50-85% of asthmatics are allergic.50-54 We found that HDM-challenged mice showed both a 
statistically significant increases in lipid peroxidation (as measured by both 8-iso PGF2α and 
MDA in both the BALF and airway tissue) (Fig. 4 – 9a-d) and a robust asthma phenotype 
(increased AHR and airway inflammation) (Fig. 4 – 9e-g). 
 
Figure 4-9. Lipid peroxidation was observed in the HDM model as shown by no change in (a) 8-iso PGF
2α
 in the BALF, (b) 
MDA in the BALF, (c) 8-iso PGF
2α
in lung tissue and (d) MDA in the lung tissue. Acute asthmatic phenotype is observed as 
before in acute OVA model as shown by an increase in (e) Airway hypperresponsiveness, (f) leukocytes in BALF and (g) IgE in 
BALF. Error bars represent SEM, n = 10, *p < 0.05, **p < 0.01, ***p < 0.001, NS = p > 0.05 
 
 Having observed a statistically significant increase in lipid peroxidation in the HDM 
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of acute asthma. We treated HDM challenged mice with POPC vehicle, 1 mg/kg or 5 mg/kg 
peridinin on the day before, same day and day after the last two HDM sensitization-challenges in 
an attempt to have peridinin in the mouse airway before, during and after the acute asthmatic 
reaction (Fig. 4 – 10).   
  
Figure 4-10. Experimental design for house dust mite acute mouse asthma model. 
 
 We observed conflicting results in the four measures of lipid peroxidation. In the BALF, 
we found a statistically significant increase in MDA concentration between the saline and HDM 
exposed mice but no change in levels of 8-iso PGF2α in the same BALF sample from the same 
mice (Fig. 4 – 11a,b). Similarly, we measured a statistically significant increase in 8-iso PGF2α in 
the lung tissue between the saline and HDM exposed mice but we did not observe a statistically 
significant change in MDA concentration in the same lung sample in the same mice (Fig. 4 – 
11c,d). Due to technical limitations in running the experiment, we were only able to use 8 mice 
per group. It is possible that with a greater number of animals we would have been able to 
observe a statistically significant change in oxidized lipids upon HDM sensitization/challenge. 
Post-hoc analysis of these results show that 15 animals/group would be required to reach a 
statistical power of 0.80 for all four markers of lipid peroxidation. 
 We observed a robust asthmatic phenotype with an increase in airway 
hyperresponsiveness, leukocyte counts or total IgE in the BALF (Fig. 4 – 11e-g). However, we 
observed no effect on lipid peroxidation or asthmatic phenotype upon peridinin administration 
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being an insufficient concentration of peridinin due to either administration of too low a dose or 
poor distribution and retention within the airway. Further experiments would be required to fully 
understand the negative results of this studying, including a more in-depth toxicity study in this 
dosing regime and a complete biodistribution study to determine the localization and half-life of 
peridinin.  
 
Figure 4-11. Lipid peroxidation results were inconclusive and showed no significant changes upon administration of peridinin as 
shown by (a) 8-iso PGF
2α
 in the BALF, (b) MDA in the BALF, (c) 8-iso PGF
2α
in lung tissue and (d) MDA in the lung tissue. 
Acute asthmatic phenotype showed no change upon peridinin administration as shown by an increase in (e) airway 
hypperresponsiveness, (f) leukocytes in BALF and (g) IgE in BALF. Shaded data represents saline sensitized/challenged animals. 
Black data points represent vehicle, green data points represent 1 mg/kg peridinin group and blue data points represent 5 mg/kg 
peridinin.  Error bars represent SEM, n = 10, *p < 0.05, **p < 0.01, ***p < 0.001, NS = p > 0.05 
 
4 – 3 SUMMARY AND CONCLUSIONS 
 Monocyte binding is a key step in the development of atherosclerotic plaques which can 
lead to heart attack and stroke. We have shown that the oxidation of endogenous lipids within 
human endothelial cells is capable of inducing monocyte-endothelial cell adhesion. Peridinin 
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first reported case of small molecule inhibition of monocyte binding mediated by endogenous 
lipid oxidation. These results exemplify how peridinin, a specific and potent small molecule 
antilipoperoxidant, was able to probe the role of lipid peroxidation in human disease. 
 The second disease we sought to further understand was asthma. The totality of these 
studies in both the OVA and HDM mouse models of asthma suggest that lipid peroxidation is not 
a key driver of the acute asthmatic reaction. We performed five mouse experiments in two 
different mouse models of allergic asthma and in only one of these experiments did we observe a 
significant increase in lipid peroxidation. If lipid peroxidation were a key driver of the acute 
asthmatic phenotype we would have expected to see both a high degree of lipid peroxidation and 
strong asthmatic response. We observed a strong asthmatic response in every experiment in both 
airway hyperresponsiveness and inflammation but only once did we observe a significant 
increase in oxidized lipids. Future experiments to answer this question will require a full 
lipidomic analysis of multiple asthmatic models including both HDM and viral antigens along 
with analysis of both the acute asthmatic response and the chronic airway remodeling observed 
in asthmatic patients. Finally, further work on peridinin in the mouse airway including full 
analysis of pharmacokinetics and pharmacodynamics (PK/PD) is required to understand why 




















































































































































































































Materials. Commercially available materials were purchased from Lonza, Sigma-Aldrich or 
Avanti Polar Lipids and were used without further purification unless stated otherwise.  Peridinin 
was synthesized as reported by Woerly and coworkers.1 Unless stated otherwise, all of the 
solvents were dispensed from a solvent purification system that passes solvents through packed 
columns according to the method described by Pangborn and coworkers (THF, Et2O, CH3CN, 
CH2Cl2: dry neutral alumina; hexanes, toluene: dry neutral alumina and Q5 reactant; DMSO, 
DMF, CH3OH: activated molecular sieves).2 Water was dispensed from a MilliQ water 
purification system (Millipore Corporation) unless stated otherwise.  
 
HPLC Analysis. All analytical HPLC analysis was performed using an Agilent 1200 series 
instrument equipped with a variable wavelength detector and analytical Agilent Eclipse XDB-
C18, 5 µm, 4.6 x 150 mm column. All HPLC solvents were filtered through 0.2-µm Millipore 
filters before use. Standard curves were utilized for quantitative determination of carotenoid and 
MDA content.   
 
Mice. All mice were female 6-8 week old wild-type BALB/c purchased from Jackson 
Laboratories. All mouse experiments were approved by the Institutional Animal Care and Use 
Committee of UCSF. 
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Samples for lipid peroxidation analysis. The supernatant from the bronchoalveolar lavage fluid 
(BALF) and the left lung lobe from each animal was frozen and shipped from UCSF to the 
Burke lab at UIUC overnight on dry ice. Samples were stored at -80 °C.  
 
I. ASSAY PROCEDURES 
Cell Culture Conditions. Primary HUVECs were cultured as before (see Chapter 3 Experimental 
Section). Monocytes were purchased from Lonza (CD14+ cells, ≥ 40 million cells, catalog # 
2W-400A) and stored in liquid N2 cryo-storage. Immediately prior to use, monocytes were taken 
out of cryo-storage, thawed, diluted in 10 mL ice cold EGM-2 with 10% FBS, centrifuged (300g 
x 5 min) and supernatant removed. Monocytes were washed three more times before being 
counted by hemocytometer and diluted to 267,000 cells/mL. The monocyte suspensions were 
stored in an ice bath prior to use in the assay. 
 
Media Used in The Monocyte Binding Assay.  
 Growth Media – EGM-2 supplemented with CC-4176: FBS, hydrocortisone, hFGF, 
 VEGF, R3-IGF-1, ascorbic acid, hEGF and heparin; GA-1000 aliquot was not used. 
 OxPUFA Media – growth media as above supplemented with 100 µg/mL PUFA (1-
 stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine) oxidized under a gentle stream of 
 air for 48 hours and delivered in 0.1% DMSO. 
 Basal Media – (EGM-2 supplemented with CC-4176: hydrocortisone, hFGF, VEGF, R3-
 IGF-1, hEGF and heparin; FBS, ascorbic acid and GA-1000 aliquots were not used) 
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 High-FBS EGM-2 Media – EGM-2 supplemented with 10% FBS and CC-4176: 
 hydrocortisone, hFGF, VEGF, R3-IGF-1, ascorbic acid, hEGF and heparin; GA-1000 
 aliquot was not used 
Monocyte Binding Assay. HUVECs were prepared as above (see Antilipoperoxidant Assay in 
Primary HUVECs) and seeded into 48-well plates with a 50,000 cell/mL suspension in EGM-2 
and 0.5 mL per well. The HUVECs were allowed to attach for 36 hours and then incubated with 
either DMSO, 2 µM astaxanthin or 2 µM peridinin for 12 hours as before (see 
Antilipoperoxidant Assay in Primary HUVECs). The cells were washed (1 x 0.75 mL) with 
either growth, OxPUFA media or basal media without added carotenoid and the appropriate 
media was added to start the experiment. The were incubated at 37 oC for 2 hours and the cells 
were washed (3 x 0.5 mL) high-FBS EGM-2 and then monocytes (0.75 mL of 267,000 cell/mL 
suspension at 0 oC) were added to each well. The cells were incubated at 37 oC for 20 minutes, 
washed with high-FBS EGM-2 (3 x 0.5 mL) and fixed at 23 oC with 500 mL of 10% neutral 
buffered formalin (Sigma-Aldrich, HT5011) for 1 hour. Finally, the cells were washed with PBS 
(3 x 0.5 mL) and imaged at 10x magnification on a phase contrast microscope. Five images of 
fully confluent cells from different sections of each well were taken for monocyte counts. Each 
image was given a number, randomized (by a second person) and adherent monocytes were 
counted in each image. The monocytes counted in each of the five images were averaged to give 
a single number for each well. This experiment was run with 24 wells per condition.  
 
Preparation of MLVs for mouse studies. Peridinin was dissolved in THF and the concentration 
was determined by analytical HPLC (average of three runs). Carotenoid solutions were diluted to 
between 2 and 7 mM in THF. To a 7 mL vial for each required dose was added the appropriate 
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amount of carotenoid THF solution and solvent removed in vacuo. To each vial was added 
POPC (1.5 mg/dose/animal). Solvent was removed in vacuo and samples placed under high 
vacuum for ~24 hours. To each vial was added sterile saline (30 µL/dose/animal). The samples 
were sonicated and vortexed to form MLVs. The MLVs were subjected to five freeze/thaw 
cycles by submerging in liquid N2 and warm water. The samples were then frozen in liquid N2 
and water removed by lyophilization. The samples were stored as a dry powder at -20 oC under 
Ar and shipped overnight to UCSF on dry ice. 
 
Intranasal Administration of Peridinin. Liposome powders were rehydrated with water (30 
µL/dose/animal) and briefly vortexed to form a homogenous liposomal suspension. Each mouse 
was lightly anesthetized by isoflurane inhalation, held on its back and a single drop (30 µL) was 
placed on its nose. The sample was readily inhaled within the mouse airway. 
 
Peridinin Toxicity Studies. The toxicity study was performed in the laboratory of Xiaozhu Huang 
at the UCSF Sandler Asthma Basic Research Center. Mice were dosed by intranasal 
administration with increasing concentrations of peridinin (0, 0.2, 1, 5 and 25 mg/kg) once per 
day for four consecutive days. On day five, the mice were weighed and sacrificed. Lung 
inflammation was measured by H&E staining (see Asthmatic Phenotype). 
 
Quantification of Peridinin in Mouse Lung and Serum. The left lung lobe and blood serum was 
frozen and shipped overnight to the Burke lab at UIUC on dry ice. The lung lobe was incubated 
for one hour at room temperature in collagenase (10 mg/mL in Kreb’s-Ringer buffer) at 1:1 
(mg:µL) for each sample.3 The lungs were then mechanically homogenized in the eppendorf by 
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plastic pestle. The homogenate was diluted with buffer (Kreb’s-Ringer, 4:1 w:v) and extracted 
with EtOAc (5 x 750 µL). The organic layers were combined and solvent removed in vacuo to 
give a dry residue. The residue was dissolved in DMSO (500 µL) and peridinin quantified by 
HPLC.  
 The serum was thawed and an aliquot (100 µL) was added to an eppendorf containing 
MeCN (500 µL). The sample was centrifuged (10,000 rpm x 5 min.), supernatant taken off and 
lyophilized to a powder. The residue was dissolved in DMSO (100 µL) and peridinin quantified 
by HPLC. 
 
Allergen Challenge Model. The OVA and HDM mouse models of acute asthma were performed 
in the laboratory of Xiaozhu Huang at the UCSF Sandler Asthma Basic Research Center as 
previously described.4, 5 Briefly, for the OVA model, mice were sensitized on days 0, 7, and 14 
by intraperitoneal (i.p.) injection of 50 µg OVA emulsified in 1 mg of aluminum potassium 
sulfate (alum). Control mice received an equal volume of alum only. On days 21, 22, and 23 
mice were challenged once per day with intranasal delivery of 100 mg OVA in 40 µL saline or 
saline alone. Twenty-four hours after the last OVA challenge the mice were sacrificed and the 
asthma phenotype and lipid peroxidation was analyzed. For the OVA model in which peridinin 
was applied, liposomal peridinin samples were prepared and mice were dosed by intranasal 
administration with either vehicle or 1 or 5 mg/kg peridinin once per day on days 20-24 as 
described above. For the HDM model, mice were sensitized/challenged on days 0, 7, 14, and 21 
by intranasal administration of 40 µL dust mite fecal pellet preparation (2.5 mg/mL; Greer 
Laboratories) or saline. Forty-eight hours after the last HDM sensitization/challenge the mice 
were sacrificed and the asthma phenotype and lipid peroxidation was analyzed. For the HDM 
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model in which peridinin was applied, liposomal peridinin samples were prepared and mice were 
dosed by intranasal administration with either vehicle or 1 or 5 mg/kg peridinin once per day on 
days 14-16 and 21-23 as described above.  
 
Asthmatic Phenotype. Asthmatic response was characterized as previously described.4, 5 Briefly, 
mice were attached to a pulmonary mechanics analyzer (FlexiVent, SCIREQ Inc, Canada), 
ventilated and paralyzed, and their airway mechanics were measured in response to acetylcholine 
administered in the tail vein. Serum samples were analyzed for OVA-specific IgE using an 
ELISA (BD Biosciences, clone R35-118). Total and differential cell counts were determined by 
hemocytometer and by light microscopic evaluation of more than 300 cells per slide. After 
lavage, lungs were inflated with 10% buffered formalin to 25"cm H2O and transferred to 10% 
buffered formalin. Sections (5 µm) were stained with H&E for semi-quantitative assessment of 
inflammation and PAS for evaluation of mucus production. To quantify inflammation, H&E-
stained lung sections were de-identified for blinding and scored for peribronchial and 
perivascular inflammatory cell infiltration: grade 0, no infiltration; grade 1, <25% of examined 
area; grade 2, 25–50%; grade 3, 51–75%; and grade 4, >75%. To quantify goblet cell 
hyperplasia, PAS stained lung sections were de-identified for blinding and scored for the 
percentage of PAS positive cells among airway epithelial cells: grade 0: none; grade 1 <25% of 
airway epithelial cells; grade 2, 25–50%; grade 3, 51–75%; and grade 4, >75%. 
 
Mouse Lung Homogenization. Each lung lobe was transferred to a 20 mL round-bottomed tube, 
massed, and placed on ice. To the tube was added 1 mL cold 0.1 M sodium phosphate buffer pH 
7.4 containing 1 mM EDTA and 0.005% BHT per 100 mg tissue (i.e. for 80 mg lung sample, 
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added 800 µL buffer). The sample was homogenized for 1 minute on ice at the highest speed 
utilizing a PowerGen 125 (Fisher Scientific) homogenizer. Between samples, the homogenizer 
was cleaned utilizing water and EtOH. The homogenate was transferred to a 15 mL conical tube 
and centrifuged (7800 rpm x 20 min.) at 4 °C to pellet the solids. The supernatant was aliquotted 
into clean eppendorf tubes, frozen in liquid N2, and stored at -80 °C.  
 
8-iso-PGF2α Sample Preparation. Mouse BALF sample was thawed and an aliquot (300 µL) was 
removed, frozen at -80 °C and lyophilized to a dry powder. This sample was then rehydrated 
with EIA buffer (300 µL) and 8-iso-PGF2α measured by 8-isoprostane ELISA kit (Cayman 
Chemical). An aliquot (50 µL) of mouse lung homogenate was frozen at -80 °C and lyophilized 
to a dry powder. The powder was rehydrated with EIA buffer (500 µL). An aliquot (100 µL) of 
this sample was diluted in EIA buffer (900 µL) and centrifuged (10,000 g x 10 min.). 8-iso-
PGF2α measured by 8-isoprostane ELISA kit (Cayman Chemical) in the supernatant. 
 
8-iso-PGF2α Assay. Briefly, the 8-iso-PGF2α antiserum and acetylcholine esterase were thawed 
and dissolved in EIA buffer (30 mL). The 50 ng/mL 8-iso-PGF2α standard in EtOH was diluted 
9:1 in ultra pure water (Cayman Chemical) and standards were made at 500, 200, 80, 32, 12.8, 
5.1, 2.0 and 0.8 pg/mL and a second set of standards made at 350, 140, 56, 22.4, 9.0, 3.6 and 1.4 
pg/mL in EIA buffer. Onto the plate was loaded each standard (in duplicate) and each sample (5 
replicates each) in addition to the necessary control wells (blank (blk), B0, total absorbance (TA), 
non-specific binding (NSB)). To each well was added AChE tracer (50 µL/well) followed by 8-
iso-PGF2α antiserum (50 µL/well). The plate was covered by an adhesive plastic cover and 
incubated at 4 °C for 18 hours. The plate was then washed with the wash buffer (5 x 500 µL) and 
! 195!
freshly prepared Ellman’s reagent (200 µL/well) was added to every well. AChE tracer (2 µL) 
was added to the TA well. The plate was incubated at room temperature in a plate-reader, 
shaking for the first 60 minutes and then absorbance was measured (412 nm) every 10 minutes 
while shaking for the next 60 minutes. The absorbance values used was the first reading in which 
the B0 wells averaged a raw absorbance value over 1 AU. The data was analyzed by subtracting 
the average of the blk wells from the absorbance value of every well. The %B/B0 was calculated 
for each well and the %B/B0 for the 15-point standard curve was fitted to a 4-parameter logistic 
curve (Origin Pro). This standard curve was used to calculate the concentration of 8-iso-PGF2α in 
each well. For the lung homogenate samples, protein concentration was determined by Pierce 
BCA Assay (Thermo Scientific) and utilized to normalize the concentration of 8-iso-PGF2α.  
 
MDA Assay.  
HPLC method. Isocratic 70:30 25 mM potassium phosphate buffer pH 6.5:MeOH, detect at 533 
nm, 1.75 mL/min, 100 µL injection, tR ~5.4 min.  
 
BALF analysis. Eppendorfs containing BALF samples were thawed in a 37 °C water bath for 1 
minute. To 2 mL glass vials was added 15 µL 0.84% BHT in EtOH, 20 µL 4.88 M aq. 
phosphoric acid, 50 µL 0.5% aq. thiobarbituric acid (TBA) followed by 400 µL BALF. The 
BALF samples were immediately refrozen in liquid N2 and returned to -80 °C. Vials were 
capped with Teflon-lined caps, sealed with electrical tape, and heated at 90 °C for 45 minutes. 
After cooling, to each vial was added 100 µL of 1:11 (v/v) 5 M NaOH:MeOH and the sample 
vortexed to mix. Each vial was placed in a 15 mL conical to allow centrifugation (7500 rpm x 10 
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min.). The supernatant was removed, filtered through a 0.2 µm filter into clean HPLC vials and 
analyzed by HPLC for MDA content.  
 
Lung homogenate analysis. Eppendorfs containing homogenate supernatant samples were 
thawed in a 37 °C water bath for 1 minute. To 2 mL glass vials was added 15 µL 0.84% BHT in 
EtOH, 150 µL 0.44 M aq. phosphoric acid, 50 µL 0.5% aq. TBA followed by 100 µL 
homogenate supernatant. The homogenate samples were immediately refrozen in liquid N2 and 
returned to -80 °C. Vials were capped with Teflon-lined caps, sealed with electrical tape, and 
heated at 90 °C for 45 minutes. After cooling, to each vial was added 300 µL of 1:11 (v/v) 1 M 
NaOH:MeOH and the sample vortexed to mix. Each vial was placed in a 15 mL conical to allow 
centrifugation (7500 rpm x 10 min.). The supernatant was removed, filtered through a 0.2 µm 
filter into clean HPLC vials and analyzed by HPLC for MDA content. Protein concentration in 
the homogenate samples was determined by Pierce BCA Assay (Thermo Scientific) and utilized 
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